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List of used acronims and abbreviations 
3BP: 3-bromopyruvate 
pABA: para-aminobenzoic acid 
ACAT: acyl-CoA:cholesterol acyl transferase 
ACT: artemisinin-based combination theraphy 
ADP: adenosine diphosphate 
ATP: adenosine triphosphate 
BBB: blood-brain barrier 
BTK: Bruton’s tyrosine kinase 
CatB: cathepsin B 
CatL: cathepsin L 
CDMT: 2-chloro-4,6-dimethoxy-1,3,5-triazine 
CL: cardiolipin 
CoA: coenzyme A 
mCPBA: m-chloroperbenzoic acid  
CTP: cytidine triphosphate 
CTPS: cytidine triphosphate synthetase 
DAPI: 4',6-diamidino-2-phenylindole 
DBF: dibromoformaldoxyme 
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM: dichloromethane 
DFMO: α-difluoromethyl ornithine 
DHFR: dihydrofolate reductase 
DHPS: dihydropteroateate synthase 
DIPEA: N,N-diisopropylethylamine  
DMAP: 4-(dimethylamino)pyridine 
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DMF: N,N-dimethylformamide 
DMP: Dess-Martin periodinane 
DMSO: dimethyl sulfoxide 
DNA: deoxyribonucleic acid 
DTNB: 5,5’-dithiobis(2-nitrobenzoic acid) 
EC50/ED50: half maximal effective concentration/dose 
EDC (or EDAC): N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EGFR: epidermal growth factor receptor 
FMT: formyl methionyl transferase 
G3P: glycerol-3-phosphate 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GCC: glycine cleavage complex 
g-HAT: gambiense HAT  
GMS: Greater Mekong Subregion 
H2F: dihydrofolate 
H4F: tetrahydrofolate 
HAT: human African Trypanosomiasis 
hERG: human ether-à-go-go-related gene 
HMEC: human microvascular endothelial cell 
HOBt: hydroxybenzotriazole 
HPLC:high performance liquid chromatography 
IC50: half maximal inhibitory concentration 
i.m.: intramuscolar 
i.v.: intravenous 
KHMDS: potassium bis(trimethylsilyl)amide 
LDA: lithium diisopropylamide 
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LiHMDS: lithium bis(trimethylsilyl)amide 
LPA: lysophosphatidic acid 
LPAAT: lysophosphatidic acid:acyl-CoA acyl transferase 
MCT: monocarboxylate transporter 
N5,N10-CH2-H4F: N5,N10-methylenetetrahydrofolate 
N5,N10-CH+-H4F: N5,N10-methenyltetrahydrofolate 
N10-CHO-H4F: N10-formyltetrahydrofolate 
NAD(P)+: nicotinamide adenine dinucleotide (phosphate), oxidized state 
NAD(P)H: nicotinamide adenine dinucleotide (phosphate), reduced state 
NMM: N-methylmorpholine 
NMR: nuclear magnetic resonance 
NOE: nuclear Overhauser effect 
NSAIDs: nonsteroidal anti-inflammatory drugs 
NTD: neglected tropical disease 
ODC: ornithine decarboxylase 
PBS: phosphate-buffered saline 
PA: phosphatidic acid 
PC: phosphatidylcholine 
PD: pharmacodynamics 
PDB: protein data bank 
PDC: pyridinium dichromate  
PE: phosphatidylethanolamine 
PG: phosphatidylglycerol 
PI: phosphatidylinositol 
PK: pharmacokinetics 
PS: phosphatidylserine 
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PTR-1: pteridine reductase-1 
PTSA: p-toluensulfonic acid 
r-HAT: rhodesiense HAT  
RNA: ribonucleic acid 
mRNA: messenger RNA 
rRNA: ribosomal RNA 
tRNA: transfer RNA 
ROS: radical oxygen species 
SEM: scanning electron microscope 
SHMT: serine hydroxymethyl transferase 
TAG: triacylglycerol 
TEA: triethylamine 
TFA: trifluoroacetic acid 
THF: tetrahydrofuran 
dTMP: deoxythymidine monophosphate 
TMS: trimethylsilyl 
TS: thymidilate synthase 
dUMP: deoxyuridine monophosphate 
VSGs: variant surface glycoproteins 
WHO: World Health Organization 
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1. Parasitic diseases 
A parasitic disease is an infection caused by a parasite, “an organism which lives in or on another organism 
(its host) and benefits by deriving nutrients at the other’s expense”. [1] 
Parasitic diseases may be really different between them. A common characteristic is that they are mostly 
diffused in the tropical and subtropical areas of the world, where hygienic conditions are often poor. In these 
regions, parassitosis have a tremendous impact on population life and economy. Some of these diseases can 
be found in developed countries as well, but they represent serious treats just in particular circumstances, such 
as in immunodepressed patients and in pregnant women. However, because of migration flows, severe diseases 
could spread over their usual borders too. 
For an easier discussion about the problem, parasites are classified according to two different criteria. The first 
one is based on Cavalier-Smith’s classification of living beings in the six kingdoms of Bacteria, Chromista, 
Fungi, Plantae, Protozoa and Animalia. [2] Human parasites are found within Bacteria, Fungi, Protozoa and 
Animalia and, in addition, viruses can be included in this list. In a different classification, parasites are divided 
in different groups according to their localization in the host’s body. Parasites which reside outside the human 
body (such as lice and fleas) are referred to as ectoparasites, while the ones which establish or inside the human 
body, such as many invertebrates, are named endoparasites. Moreover, among endoparasites we can 
distinguish facultative (e.g. Listeria monocytogenes, Legionella, Yersinia) and obligate (e.g. Toxoplasma 
gondii, Rickettsia, viruses) intracellular parasites.  
 
      a   b   c  
Figure 1. 1 Examples of parasites. a. Louse (Di Gilles San Martin - originally posted to Flickr as Male human head louse, CC BY-SA 
2.0, https://commons.wikimedia.org/w/index.php?curid=11208622). b. SEM image of a male and female Schistosoma mansoni 
(http://www.cab.unimelb.edu.au/cab_schisto.htm) c. HIV-1 virions (http://emedicine.medscape.com/article/211316-overview). 
 
The lack of systematic drug discovery programmes for these diseases in industries (for economic reasons) 
induced the World Healt Organization (WHO) to include some of these in the list of the Neglected Tropical 
Diseases (NTDs). [3] 
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2. Scope of the thesis 
This work is related to the design and synthesis of new potential drugs for the treatment of parasitic diseases, 
mainly focusing on the protozoan infections. The development of agents for malaria and human African 
trypanosomiasis (HAT), two of the most prevalent protozoan parasitic diseases, represents the heart of this 
work. Enzymes have always been of primary interest in drug discovery, especially in the antimicrobial field. 
High druggability, ease of purification (which allows performing exhaustive structure-activity relationship 
studies) and chances for selective toxicity (due to the differences in enzyme isoforms or in metabolism) clearly 
explain their potential as pharmacological targets. Therefore, I selected crucial microbial enzymes to be 
exploited as new targets. During my PhD, I also spent ten months as visiting student at the Institute of Medical 
Sciences, University of Aberdeen, Scotland, under the supervion of Professor Matteo Zanda. Duting this 
period, my work concerned the development of new potential agents to treat Chlamydia trachomatis (an 
obliged intracellular bacterium) infections. The final goal of the present thesis is to describe drug-like 
molecules with a new mechanism of action and sufficiently active to prompt in vivo studies on animal models 
of the diseases. 
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3. Protozoan parasitic diseases 
3.1 Malaria 
Key points [4] 
 Caused by 5 species of Plasmodium, transmitted by Anopheles mosquitoes; 
 Mainly in sub-Saharan Africa but also in Asia, Latin America and Middle East; 
 WHO estimates 214 million cases and 438000 deaths in 2015. Globally 3.2 billion people are at risk. 
The parasite is transmitted to humans through the bites of female Anopheles mosquitoes (30 different species 
are major vectors) seeking for blood to nurture their eggs. P. falciparum, P. vivax, P. malariae, P. ovale, P. 
knowlesi are the agents of the diseases. The most important species are P. falciparum, the most prevalent in 
Africa and responsible for most malaria-
related deaths globally, and P. vivax, diffused 
in other continents. After the injection, 
sporozoites reach host’s liver. In the 
hepatocites they start dividing and 
differentiating into merozoites (an aploid 
form). Some species (P. vivax and P. ovale) 
also produce hypnozoites, a dormant form 
responsible of relapses after weeks or months. 
This first phase (pre-erythrocytic or hepatic 
stage) lasts for 5-16 days, then parasites enter 
in the bloodstream again and invade the 
erythrocytes (erythrocytic stage). Parasites 
undergo asexual replication differentiating in 
trophozoites and then in mature schizonts, 
which break releasing newly formed 
merozoites and starting a new cycle of 
infection (fig. 3.1). This stage is characterized by cyclic occurrence of flu-like symptoms every 24 hours (P. 
knowlesi), 48 hours (tertian fever, P. falciparum, P. vivax and P. ovale) or 72 hours (quartan fever, P. 
malariae). Some merzoites enter in the sexual cycle, developing in male and female gametocytes. When a 
mosquito bites an infected person it ingests the gametocytes. In the midgut, erythrocytes burst releasing 
gametocytes which mature in gametes that fuse to form diploid zygotes. Once differentiated in ookinetes, the 
parasites burrow in midgut wall and form oocysts. Aploid sporozoites are formed in the oocyst and relased 
upon burst (after 5-18 days). Sporozoites travel back to the salivary glands of the mosquito and the infection 
cycle starts again. [5] 
Figure 3. 1 Infection cycle of the malaria parasite 
(https://www.flickr.com/photos/niaid/20771605491). 
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As mentioned above, malaria is characterized by recurrent attacks, or paroxysms, including chills (along with 
headache, malaise, fatigue, muscular pain, occasional nausea, vomiting and diarrhoea) followed by fever and 
then sweating. While in P. vivax infections the person may feel well between attacks, in P. falciparum malaria 
the symptoms persist and, without treatment, death may occur. [6] 
3.1.1 Treatment of malaria [7] 
In July 2015 the European Medicines Agency expressed a positive opinion on the RTS,S/ASO1 malaria 
vaccine. However WHO underlined that further evaluations are needed prior to its wide introduction, and did 
not recommend its use in 6-12 week old children. [8] Hence, the treatment of malaria is still based on 
chemotheraphy. 
Antimalarials are usually classified by their activity toward a specific stage of the parasite lifecycle, which will 
determine their potential application (prophylaxis versus acute treatment), and on their chemical structure. 
Because of a more homogeneous grouping, currently antimalarial drugs are here introduced in accordance with 
the second classification criterium. 
Cinchona alkaloids 
Quinine, derived from the bark of Cinchona tree, is the first known antimalarial. Its use was introduced in 
Europe in the seventeenth century by Spanish Jesuits returned from Peru, where Inca used cinchona bark to 
treat malaria. Quinine is a blood schizonticidal and, only for P. vivax and P. malariae, gametocydal as well. 
Its diastereoisomer, quinidine, is more potent and toxic. Three are the major adverse effects of quinine: 
cinchonism, a syndrome characterized by tinnitus, 
rashes, vertigo, nausea and vomiting, and abdominal 
pain; hypoglycaemia, caused by the stimulation of 
pancreatic β-cells; hypotension. Two peculiar toxic 
effects, probably due to direct neurotoxicity, are hearing 
and seeing impairments. Quinine has a short plasma half-
life (t1/2) that limits its use to acute treatments. Its major 
application is the parenteral treatment of chloroquine-
resistant P. falciparum malaria. 
9-Aminoacridines 
Mepacrine, or quinacrine, was developed in 1934 as an 
analogue of 9-aminoacridine, which was known to possess 
antibacterial activity. This drug inspired the development of 
two other classes of quinolines, characterized by a similar 
structure.  
Figure 3. 2 Structures of quinine and quinidine. 
Figure 3. 3 Structure of mepacrine. The green and the red dashed 
boxes highlight the structural motives shared with 4-aminoquiinoline 
and 8-aminoquinoline antimalarials. 
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4-Aminoquinolines 
Chloroquine is the main member of this class. It is the most 
potent derivative of the series and is usually considered a safe 
drug. Hydroxychloroquine is characterized by a better safety 
profile but is rarely used nowadays. As quinine, it is active 
toward circulating schizonts and gametocytes of P. vivax, P. 
ovale and P. malariae. Its toxicity is attributed the inhibition 
of heme aggregation, that leads to the presence of free and 
toxic heme in parasites, rather than DNA intercalation. 
8-Aminoquinolines 
Pamaquine was introduced in 1926 but has been replaced 
by primaquine. This drug is a potent gametocydal for all 
the species of Plasmodium and acts towards the latent 
forms of P. vivax and P. ovale and the hepatic form of P. 
falciparum. It is believed that its action is related to the 
formation of radical oxygen species (ROS) via 
autoxidation of the 8-amino group. Primaquine is used to 
eradicate P. vivax and P. ovale infections, often in association with chloroquine. The drug is not given for 
long-term treatment due to potential toxicity and sensitization, which is common in people with glucose-6-
phosphate dehydrogenase deficiency. 
Other quinolines derivatives 
Mefloquine was synthesized with the idea of blocking metabolic sensible positions in 
quinine. It is used as prophylactic agent against P. falciparum and against chloroquine-
resistant strains of Plasmodium. It is not effective toward the sexual forms of the 
parasites. High incidence of neuropsychiatric, gastrointestinal, dermatologic and 
cardiovascular side effects has been observed. 
Halofantrine is a 9-phenanthrenemethanol derivative.  
It is effective against P. falciparum, also against 
chloroquine-resistant strains. Cross-resistance 
with mefloquine has been reported. CYP3A4 
oxidizes the compound by N-dealkylation giving 
a more active compound, desbutylhalofantrine. 
The drug is not well absorbed but, because of side 
effects (gastrointestinal and cardiovascular), 
dosage must be limited. 
Figure 3. 4 Structures of chloroquine and of its derivative 
hydroxychloroquine. 
Figure 3. 5 Structures of pamaquine and primaquine. 
Figure 3. 6 Structure of mefloquine. 
Figure 3. 7 Structures of halofantrine and lumefantrine. 
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Lumefantrine is a compound with a structure related to the one of halofantrine. It is  used in combination with 
artemether to treat multi-resistant P. falciparum infections.  
Pyrimidines/triazines 
Pyrimethamine is a potent and selective Plasmodium dihydrofolate reductase 
(DHFR) inhibitor. The depletion of reduced cellular folates results in a slow 
blood schizonticidal action. Main toxic effects at therapeutic doses are 
occasional skin eruptions and haematopoiesis depression. 
Proguanil is a biguanide which is converted to 
cycloguanil (its active form) in vivo. This DHFR 
inhibitor is active against tissue and asexual blood 
forms of P. falciparum and P. vivax (but not 
toward hypnozoites). This drug has an optimal 
safety profile and, in contrast to pyrimethamine, 
can be administered during pregnancy.  
Sulfonamides and sulfones 
Compounds of this class are inhibitors of dihydropteroate synthase (DHPS), an enzyme involved in the 
biosynthesis of folates. The success of this class of inhibitors is due to the fact that humans, in contrast to some 
microbes, do not possess the ability to synthesize folates. DHPS inhibitors compete with p-aminobenzoic acid 
(pABA), one of the two substrates of the enzyme, blocking the synthesis of dihydropteroate or alternatively, 
they can be also incorporated in a false metabolite. Both the situations lead to blood schizonticidal effect, 
especially marked toward P. falciparum. Due to 
synergic mechanisms of action, these 
compounds are often co-administered with 
DHFR inhibitors (e.g. pyrimethamine and 
sulfadoxine, a long-acting sulfonamide) to treat 
malaria attacks.  
Figure 3. 8 Structure of pyrimethamine. 
Figure 3. 9 Structures of proguanil and of its active metabolite 
cycloguanil. 
Figure 3. 10 Structures of sulfadoxine and dapsone. 
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Endoperoxides 
Artemisinin has been isolated from the Chinese plant Artemisia 
annua. Synthetic and semisynthetic derivatives, with improved 
stability (artemether) and water solubility (artesunate), have also 
been developed. All these molecules are active in virtue of the 
presence of the endoperoxide group. It is believed that artemisinins 
are activated by the intervention of the heme iron resulting in the 
production of a free radical. This targets sarcoplasmic reticulum 
Ca2+-ATPase (PfATP6) altering calcium stores and may also form 
covalent adducts to specific membrane associated proteins. These 
drugs are active on gametocytes and on the all the asexual stages of 
Plasmodium, with the exception of the primary or latent hepatic 
forms. For these reasons, and because of a short plasma t1/2, 
artemisinins are not used in prophylaxis. In order to prevent 
development of resistance, these drugs are often administered in a 
combination therapy (artemisinin-based combination therapies, ACTs) with other drugs (e.g. artemether-
lumefantrine, artesunate-amodiaquine, and artesunate-sulfadoxine-pyrimethamine).  
Tetracyclines 
Tetracycline and doxycycline, in particular, are used to treat quinine-resistant 
infections. They interact with the rRNA in the minor ribosomal subunit 
affecting protein synthesis. These drugs are effective toward hematic schizonts 
and tissue primary form of P. falciparum but with slow action. Toxicity limits 
their use: they can easily cause photosensitization reaction and they are not 
suitable for pregnant women and children.  
Naphthoquinones 
Atovaquone is active toward hepatic forms of the parasites (but not toward 
the hypnozoites of P. vivax). Its action is based on the interference with the 
generation of mitochondrial membrane potential. It is usually administered 
together with proguanil in order to enhance efficacy.  
 
Currently, WHO recommends a 3 days ACT treatment (artemether-lumefantrine, artesunate-lumefantrine, 
artesunate-mefloquine, dihydroartemisinin-piperaquine, and artesunate-sulfadoxine-pyrimethamine) for 
uncomplicated P. falciparum malaria, except pregnant women in the first trimester (in this case a 7 days with 
quinine-clindamycin is suggested). When malaria is caused by other species, chloroquine can be used (if 
effective) alternatively to ACT. Primaquine should be used to prevent relapses of P. vivax or P. ovale but 
glyceraldehyde 6-phosphate dehydrogenase status must be carefully evaluated. In case of pregnancy or 
Figure 3. 11 Structures of artemisinin and of its 
derivatives artemether and artesunate. 
Figure 3. 12 Structures of 
tetracycline and doxycycline. 
Figure 3. 13 Structure of atovaquone. 
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breastfeeding, the use of chloroquine should be preferred. In the case of severe infection, artesunate should be 
administered i.v. or i.m. until the patient can tolerate oral medication (the parenteral treatment must last 24 
hours, at least), at this point a 3 days treatment with ACT must complete the cycle. [11] 
3.1.2 Drug resistance [9] 
Resistance to antimalarials is a major problem at date. To have a general knowledge of the extension of the 
phenomenon, I here briefly report some of the data collected by WHO, focusing on the two major species of 
Plasmodium. For a detailed view, references and corresponding updates should be consulted. 
Plasmodium falciparum 
Monotherapy is no longer recommended, even for uncomplicated infections. Withdrawal of chloroquine has 
already started years ago. It presented high to extremely high treatment failure rate in all regions with the 
exception of Central America. Resistance diminished in some areas but there is still caution about worldwide 
reintroduction of this drug. Amodiaquine is more effective than chloroquine, despite cross-resistance. 
However, treatment failure rate is very high in South America, Middle East and Africa (slightly lower in 
Western Africa). It has been chosen as first-line drug in combination with artesunate; the efficacy of this 
combination was correlated with the efficacy of amodiaquine alone (where artesunate resistance is absent or 
low). Acting on the same metabolic pathway, the combination sulfadoxine-pyrimethamine is considered as a 
monotherapy. The failure rate is low in South America, Middle East and Central Asia but high in Africa (very 
high in Eastern Africa). Resistance rapidly develops and reduction in resistance has been rarely documented. 
The efficacy for the ACT, as for amodiaquine, is correlated with the efficacy of sulfadoxine-pyrimethamine 
alone. Because of low cost, long half-life and safety in pregnant women and children, this association is still 
used with success for intermittent preventive treatment, even in areas with moderate resistance. Mefloquine 
resistance was reported few years after its introduction at the Cambodia-Thailand border, probably because of 
an improper use (i.e. low doses). It still is a great concern in the Greater Mekong subregion (GMS), while low 
treatment failure rates have been reported in Africa and South America (even if mutations related to quinolones 
resistance have been detected in the parasite). The efficacy of quinine is not clear: it remains a second-line 
treatment (especially in association with other antibiotics) and its adverse effects appear in most of the patients. 
The association of atovaquone and pyrimethamine remains effective in different areas but, because of its cost, 
it remains limited to travellers from industrialized countries. Fatty food lowers the adsorption of atovaquone. 
Plasmodium vivax 
When ACTs are not used, chloroquine remains the drug of choice for P. vivax infections. Resistance is 
confirmed in South America, Southeast Asia and Ethiopia. Mefloquine is highly effective against chloroquine 
resistant infections. Pyrimethamine is only effective toward wild-type P. vivax and key mutations related to 
resistance have been found in many countries. P. vivax shows some degree of “innate resistance” to 
sulfadoxine. Primaquine is highly active toward hypnozoites. Despite several reports of resistance, the data are 
affected by many confounding factors and then must be interpreted with caution. 
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Resistance toward artemisinin and derivatives [10] 
The importance of artemisinin could be perceived by the motivations for the conferment of the 2015 Nobel 
Prize in Physiology or Medicine to Youyou Tu, who firstly isolated the molecule: 
“The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology 
or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura […] and the other half to Youyou 
Tu for her discoveries concerning a novel therapy against malaria. Diseases caused by parasites have plagued 
humankind for millennia and constitute a major global health problem. […] Youyou Tu discovered 
Artemisinin, a drug that has significantly reduced the mortality rates for patients suffering from malaria. These 
two discoveries have provided humankind with powerful new means to combat these debilitating diseases that 
affect hundreds of millions of people annually. The consequences in terms of improved human health and 
reduced suffering are immeasurable.” [11] 
Being such important drugs, the analysis of resistance to 
artemisinins deserve a separate discussion. Artemisinin 
resistance is defined as a delayed parasite clearance, and 
actually affects only ring-stage parasites. It is, shortly, a partial 
resistance and at the date no evidences of full resistance have 
emerged. Several non-synonymous mutations in the Kelch 13 
(K13)-propeller domain were associated with delayed parasite 
clearance in vitro and in vivo and are currently monitored as 
marker for resistance. The success of ACTs therapy is 
however not compromised as long as the partner drug remains 
effective. The major concerns regard Southeast Asia, in 
particular the GMS, where resistant falciparum malaria have 
emerged independently in many areas (fig. 3.14). In 
Cambodia, the combination artesunate-mefloquine was 
reintroduced as first-line treatment in 2014 and gives a 100% 
success rate; in 2008 it was replaced by dihydroartemisinin-
piperaquine but, because of high failure rates due to increasing 
piperaquine resistance, this last association was abandoned. In 
Lao, the association of artemether and lumefantrine is losing efficacy while in Myanmar a delayed clearance 
has been observed for the three major ACTs (artesunate-mefloquine, dihydroartemisinin-piperaquine, and 
artemether-lumefantrine). Dihydroartemisinin-piperaquine is currently used as first-line treatment in Thailand 
(artesunate-mefloquine and artemether-lumefantrine showed high failure rates) while resistance to the same 
ACT developed in Viet Nam. K13 mutations and delays in parasites clearance have been also observed in 
Africa and South America. 
Figure 3. 14 Diffusion of artemisinins resistance in the 
GMS (http://apps.who.int/iris/bitstream/10665/250294/1/ 
WHO-HTM-GMP-2016.11-eng.pdf?ua=1). 
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Humans are rapidly losing their position of strength against Plasmodium parasites. The forced selection 
conditions created and the inappropriate use of available drugs led to the appearance of stronger parasites that 
often require carefully therapy evaluation to provide a complete eradication. Keeping in mind the objective of 
this tough battle (the complete eradication of malaria), it is evident that we urgently need new agents to be 
used against these parasites, since the older ones are losing efficacy (if not already ineffective). 
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3.2 Human African trypanosomiasis (HAT) 
Key points [12] 
 Caused by two subspecies of Trypanosoma brucei, transmitted by Glossina flies (tsetse flies); 
 Spread in 36 sub-Saharan Africa countries; 
 3796 cases recorded and 20000 estimated in 2014. 65 million people at risk. 
T. brucei is transmitted to humans by the bites of tsetse flies which have acquired the parasite from infected 
human beings or animals. Two different forms may develop: T. b. gambiense causes western HAT (g-HAT), 
the chronic form (found in 24 countries of western and central Africa, 98% of the reported cases), while T. b. 
rhodesiense causes eastern HAT (r-HAT), the acute form (found in 13 countries of eastern and southern 
Africa, 2% of the reported cases). The subspecies T. b. brucei is only infectious to animals, causing Nagana 
disease, and is hence used for biological studies. Other ways of infection are possible: in particular, mother-
to-child transmission, mechanical transmission through other blood-sucking insects and sexual transmission 
have been reported. Injected metacyclic trypomastigotes mature in bloodstream trypomastigotes and start 
dividing in subcutaneous tissues, blood and lymph. This is the haemo-lymphatic stage of the disease, 
characterized by headaches, itches, joint pains and bouts of fever, due to fluctuations of parasite levels in the 
blood. The immune system recognises T. brucei and destroys most of the cells. However, some of the parasites 
modify their variant surface glycoproteins (VSGs) and this allows them to escape the immune response. The 
ability of T. brucei of constantly evading the immune system renders the development of a vaccine for HAT 
impossible. A peculiar symptom of this phase of the disease is the Winterbottom’s sign, which is due to 
tremendous swollen lymph nodes along the back of the neck. When the parasites invade the central nervous 
system, the neurological (or meningo-encephalic) phase begins. It is accompanied by more specific symptoms, 
like changes of behaviour, confusion, sensory disturbances and poor coordination, which make the disease to 
be commonly known as “sleeping sickness”. In contrast to Plasmodium parasites, the life cycle of T. brucei 
is completely extracellular. When untreated, the infection invariantly ends with the death of the human host. 
In the case of r-HAT, the neurological phase develop early, compromising any possible intervention; this is 
the reason that underlies the little number of reported case of eastern HAT. 
3.2.1 Treatment of HAT [12] [7] 
The outcome of HAT treatment is strictly dependent on the moment of the diagnosis, with earlier treated 
patients having higher cure rate. Giving the different localization of the parasites during the two phases of the 
disease, drugs with different physicochemical properties are needed. In particular, the treatment of the 
neurological phase absolutely requires agents able to cross the blood-brain barrier (BBB). At the date, only 
five drugs are approved for the treatment of HAT, two (suramin and pentamidine) for the first stage, and three 
(melarsoprol, nifurtimox, eflornithine) for the second stage. 
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Suramin 
This drug was developed by Bayer in 1920 and has been sold with the brand name Germanin. This molecule 
is a polisulfone naphtylamine, formulated as hexa 
sodium salt. The mechanism of action is still unknown 
but the negative charges of the molecule seem to be 
involved. The drug is administered through slow 
endovenous infusion to treat first stage T. b. rhodesiense 
infections. It presents serious adverse effects, in 
particular high neurotoxicity and nephrotoxicity. 
Asthenia, nausea and fatigue are common acute 
reactions while a more severe reaction, which leads to  
shock and loss of consciousness, is rarer. 
Pentamidine 
This drug, developed in the 1930s, is mainly used for the treatment of 
first stage T. b. gambiense infection. The mechanism of action is still 
unclear but, after concentration in the cell (P2 transporter, among 
others, is involved), it may interact with negatively charged 
macromolecules leading to toxic effects. It is administered by 
intramuscular injections for 7 days. Due to high tissue distribution and 
high plasma t1/2, pentamidine has been successfully employed in prophylaxis. It presents moderate toxicity: 
hypoglycemia and hypertension are common; nephrotoxicity and leukopenia have been also linked to its use.  
Melarsoprol 
The story that led to this drug starts in the XIX century, 
when David Livingston observed the efficacy of Fowler’s 
solution (1% aqueous KH2AsO4) in the treatment of HAT. 
Later, Friedheim, a Swiss chemist, synthesized melarsen, an 
organic form of As(V). Melarsen oxide, a reduced form of 
melarsen, showed higher activity and toxicity. Lastly, 
melarsen oxide was conjugated with the British anti-
lewisite, an arsenic detoxifier, obtaining the pro-drug 
melarsoprol. This is the drug of choice for the treatment of 
neurological stage of r-HAT. It is rapidly metabolized in 
melarsen oxide. Its cellular effects are linked to the presence 
of the As, which causes inhibition of glycolysis and that 
forms covalent bonds with various cellular thiols. In 
addition, melarsen oxide is able to form an adduct with 
Figure 3. 15 Structure of suramin. 
Figure 3. 16 Structure of pentamidine. 
Figure 3. 17 Steps in the development of melarsoprol. 
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trypanothione, resulting in a potent competitive inhibitor of trypanothione reductase. These two effects 
probably contribute to the antiparasitic activity. Toxicity of this drug is extremely high, with 5% to 10% of the 
patients developing reactive haemorrhagic thrombocytopenia that, in half of them, leads to death. When 
possible, glucocorticoids are co-administered to reduce this risk. Thrombocytopenia and cardiac insufficiency 
also appear in some cases. Some strains of the parasite developed a reduced sensitivity to melarsoprol, probably 
due to transport defects (P2 adenine/adenosine transporter is able to bind melarsoprol). 
Nifurtimox 
Nifurtimox is effective in both early and late infections. It is activated to anionic 
nitroradicals that, in turn, promote the formation of ROS, leading to oxidative stress 
(lipids peroxidation, enzyme inactivation, DNA damage). Because of a shared 
mechanism of action, it is commonly administered in combination with eflornithine 
for the treatment of the second stage of g-HAT. Its adverse effects include 
hypersensitivity reactions, nausea, vomit, peripheral neuropathy and 
gastrointestinal symptoms.  
Eflornithine 
Eflornithine, or α-difluoromethyl ornithine (DFMO), has been initially developed as 
antineoplastic. Later on it showed activity toward g-HAT. DFMO is a suicide inhibitor of 
the enzyme ornithine decarboxylase (ODC), which catalyses the limiting step in the 
synthesis of polyamines (mainly putrescine and spermidine), which are essential for 
cellular differentiation and division. Moreover, spermidine is together with glutathione a 
constituent of trypanothione, the main cellular antioxidant in the parasite. Thus, depleting T. b. gambiense of 
polyamines also exposes it to oxidative stress. The selective toxicity of DMFO toward T. b. gambiense is due 
to a more rapid ODC turnover in humans. Eflornithine is administered through slow intravenous infusion over 
a 14 days treatment. 
With these informations in hand, it can be easily concluded that the treatment of 
HAT is rather complex. Drugs present severe adverse effects and must be 
administered through parenteral routes following complicated therapeutic 
schemes. Hospitalization and a 24 months follow-up are also required. During 
this period body fluids, as cerebrospinal fluid, must be examined to assess a 
complete cure. In order to ease the suffering of the poor people menaced by HAT, 
manufacturers donate drugs to WHO, which treats patients in the disease endemic 
areas for free. 
Despite the drawbacks of existing agents, only two drugs are currently under 
clinical investigation. The benzoxaborole SCYX-7158 successfully concluded 
phase I clinical studies in March 2015 in France and a phase II/III trial started in 
2016 in the Democratic Republic of the Congo. [13] Fexinidazole entered a phase II/III clinical trial for the 
Figure 3. 18 Structure of 
nifurtimox. 
Figure 3. 19 Structure 
of eflornithine. 
Figure 3. 20 SCYX-7158 and 
fexinidazole, two compounds 
under clinical investigation. 
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second stage g-HAT and for both the stages of r-HAT in 2012. Results of these studies are still to be disclosed. 
[14] 
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4. Bacterial parasitic diseases 
4.1 Chlamydia trachomatis 
Key points [15] 
 Caused by three biovars of the Gram negative bacteria Chlamydia trachomatis; 
 Diffused worldwide. Higher prevalence in the Americas and in the Western Pacific region; 
 Incidence rate of 38 and 33 per 1000 for women and men, respectively; WHO estimates an overall 
prevalence of 4.2% for females and 2.7% for males. 
C. trachomatis is the agent of the most common bacterial sexually transmitted infection. It causes three major 
diseases: genital infections, lymphogranuloma venereum (genital ulcer disease) and trachoma (eye infection). 
The infection is often asymptomatic (in the 70% of women and the 50% of men). Abnormal vaginal discharge, 
dysuria and post-coital and intermenstrual bleeding are common symptoms in women, who also show cervical 
friability and discharge. In men dysuria and urethral discharge are sometimes accompanied by testicular pain. 
Infection often resolves spontaneously but it can ascend the reproductive tract causing pelvic inflammatory 
disease, ectopic pregnancy, salpingitis, tubal factor infertility in women, and epididymitis in men. Rectal and 
oropharyngeal infections are also common. Infection in pregnancy is associated with preterm birth and low 
birth weight. Infants can be also infected at delivery, resulting in neonatal conjunctivitis and/or nasopharyngeal 
infection. 
Trachoma is common in the rural areas of Africa, Central and South America, Asia, Australia and Middle-
East, where hygienic conditions are low. Infection occurs through personal contact and by flies that have 
touched infected people. After several infections, the inside of the eyelid becomes scarred (trachomatous 
conjunctival scarring) at the point that it turns inward (trachomatous trichiasis). Eyelashes rub the eyeball 
causing constant pain and light intolerance. If untreated, irreversible opacities form, resulting in visual 
impairment and blindness. The sight of 1.9 million people is impaired by C. trachomatis (1.4% of the total of 
blind individuals), making it the leading infectious cause of blindness. [16] 
 
4.1.1 Treatment of C. trachomatis infections [7] 
Azithromycin and doxycycline are the drugs of election in uncomplicated case and the first can be used during 
pregnancy and for the treatment of neonates conjunctivitis as well. Lymphogranuloma venereum and anorectal 
infections are preferentially treated with doxycycline. [15] 
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Macrolides (azithromycin, erythromycin) 
Macrolides are antibiotics that work blocking 
protein synthesis. They bind to the ribosomal 
50S subunit, close to chloramphenicol binding 
site, inhibiting the translocation of the growing 
peptide. They are absorbed from the 
gastrointestinal tract and rapidly reach 
effective concentration in all the tissues. These 
drugs are better accumulated in Gram positive 
bacteria. Azithromycin is more active than 
erythromycin toward C. trachomatis. Several mechanisms of resistance have been described. They include: 
efflux pumps; expression of methylases that modify ribosomes, reducing affinity for the drugs; hydrolysis by 
esterases (Enterobacteriaceae); mutations that alter a protein in 50S ribosome subunit. Cross resistance has 
been described as well. These drugs are macro lactones bound to two deoxysugars. Azithromycin presents a 
cyclic amine which improves acid stability, tissue penetration and broaden the activity spectra of the drug. 
Adverse effects to these drugs are little; the major concern regards the development of cholestatic hepatitis, 
since these drugs are mainly eliminated with the bile. They might interfere with other drugs because they cause 
inhibition of CYP3A4. 
Tetracyclines (doxycycline, tetracycline) 
Tetracyclines, as mentioned in paragraph 3.1.1, inhibit protein synthesis binding to the 30S ribosomal subunit. 
They can be given either by oral or by parenteral (intravenous) administration. Since these molecules are avid 
chelators of divalent cations, oral administration with concomitant ingestion of 
high quantities of metal cations causes a reduction in adsorption. For the same 
reason, they accumulate in bones, leading to reduction of growth in children and 
teeth spotting. Other adverse effects include hepatotoxicity, photosensitization, 
renal toxicity and, in fewer cases, hypersensitivity. Resistance is diffused and 
occurs through the following mechanisms: reduced accumulation (combination 
of reduced penetration and improved efflux); synthesis of a ribosomal protein 
that displaces tetracyclines; enzyme inactivation. 
Ofloxacin 
Ofloxacin is a member of the class of the fluoroquinolones antibiotics. 6-
Fluoroquinol-4-ones act inhibiting DNA supercoiling. In many Gram negative 
bacteria they inhibit DNA gyrase, while in Gram positive the principal 
macromolecular target is represented by topoisomerase IV. They can be assumed 
by oral administration, but these drugs should be avoided during pregnancy. They 
distribute well in the body and are excreted with urine. Most common adverse 
Figure 4. 1 Structures of azithromycin and erythromycin. 
Figure 4. 2 Structures of 
tetracycline and doxycycline. 
Figure 4. 3 Structure of 
ofloxacin. 
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reactions involve the gastrointestinal system (nausea, vomiting, abdominal pain, diarrhoea), while other severe 
reactions are rare.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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5. Enzymes as drug targets 
Enzymes are proteins that act as catalysts in cells. The substrate(s) of the enzyme binds to the active site, a 
binding pocket with a unique three dimensional structure. The stereo-electronic properties, resulting from the 
tertiary structure of the whole protein, are optimized to establish a specific network of interactions with the 
substrate, giving a stabilized transition state. The active site must not be consider as a fixed structure, but as a 
flexible architecture, which exists in different microstates with different affinities for ligands (e.g. substrate, 
product, inhibitors). In the following section, I will give descriptive and analytical information of enzyme 
catalysis and inhibition. This chapter is thought as a practical guide for the interpretation of the results 
presented in this thesis and thus is just focused on few relevant aspects. Additional information on enzymes 
are provided in the appendix (chapter 11). 
5.1 Enzyme reaction mechanism 
Enzyme catalyzed reactions is characterized 
by the transition through different states (fig. 
5.1), which are connected by a set of micro-
reversible equilibria. The first step in enzyme 
catalysis is represented by the formation of the 
enzyme-substrate binary complex ES. In most 
of the cases, this is a reversible equilibrium 
process that can be described by a pseudo-
first-order association constant (kon) and a 
first-order dissociation constant (koff). The 
formation of the ES complex represents a 
thermodynamic equilibrium, quantifiable in terms of an enzyme-substrate 
dissociation constant (Ks), defined as the ratio of reactant and product 
concentrations, and as the ratio of the constants koff and kon (eq. 1). The value of 
Ks in inversely proportional to the affinity of the substrate to the enzyme.  
𝐾𝑠 =
[𝐸][𝑆]
[𝐸𝑆]
=
𝑘off
𝑘on
       (eq. 1) 
Along the reaction course, the complex proceeds to the formation of a bound transition state (ES‡), which has 
a lower energy compared to the transition state for uncatalyzed reaction (S‡). Enzymes stabilize the transition 
state with different mechanisms: approximation of the substrates, the formation of covalent intermediates, acid 
or basic catalysis and the distortion of the substrate(s). ES‡ evolves in a product-enzyme complex (EP) and, 
finally, the product is released. The overall rate of conversion of ES to E+P is quantified in terms of a composite 
rate constant (kcat). However, since the formation of ES‡ is the rate-limiting step in the process (due to its high 
thermodynamic barrier) we can consider kcat to be a first-order constant for the transition from ES to ES‡.  
Figure 5. 2 Equilibrium of the 
formation of ES. 
Figure 5. 1 The course of enzyme-catalyzed reaction compared to the one 
of uncatalyzed reaction. 
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Commonly, enzyme reaction studies are performed under steady state 
conditions: working with a high molar excess of S, compared to E, the 
concentration of ES will be constant. Since the reaction rate depends on 
[ES], it will also be constant over time (it can be defined by the slope of 
the plot of [S] or [P] as a function of time). Once [S] decreases, reaction 
rate slows down until an equilibrium between the forward and the reverse 
reactions is established. Independently, Henri, and Michealis and Menten 
studied the variation of the reaction rate as a function of [S] in a rapid 
equilibrium model (koff>>kcat), leading to the mathematical expression 
reported in equation 2. The term Vmax refers to the maximum velocity 
obtained at infinite [S] and is equal to the product of kcat and [E] (eq. 3). 
                                     𝑣 =
𝑉max[𝑆]
𝐾s+[𝑆]
     (eq. 2)                                       𝑉max = 𝑘cat[𝐸]     (eq. 3) 
Later, Briggs and Haldane demonstrated that equation 2 can be used in the case of steady state with the 
substitution of Ks with the kinetic constant KM (eq. 4, the Michaelis-Menten equation). 
𝑣 =
𝑉max[𝑆]
𝐾M  + [𝑆]
 (eq. 4) 
KM (as Ks) has the unit of molarity. When [S] is fixed to be equivalent to KM we obtain that 𝑣 =
1
2
𝑉max. We 
can consider KM as a measure of the relative affinity of the ES complex under steady state conditions. KM and 
kcat can be determined from the plot of v over [S], which can also be displayed on a semilog scale. The 
Michaelis-Menten equation can be linearized (eq. 5) and data displayed on plot of 1/v as a function of 1/[S]: 
the slope of the obtained line is equal to KM/Vmax, the y-intercept to 1/Vmax and the x-intercept to -1/KM. 
However, because of the need of algebraic manipulation, double reciprocal (or Lineweaver-Burk) plots are not 
used to determine kinetic constants. 
On the other hand, they are highly 
predictive of the inhibition modality 
of assayed inhibitors.  
1
𝑣
= (
𝐾M
𝑉max
∙
1
[𝑆]
) +
1
𝑉max
     (eq. 5) 
 
 
 
 
  
Figure 5. 2 The semilog plot and the Lineweaver-Burk plot are reported on the left. 
Up in the page is reported the direct fit plot. 
Figure 5. 1 Plot of reaction velocity as a 
function of [S]. 
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5.2 Enzyme inhibitors 
For enzyme inhibitors the affinity for the enzyme is described by the dissociation constant Ki. Inhibitors can 
bind to the binary complex ES or to the free enzyme, causing a variation of the affinity of the enzyme for the 
substrate of a factor α. For reversible enzyme inhibitors, three different modalities of inhibition are 
distinguished, basing on the different behaviour in relation with the substrate. In this chapter, only competitive 
inhibition is examined, while non-competitive and uncompetitive inhibition are presented in the appendix. 
Inhibition of the catalytic activity could be partial, in the case of partial inhibitors, or complete, for dead-end 
inhibitors. 
5.2.1 Competitive inhibitors 
Competitive inhibitors bind exclusively to the free enzyme (α= ∞). The value of Vmax will be unaffected but 
the apparent KM [defined as KM(1+[I]/Ki)] will increase with increasing inhibitor concentration. The steady-
state velocity equation in this situation is represented by equation 6 and plots for this situation are reported in 
figure 5.3 
𝑣 =
𝑉max[𝑆]
[𝑆] + 𝐾M (1 +
[𝐼]
𝐾i
)
         (eq. 6) 
A saturable binding is expected for reversible inhibitors. The fraction of free enzyme is equal to the fractional 
activity (vi/v0), while the fraction of enzyme bound to the inhibitor is equal to 1-(vi/v0), so % inhibition is 
defined as 100(1-(vi/v0)). Fractional activity can be plotted as a function of [I]. The concentration of the 
inhibitor corresponding to the [I] needed to reach 50% inhibition is referred to as the IC50,. The isotherm 
equations that link fractional activity or % inhibition to [I] are described below (eq. 7 and 8, respectively). 
𝑣i
𝑣0
=
1
1 + ([𝐼] IC50)⁄
       (eq. 7)                             % Inhibition =
100
1 + ([𝐼] IC50)⁄
       (eq. 8) 
IC50 is a measure of relative inhibitory potency, being influenced by solution conditions (pH, ionic strength, 
temperature) and, especially, by [S]. In particular, with increasing [S], IC50 will increase curvilinearly for 
competitive inhibitors. Nevertheless, giving the convenience of their determination, IC50 values are widely 
Figure 5. 3 Direct fit, semilog and double reciprocal plots for competitive inhibition. In the plots here reporterd, highest [I] situation 
is represented by the filled square curve while empty circle curve is for lowest [I]. 
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used to compare the activities of inhibitors with the same inhibition modality and assayed under the same 
conditions. 
Reversibility of inhibition is usually determined by a large dilution of the enzyme-inhibitor complex (“jump-
dilution”). The target is incubated at a concentration 100-fold over the concentration required for the assay and 
with [I] equivalent to 10-fold the IC50. After an equilibration time, the mixture is diluted 100-fold in reaction 
buffer containing the substrate to initiate the reaction. In this way, [I] rapidly change from 10 IC50 to 0.1 IC50, 
which correspond to approximately 91% and 9% inhibition, respectively. Following the reaction progress 
curve we aspect a straight line in the cases of fully reversible inhibition and of irreversible (or very slow 
reversible) inhibition: in the latter case, residual activity will reach a value close to 9%. If the inhibition is 
slowly reversible we will instead obtain a curve in which the linear phase follows a curvilinear lag phase. The 
inhibition modality is then determined observing the effects of the variation of both [S]/KM and [I]/IC50 on 
activity. 
 
 
 
 
 
 
For an accurate comparison of inhibitory potencies of different inhibitors, only Ki values should be taken in 
account. Cheng and Prusoff derived equations that, knowing the IC50, [S], KM and the inhibition modality, 
allow to derive Ki.The relationship of IC50 and Ki for competitive inhibitors is described by equation 9. 
IC50 =  𝐾i (1 +
[𝑆]
𝐾M
)    (eq. 9) 
Cheng-Prusoff equations also represent an alternative method for determining the inhibition modality. 
 
5.2.2 Covalent inhibitors 
Covalent inhibitors irreversibly bind to a critical amino acidic residue of the enzyme abolishing its activity. 
Other inactivators (without the potential application as drugs) are protein denaturants, as detergents, urea, 
guanidine and some oxidants. All irreversible covalent inhibitors will display a slow binding behaviour, with 
kobs describing the rate of inactivation. Given [I]>[E]T, equation 10 describes the reaction curve (where vi is the 
highest observed reaction rate). 
Figure 5. 4 Determination of inhibition reversibility with a rapid dilution approach. Effect of dilution on % activity (left) and 
observed recovery of activity for different inhibition behaviours (right).  
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[𝑃] =
𝑣i
𝑘obs
[1 − exp(−𝑘obs𝑡)]          (eq. 10) 
Depending on the mechanism of irreversible inhibition (considering the cases of a one-step reaction), the 
relationship between kobs and [I] will change. For nonspecific affinity labels the plot will be linear, with a slope 
with the unity of a second-rate constant (usually expressed as kobs/[I] or kinact/KI), and will pass through the 
origin. For quiescent affinity labels and mechanism-based inhibitors (with a two-step mechanism) the curve 
will pass through the origin but, at high values of [I] will reach a plateau. The maximum rate of inactivation 
(reached at infinite value of [I]) is referred to as kinact. In this case the relationship between of kobs and [I] is 
expressed by equation 11, similar to Michaelis-Menten equation, and the inhibitory efficiency is usually 
measured as the half-life for inactivation at infinite [I], t1/2
∞  (equal to 0.693/kinact). KI (which should not be 
confused with the dissociation constant for the initial complex) has a meaning for inactivators similar to the 
meaning of KM for substrates. When [I]<< KI, the plot of kobs as a function of [I] will be linear, with a slope 
equal to kinact/KI. This parameter is then used during SAR for the comparison of inactivation efficacy for all 
enzyme inhibitors. 
𝑘obs =
𝑘inact[𝐼]
𝐾I + [𝐼]
       (eq. 11) 
We can distinguish three different mechanisms of action for irreversible inhibitors: 
a. Nonspecific affinity labelling 
Affinity labels are reactive molecules, generally containing an electrophile, that form 
covalent bonds with cellular macromolecules without specificity. The only some 
drugs antineoplastic, as nitrogen mustards and nitrosoureas act with this mechanism. For other 
therapeutic areas such general reactivity is not acceptable. 
b. Quiescent affinity labelling 
This kind of inactivators present a weak electrophile and this allows then 
to selectively react with catalytic residues after a proper orientation in 
the enzyme active site (during the reversible binding step). Acetil 
salicylic acid and omeprazole are two examples of quiescent affinity labels. 
c. Mechanism-based inactivators 
Mechanism-based inactivators, commonly known as 
suicide inhibitors, are molecules that are recognised by the 
enzyme and are converted into an affinity label, a 
transition state analogue or a very tight binding reversible 
inhibitor, prior to release from the active site. Because of their mechanism, they can be very specific 
for a family of enzymes that catalyse a common reaction. The activated species (A) can be released 
from the enzyme, reducing the fraction of inhibitor that goes directly from the isolated form (I) to the 
covalent adduct E-A. The ratio k6/k7 (the partition ratio, r) is then used as a measurement of efficiency 
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of mechanism-based inhibition (with higher efficiency for values of r close to zero). For this type of 
inhibitors kinact and KI have the form described in equations 12 and 13. 
 
𝑘inact =
𝑘3𝑘5
𝑘3 + 𝑘5 + 𝑘6
     (eq. 12)                      𝐾I = (
𝑘1 + 𝑘3
𝑘2
) (
𝑘6 + 𝑘5
𝑘3 + 𝑘5 + 𝑘6
)     (eq. 13) 
Only in situation of rapid equilibrium (when k1 and k2 are very large and k3 is rate-limiting) KI will be equal to 
Ki, while in other situations the two constants will have different meanings. 
 
5.2.3 Re-evaluation of covalent inhibitors 
Covalent inhibitors have always been considered with suspect. Only suicide inhibitors are generally considered 
considerably safe, because of the need of activation by a specific enzyme. The concerns regarding off target 
reactions, which can result in toxic effects, in particular idiosyncrasic reactions (after protein haptenization) 
make people working in the drug discovery area to abandon molecules containing electrophiles in their 
structure. This caution is absolutely legitimate. Some of the approved covalent inhibitors (or, more generally, 
covalent approach-based drugs), as nitrogen mustards and nitrosoureas, are only used in critical acute states 
because their intrinsic very high toxicity. Even when targeting non-human enzymes, covalent drugs can lead 
to severe allergic reactions in sensible patients, as in the case of β-lactam antimicrobials. However, several 
covalent inhibitors are approved for the human use from a long time and they are assumed almost every day 
without the need of any medical prescription. Two examples are the NSAIDs acetylsalicylic acid and 
acetaminophen. Other covalent approach-based drugs are used for chronic therapies: dutasteride and 
finasteride (5α-reductase inhibitors) are used in the treatment of benign prostatic hyperplasia, clopidogrel 
(P2Y12 receptor inhibitor) is an antiplatelet used to prevent heart attacks and strokes in patient at risk and 
orlistat (pancreatic lipases inhibitor) is used to treat obesity. When properly used, these drugs do not present 
serious adverse effects. Many scientists, both from industry and academia, have underlined the underestimated 
role that covalent inhibitors already play in therapy and all their unexploited potential. [17] [18] [19] [20] 
Targeted covalent inhibitors (quiescent affinity labels), in particular, are gaining more and more attention. The 
success in this field is granted through the optimization of the two portion of the inhibitors: the warhead, the 
electrophilic portion of the molecule, must possess a balanced reactivity (low enough to avoid off target 
reactions but still able to form covalent bond with the targeted nucleophile); the recognition moiety, instead, 
must be properly designed in order to establish a specific network of non-covalent interactions with the 
macromolecule of interest with the aim to enhance selectivity of action and, at the same time, to properly 
orientate the warhead for a faster reaction. The advantages that target covalent inhibitors present are notable. 
The non-equilibrium condition that underlie covalent inhibition lead to a greater biochemical efficiency 
(escaping competition with the substrate). For the same reason, PD and PK effects are dissociated, prolonging 
the efficacy of drugs with low plasma t1/2 and allowing to administer the drugs less frequently and at lower 
doses. This also greatly reduces the risk of idiosyncrasic reactions, which have been correlated with daily dose 
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more rather than the mechanism of inhibition (the same kind of toxicity is caused by several non-covalent 
drugs as halothane, carbamazepine, and felbamate). The growing interest in the field is testified by the number 
of recently approved drugs that acts through a covalent modification of their biological target (e.g. afatinib, 
osimertinib, ibrutinib, dimethyl fumarate).  
This approach is then absolutely valuable but, as general recommendations, it 
should be applied this strategy only toward targets with high t1/2 using warheads 
with moderate reactivity. To further improve opportunities in this field, Taunton 
and co-workers described that the introduction of an electron-withdrawing 
substituent at the α-position of acrylamide Michael acceptors results in a reversibile 
electrophile. The reason behind this is that the stronger acidity of the α-proton in 
the adduct favours the retro-Michael reaction. [21] [22] This approach has been 
applied in the design and synthesis of the reversible inhibitors bardoxolone methyl 
(EGFR inhibitor, fig. 5.6). In principle, the development of prodrug of covalent inhibitors could be considered 
as well. This approach has been just little exploited, but it demonstrated great effectiveness as in the case of 
proton pump inhibitors (e.g. omeprazole, lansoprazole, pantoprazole, fig. 5.7), which revolutionised the 
treatment of peptic ulcer. These molecules are converted to reactive sulfenic acids/sulfenamides only in the 
acidic environment of the stomach, where they covalently bind to their target, the H+/K+-ATPase in parietal 
cells, granting a selective action. 
 
 
 
 
 
 
  
Figure 5. 7 Examples of proton pump inhibitors (above) and mechanism of activation of omeprazole (below). 
Figure 5. 5 Recently approved drugs (the brand name and the year of approval are reported in brackets) that act alkylating 
target enzymes (reported below). 
Figure 5. 6 Structure of the α-
cyano enone bardoxolone 
methyl. 
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5.3 Beyond the target 
Knowing the molecular target is, nowadays, an essential requirement in the drug discovery process. However, 
the quality of the hits (the chemical starting points) is ultimately assessed by cellular assays. In a quite recent 
perspective [23], different partnerships involved in the discovery of new drugs for infectious tropical diseases 
proposed disease-specific criteria for the progression from hit to lead and for reliable early leads.  
Good hits must be characterized by: 
 Adequate in vitro potency: for antimalarials EC50< 1 µM, for Trypanosomatidae disease EC50< 10 µM; 
 Limited cytotoxicity toward mammalian cell lines (>10-fold selectivity window); 
 Acceptable in vitro response (concentration-growth inhibition correlation); 
 Tractable chemotype: no instable moieties, amenable to structural variation, and must pass drug-like 
filters (such as the pan-assay interference filters, PAINS). [24] Conformity to Lipinski’s rule of five 
[25] is preferred; 
 Selectivity in biochemical counter-assay (e.g. mammalian homologous), where relevant; 
 No major synthesis or formulation issues (≤ 5 synthetic steps, acceptable yields, acceptable solubility). 
For lead compounds, the requirements become more and more stringent: 
 Adequate in vitro potency: for antimalarials compounds must show EC50< 100 nM; 
 A selective toxicity 100-fold higher for pathogens compared to mammalian cells (a tighter selectivity 
window could be accepted in particularly challenging fields); 
 Oral efficacy in the appropriate disease model; 
 Series expansion should be amenable; 
 No detrimental chemical feature associated with the pharmacophore; 
 Acceptable physicochemical properties: solubility in PBS> 10 µM and acceptable lipophilicity (logP< 
5); 
 At least, good oral bioavailability in rodents (F> 25%); 
 Manageable drug metabolism and pharmacokinetic profiles (i.e. liver microsomal and hepatocyte 
stability; good membrane permeability; manageable CYP450 inhibition); 
 Acceptable early safety assessment based on target (orthologue) and compound liabilities, in vivo 
observations, in vitro studies (e.g. genotoxicity, mini-Ames test), cytotoxicity, cardiac safety (e.g. 
hERG interaction), and in silico approaches. Selectivity, based on the assay on human orthologues and 
paralogues of the targeted enzyme, should be reached; 
 No acute in vivo toxicity (derived from of the observation of the efficacy studies, particularly at high 
and repeated doses). 
These guidelines are based on the experience and delined to increase the success rate in drug discovery. 
However, every therapeutic area involves different demands that should be kept in consideration. For example, 
antimalarial agents should ideally display efficacy toward the different stages of the parasite (since most of the 
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available drugs are only active on the asexuate form of Plasmodium) and toward a panel of resistant strains; 
on the other hand, antitrypanosomal agents should be able to cross the BBB. In addition, the existence of 
intellectual properties conflicts should be evaluated in each case. 
These recommendations highlight the advantages of a rational drug discovery process, which will anticipate 
liabilities connected with the followed approach (from chemistry and biology points of view). Moreover, it is 
once again recalled the importance of optimizing biopharmaceutical properties together with potency. 
  
Page | 33  
 
6. Inhibitors of Plasmodium falciparum glyceraldehyde-3-phosphate 
dehydrogenase (PfGAPDH) 
6.1 PfGAPDH as target 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12) is a homotetrameric enzyme involved in 
glycolysis. [26] It catalyses the conversion of glyceraldehyde 3-phosphate in 1,3-biphosphoglycerate with the 
concomitant reduction of the NAD+ cofactor: remarkably, the reaction catalysed by GAPDH is the first in 
which energy is produced (as NADH) within glycolysis (while in the previous steps energy is consumed). 
Since it represents the bottleneck for the production of high energy containing cofactors (NADH and ATP), 
GAPDH is considered a valuable target to inhibit the growth of those cells that only rely on glycolysis for 
energy production, as P. falciparum [27] and cancer cells. [28] [29] 
The catalytic mechanism (scheme 6. 2) involves the intervention of a cysteine residue, activated by a proximal 
histidine residue (Cys153 and His180 in PfGAPDH): the generated thiolate reacts with glyceraldehyde 3-
phosphate giving a thioester intermediate and reducing the NAD+ cofactor; subsequent phosphorolysis releases 
1,3-biphosphoglycerate and the catalytic thiolate. 
Scheme 6. 1 Glycolysis sequence. Glucose is partially oxidized to two molecules of pyruvate with production of two molecules of 
ATP and two molecules of NADH. GAPDH occupies a central role in the whole process. 
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Scheme 6. 2 Schematic representation of GAPDH catalysis. 
 
GAPDH possesses additional functions from its key position within anaerobic catabolism. [30] In parasites, 
bacteria and humans, its involvement in other cellular processes, such as DNA repair, control of gene 
expression, membrane trafficking, cell signalling, interaction with RNA and other proteins (particularly in 
neurodegenerative disease) has been postulated. [31] PfGAPDH was found to be able to interact with 
Pfenolase, plasminogen, α-tubulin and lysozyme in a specific way. [32] In addition, surface-expressed 
Plasmodium GAPDH is involved in Kupffer cells traversing through interaction with CD68 receptors and, 
because of this, is a promising candidate for the development of preerythrocytic vaccine. [33] All these aspects 
highlight the enormous potential of PfGAPDH as a target for the treatment of malaria.  
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6.2 PfGAPDH structure 
The structure of PfGAPDH, coded by the PF14_0598 gene, has 
been independently determined at high resolutions (2.25 Å and 
2.6 Å) by two different groups. [34] [35] The protein has a mass 
of 36.6 kDa and a pI of 7.6. The enzyme does not present any 
targeting signal, hence the different cell localization is probably 
due to post translational modifications. Each monomer is 
composed by 334 amino acid residues organized in the following 
way: residues 4-152 and 320-337 constitute the NAD+ binding 
domain, adopting a classical Rossmann fold (NAD+ is found in 
every monomer); residues 153-319 constitute the catalytic 
domain; residues 181-209 are arranged in a feature known as S-
loop that connects the two domins. NAD+ binds in extended 
conformation bringing the nicotinamide ring in proximity of the 
active site, located at the interface of the two domains. Parasite 
and human GAPDHs show a relatively high sequence identity 
(63%). The major difference from the human isoform is found in the S-loop, where a Lys-Gly dipeptide, absent 
in hGAPDH, is inserted. This creates a bulge that reduces the opening of the solvent accessible channel that 
spans close to the NAD+ cofactor.   
 
6.3 The first PfGAPDH selective inhibitors 
Know inhibitors of PfGAPDH, 3-bromopyruvate (3BP) and iodoacetamide, are alkylating agents that react 
with the catalytic cysteine abolishing the enzyme activity, but these molecules are not selective and do not 
possess drug-like properties. Iodoacetamide is an alkylating reagent able to form covalent bonds with cysteine 
residues and, more slowly, with histidine residues in an aspecific way. 
3BP has emerged in the last years as a potential anticancer agent. [36] 
Its preferential action toward cancer cells depends on several factors, as 
higher glycolytic rate (the “Warburg effect”), acidic microenvironment 
and overexpression of monocarboxylate transporters (MCTs) MTC-1 
and MCT-4. However, GAPDH is just one of the number of proteins that this molecule is able to alkylate (its 
principal target is hexokinase-2). The high reactivity of this molecule is reflected as well by its low t1/2 (77 min 
at physiological temperature and pH). This property, together with the lack of documentation of safety in 
humans (no clinical studies were performed), tells that 3BP could not be seriously considered for the 
employment as antimalarial agent. Indeed some of the patients may be healthy and just need a prophylactic 
treatment, so a high safety profile and the possibility of enteral administration are required (requirements are 
very different from cancer therapy). In order to obtain selective GAPDH inhibitors, I decided to exploit the 3-
NAD+
 
binding domain 
Catalytic domain 
S-loop 
Figure 6. 1 GAPDH monomer (PDB 2B4R). The 
domains are highlighted and different secondary 
structures are depicted in different colours. 
Figure 6. 2 Two known inactivators of 
GAPDH. 
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bromo-Δ2-isoxazoline ring, which was recently proposed as a novel warhead for the design of inhibitors of 
reactive cysteine containing enzymes. [37] In a recent research, 3-bromoacivicin [(S,S)-1] [a synthetic 
analogue of the natural compound acivicin, (S,S)-2] was 
described as a potent inhibitor of the enzyme cytidine 
triphosphate synthetase of T. brucei (TbCTPS). [38] 
This enzyme is a glutamine amido-transferase that catalyses the 
de novo synthesis of CTP in the parasite. Both (S,S)-1 and (S,S)-
2 are able to bind the glutaminase domain of the enzyme, due to 
the fact that their structures mimic L-glutamine, and to react 
with the catalytic Cys residue forming a covalent adduct. Because of higher reactivity in the proposed addition-
elimination mechanism, (S,S)-1 turned out to be three times more potent than (S,S)-2 (TbCTPS IC50= 98 nM 
vs 320 nM); this difference was even greater for T. brucei cultures (ED50= 38 nM vs 450 nM). The most 
important feature of the 3-bromoisoxazoline warhead is that its reactivity seems to be moderate enough to 
avoid a catastrophic aspecific effect: indeed, when assayed in vitro against human cells, the compound showed 
300 fold higher IC50 [12.91 µM; for (S,S)-2 IC50 was 15.65 µM]. [39] Starting from these promising results, I 
synthesized compound (S,S)-1 to be assayed against PfGAPDH. This compound showed complete irreversible 
inhibition of PfGAPDH enzymatic activity but with low potency (kinact/Ki = 0.7 s-1M-1). A characteristic of the 
inhibition kinetic is that the rate was very high in the initial phase and then reduced during the second phase. 
The values of kinact/Ki were obtained from the slow phase of this biphasic inhibition. In order to understand the 
role of the amino and carboxyl groups, I synthesized analogues of (S,S)-1 following a simplification strategy. 
At the same time I wanted to obtain inhibitors able to bind PfGAPDH more tightly while losing affinity toward 
TbCTPS. To pursue these objectives, I introduced in the molecules additional functionalization (e.g. 
carbamate, ester) that might establish additional interaction with the target enzyme while removing the amino 
acidic function, responsible for the recognition by glutamine-dependent enzymes such as CTPS (fig. 6.4). 
In parallel, I synthesized a series of inhibitors in which the amino acidic recognition moiety was replaced by a 
phenyl ring, so to obtain a very simple model molecule easy to be further decorated. The position 4 of the ring 
was differently functionalized with substituents able to tune the electronic properties or that can be exploited 
for further functionalization (fig. 6.5). 
Figure 6. 4 Analogues of (S,S)-1. 
Figure 6. 3 Structures of 3-bromoacivicin [(S,S)-1], an 
analogue of the natural antibiotic acivicin [(S,S)-2], 
from Streptomyces sviceus. 
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The key step in the synthesis of these compounds was the 1,3-dipolar cycloaddition between bromonitrile 
oxide, generated in situ from dibromoformaldoxyme (DBF) in presence of a base through the loss of HBr, and 
the required alkene, which acts as a dipolarophile (scheme 6.3). To prevent the side reaction which produces 
furoxane, reactions were performed in organic solvents using an inorganic base, which allowed a slow 
formation of bromonitrile oxide. As known, because of relative frontier molecular orbitals energies, the 1,3-
dipolar cycloaddition gave as a major product (≥ 90%) the 5-substituted bromoisoxazoline over the 4-
substituted bromoisoxazoline. 
Some alkene were commercially available, while others were synthesized through Wittig olefination of 
commercial aldehydes. The alkene used for the synthesis of compound (±)-6 was synthesized starting from 
cis-1,4-dichloro-2-butene, following a published procedure. [40] The racemate was resolved by mean of 
preparative HPLC on chiral stationary phase. (S,S)-6 was crystallized and its absolute configuration was 
determined by X-ray crystallography (by Dr. Leonardo Lo Presti, University of Milan), thanks to anomalous 
scattering due to the heavy bromine atom. Enantiopure analogues of (S,S)-1 were obtained starting from a 
chiral alkene derived from D-serine. The synthetic strategy exploited the intrinsic stability of Garner’s 
aldehyde [(R)-22], which is olefinated and used in the 1,3-dipolar cycloaddition (scheme 6.4). The two 
resulting cycloadducts could be separated as well as their deprotected analogues (scheme 6.5). Mainly because 
of an easier purification (due to lower lipophilicity of the compounds), I preferred to perform diastereoisomers 
Figure 6. 5 3-Bromo-5-phenyl-isoxazoline analogues. 
Scheme 6. 3 Overview of 1,3-dipolar cycloaddition reaction of bromonitriloxide and alkenes. 
Page | 38 
 
separation on the two alcohols. The chance of inverting the order of the cycloaddition and deprotection stepw 
was also took in consideration but, because of a lower (S,R)/(R,R) diastereoisomeric ratio, it was discarded.  
Synthesized compounds were assayed on the isolated enzyme and the results are reported in the following 
table, only showing the potencies of compounds able to produce inhibition. The biochemical assays were 
performed by Professor Stefano Bruno and co-workers, at the University of Parma. 
 
Table 6. 1 Relative potencies of active PfGAPDH inhibitors. Compounds that are not able to inhibit the enzyme are not reported. 
Compound (S,S)-8 (±)-10 (S,S)-9 (±)-6 (±)-15 (±)-4 (S,S)-7 (S,S)-1 (±)-3 (±)-12 (±)-17 
PfGAPDH 
kinact/Ki (s-1M-1) 
10.7 10.3 6.6 4.8 3.1 2.9 2.6 0.7 0.7 0.47 0.34 
 
  
Scheme 6. 4 Synthesis of alkenes to be uses as dipolarophiles in 1,3-dipolar cycloaddition reaction. 
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Scheme 6. 5 Synthetic scheme of 3-bromoisoxazoline compounds. 
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Several analogues from both series showed greater potency compared to (S,S)-1. The most active compounds 
were characterized by an amino ester moiety, showing that the free carboxylate is not implicated in any key 
interaction. Only few compounds of the 5-phenyl series showed inhibitory activity, but, notably, compound 
(±)-10 was among the most potent compounds, unequivocally demonstrating the the amino acidic portion is 
not necessary for the recognition by PfGAPDH. A subset of compounds was submitted to a computational 
study in order to rationalize the obtained range of potency. Covalent docking studies of the two most potent 
compounds were performed by the group of Professor Ettore Novellino. For (S,S)-8, two hydrogen bonds were 
observed between the isoxazoline nitrogen and Cys153 backbone NH, and between the carbonyl oxygen and 
a NAD+ ribose hydroxyl. The methoxy group establishes a hydrophobic interaction with Ala184 side chain 
and a weak hydrogen bond with Thr183 hydroxy group; the protonated amine is not involved in any interaction. 
When compound (±)-10 was docked into the PfGAPDH-NAD+ binary complex, both the isoxazoline and the 
nicotinamide rings adopted a different orientation from the one observed for (S,S)-8. This allows the phenyl 
ring two establish two π-cation interactions on its two faces, one with the protonated pyridinium of NAD+ and 
the other with Arg237 side chain. 
 
Figure 6. 6 Binding modes of (S,S)-8 and (±)-10 (A and B, respectively). The enzyme structure is depicted in blue. The inhibitors, the 
NAD+, and the interacting residues are depicted as sticks with atomic positions colored red O, blue N, orange P, yellow S, and C 
magenta for the inhibitors and cyan for the cofactor and for the enzyme residues in the active site. 
However, these findings were not sufficient to explain the great differences in observed activity despite similar 
binding modes. An exhausting answer to this discrepancy was obtained through the analysis of the electronic 
properties of the inhibitors. In the series related to (S,S)-1, activity was proportional to the ability of the 5-
substituent to withdraw electrons from the electrophilic carbon, while for the 5-phenyl substituted analogues 
activity was correlated to the electron density of the aromatic ring. Noticing the proximity of the side chain of 
Tyr323 to the oxygen atom of the 3-bromoisoxazoline, I thought that introducing a group able to establish 
interactions in that position could be 
positive in terms of efficacy. Due to 
chemical accessibility of compound 
(±)-10, I used it as model compound 
to replace the 3-bromoisoxazoline 
warhead with other electrophiles. Figure 6. 7 Structures of compounds (±)-51, (±)-52 and (±)-53. 
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In compound (±)-51 I introduced a 3-chloroisoxazoline, while in compounds (±)-52 and (±)-53 a 1-alkyl-3-
chloro-pyrazoline, which allowed to introduce an additional position of diversification (fig. 6.7). Compound 
(±)-51 was obtained treating (±)-10 with a 10 M solution of HCl in THF leading to bromine/chlorine exchange. 
In order to obtain pyrazolines (±)-52 and (±)-53, a one-pot condensation/cyclization reaction between methyl 
E-cinnamate (54) and hydrazine was performed, obtaining the key intermediate 5-phenylpyrazolin-3-one [(±)-
55]. This intermediate was alkylated through reductive amination or nucleophilic substitution obtaining 
intermediates (±)-56 and (±)-57, which were chlorinated using POCl3 (scheme 6.6). None of these three 
compounds were able to inhibit PfGAPDH. While for (±)-51 this confirmed that 3-chloroisoxazoline is less 
reactive than 3-bromoisoxazoline, compounds (±)-52 and (±)-53 inactivities were in contrast with the results 
obtained during the screening against TbCTPS [39], when some 1-alkyl-3-chloropyrazoline analogues of (S,S)-
1 showed good inhibition potency toward the isolated CTPS. 
In order to demonstrate that the inhibition of PfGAPDH is due to the alkylation of catalytic Cys residue, an 
additional study was necessary. Indeed, beside the one involved in catalysis, each monomer of GAPDH 
possesses 4 reactive cysteine residues (determined upon reaction with iodoacetamide and DTNB) which might, 
at least in principle, react with the 3-bromoisoxazoline. The enzyme was then incubated with inhibitors and, 
after extensive dialysis, MS studies of the undigested and digested protein were performed. In the first case, 
the obtained m/z values were consistent with alkylation of one cysteine residue for each monomer. MS analysis 
of the trypsin-digested enzyme, with comparison of predicted fragments, allowed assessing that the alkylated 
residue was really the catalytic one. This amazing result strengthen the value of 3-bromoisoxazoline as 
warhead, showing in a very clear way how its balanced reactivity is optimal in the design of covalent targeted 
inhibitors. [41] Another important question to be sorted out regarded the ability of inhibitors to discriminate 
between PfGAPDH and hGAPDH. Compounds were then assayed on the isolated human isoform and, in this 
case, a maximum 25% inhibition was observed. This result was, after a careful analysis of all the possible 
explanations, rationalized by a negative cooperativity effect happening after the binding of the first molecule 
of inhibitor to GAPDH. While in P. falciparum isoform this just reduces the binding affinity (explaining the 
bifasic rate of inhibition), in the human enzyme it completely prevents further alkylation. Despite a very fast 
initial phase of inhibition of hGAPDH (faster than the one observed for PfGAPDH), the inhibitors I synthesized 
showed thus a selective action toward the parasitic enzyme. [42] Having a reasonable number of active 
Scheme 6. 6 Synthesis of 3-chloroisoxazoline and 1-alkyl-3-chloro-pyrazoline analogues. 
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compounds in hand, inhibitors were submitted for in vitro activity evaluation toward P. falciparum cultures. 
These biological assays were performed by the group of Professor Donatella Taramelli at the University of 
Milan. D10 and W2 strains of the parasite (chloroquine-sensitive and chloroquine-resistant, respectively) were 
employed. Some compounds showed submicromolar EC50 for both the strains. Without keeping (S,S)-1 in 
consideration, because this compound is likely to exhibit toxic effects through multiple mechanisms, 
compounds (S,S)-8 and (S,S)-9 were the other two active compounds. In particular, (S,S)-9 showed the highest 
activity, even greater on the W2 strain. Toxicity toward human cell lines (HMEC-1) was sensibly lower 
(selectivity index in the range of 104). 
Table 6. 2 Summary of biological assay for the presented compounds. Please note the different dimensions for IC50. 
Compound PfGAPDH  
kinact/Ki (s-1M-1) 
P.falciparum 
D10 IC50 (µM) 
P.falciparum 
W2 IC50 (µM) 
HMEC-1 
IC50 (mM) 
Selectivity 
index 
(S,S)-8 10.7 0.792±0.211 0.880±0.231 34.8±10.4 3.9(104) 
(±)-10 10.3 inact. inact.   
(S,S)-9 6.6 0.368±0.116 0.259±0.048 >63.9 >17.4(104) 
(±)-6 4.8 inact. inact.   
(±)-15 3.1 inact. inact.   
(±)-4 2.9 / /   
(S,R)-58 2.6 inact. inact.   
(S,S)-7 2.6 / /   
(S,S)-1 0.7 0.346±.079 0.341±0.119 19.7±6.9 5.7(104) 
(±)-3 0.7 / /   
(S,S)-59 0.63 0.365±0.110 0.476±0.177 14.9±4.3 3.1(104) 
(±)-12 0.47 / /   
(±)-17 0.34 inact. inact.   
Chloroquine / 0.0186±0.0057 0.486±0.053   
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With the aim of generating more active analogues with improved stability, in view of future development, I 
synthesized compounds (S,R)-58 and (S,S)-59, in which the potentially liable benzyl ester is replaced by a 
benzyl ether or by a benzyl amide, respectively. (S,R)-58 was obtained alkylating (S,R)-40 with benzyl bromide 
in presence of Ag2O and deprotecting the obtained product. These conditions proved to be the most effective, 
among the explored ones (not reported here) for this reaction. Yields were low still acceptable from a drug 
discovery point of view. Coupling (S,S)-41 to benzylamide using the classical EDC/HOBt procedure and 
removing the protective group gave compound (S,S)-59 in good overall yield (scheme 6.7).  
Following the same synthetic approach, I synthesized amino ethers (S,R)-62-64 and amino amides (S,S)-65-68 
in which the position 4 of the phenyl ring was differently substituted (scheme 6.8). For the synthesis of these 
compounds, commercial benzyl bromides and benzyl amines were employed. Notably, it was not possible to 
obtain the compound that derives from the 4-methoxybenzyl bromide. Indeed the 4-methoxybenzyl radical is 
employed as protective group of alcohols, phenols and carboxylates, and is removed in presence of Ag2O or 
strong acids (e.g. TFA), making it unsuitable for the synthesis of a derivative following the above described 
strategy. Compounds (S,R)-58 and (S,S)-59 were assayed on the isolated enzyme and toward P. falciparum 
cultures. The obtained results were conflicting: while (S,R)-58 displayed higher enzyme inhibition activity 
toward PfGAPDH, it was inactive in vitro, instead (S,S)-59 showed growth inhibition activity comparable to 
compound (S,S)-9. I speculated that this discrepancy could be related to a different grade of penetration in 
parasite cells. Looking at calculated physicochemical properties of the two molecules, I noticed that the 
calculated pKa of (S,R)-58 (pKa 8.5) is greater than the one of (S,S)-59 and (S,S)-9 (pKa 7.2 and 6.2, 
respectively). [43] Thus, at physiological pH (7.4) the penetration of (S,R)-57 by simple diffusion is greatly 
reduced by its higher degree of protonation, although different mechanism of penetration (e.g. active transport) 
cannot be ruled out at this moment. In vitro studies to assess the membrane penetration properties of (S,R)-58 
and (S,S)-59 are currently on going, using the PAMPA assay.  
Scheme 6. 7 Synthesis of compouds (S,R)-58 and (S,S)-59. 
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Since the most active molecules possessed the benzyl group and a weakly basic amino group, I synthesized 
compounds (R,S)-83 and (S,S)-84 in which a sulfone group was introduced between the two functionalities, 
working as a linker while reducing the basicity of the amine (calc. pKa 7.4). To obtain them, alcohol (S)-24 
was converted into mesilate (S)-85 and substituted with commercial benzyl mercaptan in presence of a strong 
base (DBU). The obtained intermediate (S)-86 was used as dipolarophile in the 1,3-dipolar cycloaddition with 
bromonitrile oxide obtaining the two separable diastereoisomers (R,S)-87 and (R,S)-88. Oxidation and 
deprotection reactions finally allowed me to obtain the desired compounds (scheme 6.9).  
Compounds (R,S)-83 and (R,S)-84 are currently under evaluation for their activity on isolated PfGAPDH and 
on parasite cultures. 
Scheme 6. 9 Synthesis of the 1,2-(benzylsulfonyl)amines (R,S)-83 and (S,S)-84. 
Scheme 6. 8 Synthesis of compounds (S,R)-62-64 and (S,S)-65-68. 
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6.4 A useful biochemical tool 
Despite the good results obtained with the described compounds, it cannot be assumed that the observed 
antiparasitic activity is related (or is only related) to PfGAPDH inhibition. In order to prove it, there are two 
possible approaches:  
 using GAPDH knockout P. falciparum strains the antiparasitic activity of the compounds should be 
abolished; if instead cells are not viable, they should present similar cellular effects to the one observed 
during the exposure to compounds; 
 since described inhibitors showed irreversible binding, isolating bound enzymes after incubation and 
performing a proteomic study would allow to identify all the inactivated molecules, which may 
underlie cell death. 
The second strategy represents a more convenient way to assess the hypothesis that active compounds killed 
P. falciparum cell through GAPDH inhibition. The major problem is associated with purification of the 
enzyme-compound adducts from a complex mixture. Therefore, I decided to link the 3-Br-isoxazoline scaffold, 
present in all the active compounds, to biotin, which is a molecule well-known for its very high affinity to 
streptavidin. I synthesized molecule (S,S,S,S,R)-91 in which a 1,5-pentyldiamine spacer links biotin to the 
carboxylate of (S,S)-1. In this way I obtained three desired effects:  
 the distance between biotin and the inhibitor is long enough to expect no perturbation of the binding 
with PfGAPDH;  
 the two moieties are linked through stable (at least for in-vitro conditions) amide bonds  which will 
prevent dissociation; 
 the absence of an amino acidic group, due to conversion of the carboxylate into an amide, prevents 
binding to CTPS and other glutamine-dependent enzymes known to interact with Br-Acivicin. 
 
 
 
 
 
 
 
 
 
 
Page | 46 
 
As minor drawback, this way of linking biotin to compounds is known to reduce cell permeation; working on 
cell lysates is then necessary to obtain reliable results. [44] The synthesis of this molecule started from the 
coupling of commercial N-Boc cadaverine (92) and biotin ((S,S,R)-93) using the common EDAC/HOBt 
chemistry. Deprotection of (S,S,R)-94 gave the pure amine (S,S,R)-95 which was coupled to (S,S)-41 with the 
above reported reagents. tert-Butoxycarbonyl protective group of 96 was finally removed under acidic 
conditions and (S,S,S,S,R)-91 obtained and used as a trifluoroacetate salt (scheme 6.10). 
The compound showed inhibition toward PfGAPDH and the planned biochemical studies are still in progress 
at the University of Parma (in collaboration with the group of Prof. Stefano Bruno), therefore I cannot report 
the results of this investigation.  
Scheme 6. 8 Synthesis of compound (S,S,S,S,R)-91*TFA 
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7. Inhibitors of Trypanosoma brucei cathepsin L-like protease (TbCatL 
or rhodesain) 
Rhodesain is the major cysteine protease in T. brucei. [45] In addition to proteolytic activity, it participates to 
several other functions which are essential for the virulence and defense of the parasite. In the past, several 
covalent inhibitors have been described; among the most potent, are the ones characterized by a peptidic 
recognition moiety mimicking the natural substrate coupled to an electrophilic warhead. In this chapter I 
describe the synthesis of new TbCatL inhibitors inspired by known azadipeptide nitriles and containing the 
promising 3-bromoisoxazoline warhead. This project was performed in collaboration with Dr. Roberta Ettari 
from University of Messina. My major role in this work was the synthesis of the warhead in racemic and 
enantiopure form. 
7.1 The multiple roles of TbCatL [46] [47] 
Rhodesain consists of a single peptide chain (215 amino acid 
residues in total) which folds creating two distinct domains. 
Between them, located in a cleft, is the catalytic triad 
Cys25/His162/Asn182. As seen in other proteases, the catalytic Cys 
residue is activated by His, which works as a base catalyst; Asn, 
through a hydrogen bond, stabilizes the correct tautomer of the His 
imidazole ring for catalysis. In addition to proteolysis, the activity 
of TbCatL has been linked to the ability of the parasite to cross the 
BBB and to variant surface glycoproteins (VSGs) turnover. As 
mentioned before, invasion of the CNS by T. brucei represents the 
critical point of HAT: this phase presents indeed the most severe 
symptomatology and often resolves with the death of the patient. It seems that this BBB penetration is 
facilitated by the activation of Gq-protein-coupled receptors (known as protease activated receptors) by 
rhodesain. Variant surface glycoproteins coat the cell membrane of the parasites preventing the host’s immune 
system to reach surface epitopes. VSGs are themselves antigenic but their periodic modification allows the 
parasite to evade immune response, rendering also the development of a vaccine impossible. Another 
hypothesized role of TbCatL is the extracellular degradation of host’s immunoglobulins, further reducing the 
efficacy of immune response. Keeping all this in mind, rhodesain clearly appears a central tool of the parasite 
and its inhibition may be a successful approach for the treatment of such harsh disease. 
Figure 7. 1 Cartoon representation of rhodesain 
(PDB 2P86). The different secondary structures 
are depicted in different colours. 
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7.2 Peptide inhibitors of TbCatL 
Before describing some examples of peptide-
based inhibitors, it is necessary to introduce 
some nomenclature. Both the enzyme pocket 
and the substrate residues (indicated with letters 
S and P, respectively) are numbered according 
to their position with regards to the scissile bond. 
Numbering goes from 1 to n toward the N-
terminus of the substrate and from 1’ to n’ toward the C-terminus of the substrate (fig. 7.2). This way of 
indicating inhibitor subunits greatly helps the discussion of the structure-activity relationships. I will now 
describe some class of peptide inhibitors following a classification based on the chemical properties of their 
warheads. 
7.2.1 Aldehyde and ketone derivatives 
These inhibitors possess an aldehyde or an alkylmethyl-/diazomethyl-ketone as reversible or irreversible 
warhead, respectively. Their recognition moiety is represented by a dipeptide containing lipophilic residues in 
the P1 and P2 sites. kinact/Ki values of these inhibitors are in the 108-107 min-1M-1 range; some of them also 
showed trypanocidal activity in vitro. Cbz-Phe-Ala-CHN2 (89), Cbz-Phe-Phe-CHN2 (90) and Cbz-Phe-Phe-
CH2Cl (91) are ketone derivatives that showed potent enzyme inhibition and growth inhibition of T. b. brucei 
(a subspecies non infective for humans) in the micromolar range (6.1, 4.8 and 3.6 µM, respectively). Two 
peptidyl aldehydes, Cbz-Phe-Tyr-CHO (92) and 1-NapSO2-Ile-Trp-CHO (93), showed higher potency on the 
enzyme and 93 showed great antiproliferative activity (ED50= 18 nM). 
7.2.2 Michael acceptor derivatives 
In this group, we find the well characterized vinyl sulfone irreversible inhibitors (fig. 
7.3). The structure of these inhibitors allowed to investigate the preference for S1’ 
occupancy, showing that the introduction of a phenyl ring with a short linker is 
positive for enzyme inhibition (R= OPh, CH2Ph, Ph), while a longer linker (R= 
CH2CH2Ph) or the modification of the sulfone in a sulphonamide (R= NHPh) reduces 
the activity. Regarding the S2 pocket, it showed preference for large hydrophobic 
residues (R’= iBu, Bn). In addition to Cbz (R’’= OBn), other groups have been 
introduced in the P3 site. Despite lower enzyme inhibition, introduction of groups such as morpholine or 4-
methyl-pyperazine through a urea linker improve pharmacokinetic properties of the inhibitors, such as oral 
bioavailability. Another group of inhibitors reported in literature are polypeptides characterized by the 
presence of fumaric acid acting as electrophile. The most potent ones bear hydrophobic residues (Ile, Phe, 
Chg) at the P2 position and Asn or Glu at the P1 site. Unfortunately, these compounds were not active on T. 
b. brucei cultures, probably because of stability or cell penetration problems. Other acrylic and crotonic acid 
derivatives have been described but some of them behave as non covalent inhibitors. 
Figure 7. 2 Numbering method used for substrate residues and binding 
sites of proteases. 
Figure 7. 3 General structure 
of vinyl sulfone inhibitors. 
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7.2.3 Constrained heterocycle derivatives 
In this class of inhibitors the warhead is represented by an electrophilic 3-term heterocycle (α,β-epoxyester, 
aziridine trans-2,3-dicarboxylate). The epoxide derivatives were linked to the CbzPhe-HPhe recognition 
moiety and showed good enzyme inhibition and promising in vitro activity (micromolar T. b. brucei IC50 and 
significant selectivity toxicity, compared to human cell lines growth inhibition). Aziridines, instead, were 
characterized by a dipeptide, containing a cyclic α or β amino acid, linked to the heterocyclic nitrogen. The 
two esters, usually benzyl esters, should be in trans configuration for covalent inhibition. Despite promising 
activity toward isolated TbCatL, trypanocidal activity of these compounds is just modest. 
7.2.4 Nitrile derivatives 
In these compounds, the Cα of the amino acid residue in the P1 position is replaced 
by a tertiary nitrogen, which binds an alkyl residue and the reactive nitrile. These 
inhibitors react with Cys giving, in a reversible way, an isothiosemicarbazide 
adduct. The occupancy preferences are a methyl group at P1 and, confirming 
precedent observations, a large hydrophobic Phe or Leu residue at P2. At the 
enzyme level, strong inhibition was observed for  compounds carrying at the P3 
position a tert-butyl carbamate (IC50= 0.06 nM, the most potent inhibitor, fig. 7.4), 
a benzyl carbamate and a benzodioxane Some inhibitors showed good inhibition 
of the parasites in vitro with a good correlation with the enzyme inhibitory activity. This might be due to 
optimal penetration into cells and to an increased proteolytic stability, because of the presence of the 
methylated nitrogen at the peptide bond between the P1 and P2 residue. 
7.3 Design and synthesis of 3-bromoisoxazoline inhibitors [48] 
Despite the great number of different warhead used in the 
development of peptidic covalent TbCatL inhibitors, 3-
bromoisoxazoline was never exploited in any series. Because of the 
interesting properties of this electrophile, I planned to couple this 
warhead to known recognition moieties. In particular, I noticed a 
similarity between the azanitrile and the bicyclic compound (±)-6 
(fig. 7.5). In particular, the CH2 of the pyrrolidine ring nicely mimics the methyl bound to the nitrogen involved 
in the peptidic bond and the distances between the nitrogen and the electrophilic carbon are comparable. The 
designed inhibitors are then characterized by the presence of the bicyclic scaffold 
containing the 3-bromoisoxazoline at the P1 site, different amino acid residues at 
the P2 site (Leu, Phe, homoPhe, given the above discussed preferences of the S2 
binding pocket of rhodesain) and different carbamates at the P3 site (fig. 7.6). The 
planned synthetic scheme involves the carbamoylation of the desired enantiopure 
aminoester, followed by ester hydrolysis. The obtained acid is then coupled to amine 
(±)-148, obtained from the deprotection of (±)-6, using EDC/HOBt to prevent 
Figure 7. 4 Structure of the 
most potent TbCatL 
inhibitor, characterized by 
the azadipeptide nitrile 
warhead. 
Figure 7. 5 Comparison of the azanitrile 
warhead and the bicyclic compound 6. 
Figure 7. 6 Structure of 
designed inhibitors. 
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racemization (scheme 7.1). Compounds were initially obtained and assayed as diastereoisomeric mixtures 
because of the impossibility of purification using conventional methods. For some of the more interesting 
pairs, the single diastereoisomers were synthesized starting from enantiopure (R,R)-6 and (S,S)-6, in turn 
obtained after chiral HPLC resolution [see schemes 6.4 and 6.5 for the synthesis of (±)-6]. In particular, 
compounds synthesized as single enantiomers are (S,S,S)-126, (S,R,R)-127, (S,S,S)-134, (S,R,R)-135, (S,S,S)-
142 and (S,R,R)-143. 
 
 
 
 
 
 
 
 
7.4 Biological evaluation 
The new compounds were assayed on the isolated enzyme (table 7.1). The most active mixture was the one 
bearing the allyl carbamate at the P3 site and the homoPhe at the P2 site [(S,S,S)-142/(S,R,R)-143]. The activity 
decreased when the homoPhe was replaced by other residues, while it was completely lost varying the 
carbamate substituent. When Phe is present at the P2 site, both allyl and benzyl carbamates are tolerated, while 
only allyl and tert-butyl carbamates are compatible with Leu at the P2 site. The single diastereoisomers assayed 
displayed similar enzyme inhibition, indicating that the configuration of the two bridging carbons in the 
warhead plays a marginal role. 
The same compounds were assayed on hCatB and hCatL and none of them showed inhibition up to a 
concentration of 100 µM, highlighting great selectivity. Active compounds were also evaluated in vitro against 
T. b. brucei cultures and J774.1 mouse macrophages. The active compounds, although with modest potency, 
were the diastereoisomeric mixture (S,S,S)-138/(S,R,R)-139 (IC50= 16.45 µM) and (S,R,R)-143 (IC50= 32.04 
µM). Interestingly none of the compounds exerted toxic effects toward mammalian cells (IC50> 100 µM). 
 
 
 
 
Scheme 7. 1 Synthetic scheme for the 3-bromoisoxazoline inhibitors. 
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Table 7. 1 Inhibitory data of the presented compounds against rhodesain. 
 
7.5 Discussion 
As often seen in the development of new antiparasitic drugs, promising activity against the target is not always 
reflected in antiparasitic activity, probably because of poor cell penetration. Covalent docking studies allowed 
to understand the relationships between P2 and P3 substituents. In particular, in the case of bulky P2 substituent 
(homoPhe), a small group (e.g. allyl carbamate) at P3 is preferred; when the P2 residue is less bulky (Phe), an 
aromatic substituent at P3 (e.g. benzyl carbamate) is instead preferred. This demand is very likely due to the 
relative sizes of the S2 and S3 pockets. Interestingly, this was confirmed by the observation that inhibitors 
having the Leu residue at the P2 site place the side chain in the S2 or in the S3 pocket depending on the different 
P3 substituent. The ability of the P2 and P3 substituents to exchange the binding with their relative binding 
pockets may be also the reason for the similar activities of the single diastereoisomers. These results represent 
the basis for future development of 3-bromoisoxazoline based covalent inhibitors of rhodesain. The moderate 
activity could be enhanced with proper modifications suggested by the performed docking studies, obtaining 
more potent compounds while preserving the already remarkable high selectivity. 
  
Compound 
TbCatL Ki (µM) or 
% inhibition at 100 µM 
Compound 
TbCatL Ki (µM) or 
% inhibition at 100 µM 
(S,S,S)-124/(S,R,R)-125 11.3% (S,R,R)-135 15.14 ± 0.16 
(S,S,S)-126/(S,R,R)-127 8.36 ± 0.63 (S,S,S)-136/(S,R,R)-137 17.73 ± 1.19 
(S,S,S)-126 8.52 ± 0.57 (S,S,S)-138/(S,R,R)-139 8.41 ± 0.09 
(S,R,R)-127 9.05 ± 0.08 (S,S,S)-140/(S,R,R)-141 15.3% 
(S,S,S)-128/(S,R,R)-129 13.6 ± 0.35 (S,S,S)-142/(S,R,R)-143 2.62 ± 0.21 
(S,S,S)-130/(S,R,R)-131 8.3% (S,S,S)-142 3.35 ± 0.12 
(S,S,S)-132/(S,R,R)-133 13.1% (S,R,R)-143 2.73 ± 0.29 
(S,S,S)-134/(S,R,R)-135 16.78 ± 0.09 (S,S,S)-144/(S,R,R)-145 5.8% 
(S,S,S)-134 16.58 ± 0.59 (S,S,S)-146/(S,R,R)-147 No inhibition 
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8. Inhibitors of Trypanosoma brucei N5,N10-methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase (TbDHCH or TbFolD) [49] 
In this chapter I describe the synthesis of TbDHCH inhibitors. Despite the importance of this enzyme in T- 
brucei metabolism, it has never been taken in consideration as a target by medicinal chemists.  
8.1 The crucial role of DHCH in T. brucei folate metabolism 
Folates are versatile molecules which are widely 
exploited from living beings as cofactors that carry 
monocarbon units. In medicinal chemistry, folate 
pathway has always represented an amazing source of 
biological targets, ranging from biosynthetic to 
reductive enzymes. Successful examples of drugs are 
sulphonamides (DHPS inhibitors) and trimethoprim 
and methotrexate (DHFR inhibitors). The great 
diversities in the pathway and in enzyme isoforms 
from different organisms are at the basis of the 
achievements obtained in this field. For example, 
sulphonamides are not toxic to humans because we do 
not possess the enzymes, such as DHPS, necessary for 
the synthesis of folates, while selectivity of DHFR 
inhibitors is due to the differences in structure among 
microbial and human orthologs. In contrast to 
different organisms, in T. brucei the folate pathway is 
relatively simple (scheme 8.1). The parasite assumes 
folates from the environment and reduces it mainly through DHFR activity (in T. brucei this enzyme is fused 
with a thymidilate synthase, TS) to dihydrofolate (H2F) and tetrahydrofolate (H4F). Another enzyme, pteridine 
reductase-1 (PTR-1), offers an alternative to DHFR-TS for the reduction of folates. H4F is the central point of 
the folate cofactor network. It can be modified by different enzymes generating derivatives bringing a 
monocarbon unit at different states of oxidation. By intervention of the glycine cleavage complex (GCC; T. 
brucei do not possess any serine hydroxymethyl transferase, SHMT), it is converted to N5,N10-
methylenetetrahydrofolate (N5,N10-CH2-H4F). This cofactor can be used from TS for the conversion of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) regenerating H2F. Another 
destiny of N5,N10-CH2-H4F is its oxidation to N10-formyltetrahydrofolate (N10-CHO-H4F). In human, this 
cofactor can be synthesized by the intervention of different enzymes: a cytoplasmatic C1-tetrahydrofolate 
synthase (MTHFD1) possesses methylenetetrahydrofolate dehydrogenase, methylenetetrahydrofolate 
cyclohydrolase and formate-tetrahydrofolate ligase activities, while in mitochondrial two bifunctional 
enzymes with dehydrogenase/cyclohydrolase activity (MTHFD2 and MTHFD2L) and a monofunctional 
Figure 8. 1 Antifolates in clinical use. The target and the 
application of each compound are reported in brackets. 
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formate-tetrahydrofolate ligase (MTHFD1L) are present. [50] In T. brucei, in contrast, only N5,N10-
methylenetetrahydrofolate dehydrogenase/cyclohydrolase (DHCH or FolD) possesses this activity. TbDHCH 
is a bifunctional enzyme, it catalyzes two subsequently reaction in the same catalytic site. The first reaction is 
the oxidation of N5,N10-CH2-H4F to N5,N10-methenyltetrahydrofolate (N5,N10-CH+-H4F), with reduction of 
NADP+. Following, N5,N10-CH+-H4F is hydrolysed to the final product N10-CHO-H4F. This cofactor is essential 
for the methylation of the initial methionyl-tRNAMet in the fMet-tRNAMet, the initiator amino acyl-tRNA in the 
mRNA translation process. This reaction is catalysed by formyl methionyl transferase (FMT) and the cofactor 
is released as H4F. Any involvement of N10-CHO-H4F in purines biosynthesis, differently from many 
organisms, is discarded since T. brucei only depends of foreign sources of purines. Interestingly, DHCH has 
been validated as target for the treatment of bacterial infections [51] and, through genetic and chemical 
approaches, for the treatment or L. major infections, [52] a protozoan parasite related to T. brucei. Because of 
these evidences, I decided to investigate TbDHCH as a target. I selected molecule LY374571 [(S)-149], 
developed as a potential antineoplastic from Ely Lilly researchers, [53] as model compound for the 
development of a new series of inhibitors. 
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8.2 Reassignment of LY374571 structure 
I started this project synthesizing compound (S)-149, following the reported synthetic procedure. [53] The first 
step in the synthesis was the reaction of the 2,5,6-triaminopyrimidin-4-ol (150) with the ethyl 4-
isocyanatebenzoate (151) forming the urea derivative 152. Although, as described, I obtained a single product, 
I found out that it possessed a different connectivity from the one of described in the literature for this 
intermediate. The obtained structure observed by NOE NMR experiments, corresponded to that of intermediate 
153 instead of 152. Indeed, the predicted nucleophilicity of the nitrogens anticipates the formation of 153 
rather than 152, supporting my result. To unequivocally confirm the new structural assignment, I submitted 
the compound to X-ray crystallography. In collaboration with Dr. Leonardo Lo Presti (University of Milan), I 
was thus able to unambiguously determine the structure of the intermediate, which indeed possessed the 
connectivity described by the chemical strucutre 153 (fig. 8.1).  
Scheme 8. 1 Folate pathway in Trypanosoma brucei. 
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The ester was then hydrolysed and the resulting acid (154) was coupled with (S)-glutamate diethylester 
hydrochloride [(S)-158] following a procedure based on the use of CDMT and NMM. Intermediate (S)-155 
was finally hydrolysed obtaining the desired product (S)-156, which describes the actual structure of 
LY374571 (scheme 8.2). In a previous study, a strange electronic density was observed from the X-ray co-
crystal structure of (S)-149 with the DHCH of Acinetobacter baumanii. [54] In particular, the researchers 
observed a structure similar to (S)-156 rather than (S)-149; with my work I have corroborated the hypothesis 
that the structure attributed to LY374571 was not correct.  
  
Figure 8. 2 XRD of the crystal of the product of the first reaction in the synthetic procedure revealed connectivity of intermediate 
153 (different from described intermediate 152). This will ultimately lead to product (S)-156. 
Scheme 8. 2 Synthetic scheme for compound (S)-156. 
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8.3 Design and synthesis of analogues of (S)-156 
Based on the observation that the synthetic intermediate 154 showed a notable enzyme inhibition (60% at 100 
µM), I hypothesized that the glutamate residue of (S)-156 could be replaced by other groups. I then decided to 
perform a structure activity relationship study of this compound focusing on the amino acid tail. In the design 
of new inhibitors, I exploited classical medicinal chemistry strategies such as simplification, homologation 
and addition of aromatic rings that can establish additional interactions with the target. Some of the used amino 
esters were commercially available while others were synthesized from the corresponding amino acid (scheme 
8.3). With the aim of understanding the optimal 
distance between the two carboxylates, I 
synthesized the derivative coupled with (S)-
aspartic acid [(S)-175] and with (S)-2-
aminoadipate [(S)-176], the lower and the higher 
homologs of (S)-glutamate, respectively. I also 
synthesized analogues in which the proximal or 
the distal carboxylate is removed: this was 
achieved using γ-amino butyrate and (S)-alanine 
as amino acid tails [compounds 177 and (S)-178, 
respectively]. Among this subset of analogues, I 
synthesized a derivative in which only the distal 
group is present but only two methylenes separate 
it from the amino group (β-alanine residue, 
compound 179). Lastly, (S)-phenylalanine and 
(S)-tyrosine were exploited as amino acidic tails 
[compounds (S)-180 and (S)-181, respectively]. The phenyl ring of these derivatives may establish interactions 
with the amino acid residues present in the active site, such as π-π interactions or π-cation interactions, giving 
a stronger binding to the enzyme. Moreover, (S)-181 presents a hydroxyl group, able to form hydrogen bonds 
with the amino acid residues or with the NH or CO groups of the enzyme backbone. The synthesis of these 
analogues followed the one described for (S)-156 with the use of the desired amino ester (ethyl or methyl ester) 
in the coupling step with 154. 
Scheme 8. 3 Amino esters hydrochloride employed in the SAR study. 
Above: synthesized ones; below: purchased ones. 
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8.4 Biological assays 
A subset of the presented compounds [(S)-156, (S)-176, 177, (S)-178, (S)-180 and (S)-181] were assayed on 
isolated TbDHCH. With the exception of 177, all showed a competitive micro/submicromolar inhibition of the 
enzyme, remarking the importance of the proximal carboxylate for activity. Compounds (S)-176 and (S)-180 
were about two times more potent than the model compound (S)-156, indicating that the distal carboxyl group 
can be moved to a different distance or it can be removed. The difference in activity between (S)-180 and (S)-
181 could be due to a steric clash between the hydroxyl group of (S)-181 and a residue in the active site. The 
compounds were assayed on T. brucei cultures and only (S)-156 showed a weak growth inhibition. This result 
was very disappointing considering the promising activities of the analogues towards the enzyme. A good 
result is the relative low toxicity of these compounds toward human cell cultures (THP1 macrophages were 
used). 
 
Table 8. 1 Resume of the biological assays (against isolated enzyme, T. brucei and human macrophages cultures). 
Compound TbDHCH Ki (µM) T. brucei IC50 (µM) THP1 IC50 (µM) 
(S)-156 1.1 ± 0.8 49 ± 3.2 194 ± 8.2 
(S)-176 0.48 ± 0.7 No inhibition 90 ± 16 
177 168 ± 8.5 No inhibition 98 ± 12 
(S)-178 3.2 ± 0.3 No inhibition 113 ± 17 
(S)-180 0.54 ± 0.08 No inhibition 94 ± 8 
(S)-181 7.3 ± 0.7 No inhibition 77 ± 7 
 
Scheme 8. 4 Synthesis of analogues of (S)-156. 
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8.5 TbDHCH crystal structure and computational docking studies 
The group of Professor William N. Hunter 
determined the structure of TbDHCH in 
ternary complex with compound (S)-156 and 
NADP+ cofactor (at 2.05 Å resolution, PDB 
4CJX). (fig. 8.3 A). The enzyme is a dimer of 
two subunits of 297 amino acid residues. Each 
subunity consists in 11 α-helices and 11 β-
sheet organized in a C-terminal NADP+-
binding domain (with the characteristic 
Rossmann fold) and an N-terminal substrate 
binding domain. The pyrimidine is stacked 
between Lys56 and Gln100 residues (which 
are in contact through a hydrogen bond) one 
one side and Ile174 on the other side. Asp123 
side chain, backbone carbonyls of Leu101 and 
Val99, and the backbone amide of Leu101 are 
also involved in interaction with the pyrimidine 
head of (S)-156. Moreover, solvent mediated 
interactions link the pyrimidine oxygen to the 
side chains of Lys56 and Asp123; this last 
residue also binds the urea carbonyl. The 
phenyl ring of (S)-156 establish a π-π 
interaction with Tyr52 side chain, on one face, 
and van der Waals interactions with the side 
chains of Gly276, Pro277 and Thr279. The side 
chains of Thr, Leu, Leu and Pro form a 
hydrophobic channel in which the tail of the 
inhibitor is positioned. The α-carboxylate 
establishes a hydrogen bond with the side chain 
nitrogen of Gly273 and a long-range ionic 
interaction with Arg10; the γ-carboxylate 
similarly interacts with Arg54. Bindings of (S)-176 and (S)-180 were predicted by means of docking studies. 
The homologation of the glutamate tail allows the γ-carboxylate to establish an ionic interaction with Arg54 
or Arg10 (in two different plausible binding modes) at a closer distance and this may cause the observed 
increase in affinity. Two different binding modes were also described for (S)-180. In the first one the phenyl 
ring establishes a π-cation interaction with Arg10, while in the other the same group establishes hydrophobic 
Figure 8. 3 A The dimer of TbFolD. Secondary structure is 
depicted as helices colored cyan, β-strands red, and loops and 
coils brown. NADP+ and (S)-156 are depicted as sticks with 
atomic positions colored red O, blue N, orange P and C yellow 
for the co-factor, green for the inhibitor; B (S)-156 bound in the 
active site of TbFolD. The polypeptide is depicted as off-white 
ribbon, the interacting residues, and the nicotinate moiety of the 
cofactor, which was modeled, are represented with C atoms as 
orange sticks, the ligand as cyan sticks. All O, N, and H atom 
positions are red, blue, and white, respectively. Blue dashed lines 
represent potential hydrogen bonding interactions. 
A 
B 
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contacts with Tyr52, Tyr250 and Leu252. Because of the loss of activity with the introduction of a hydroxyl 
group in compound (S)-181, it is likely that only the second pose is relevant. 
8.6 Conclusions 
In this project I described the first series of TbDHCH inhibitors, selecting (S)-156 as the reference compound 
and performing a study of the structure activity relationships around the amino acidic tail. In particular, I 
showed how the replacement of the glutamate residue with a 2-amino adipate [(S)-176] or a phenylalanine 
[(S)-180] residues generates a sensible improvement in the inhibitory potency of these analogues. The obtained 
results were explained through docking studies using the X-ray crystal structure of the ternary complex (S)-
156-NADP+-TbFolD. Considering the similarities in the physicochemical properties of these compounds, I 
speculate that modifications in the amino acidic tail, while improving potency, may reduce the affinity towards 
transporters, possibly involved in the active transport of the inhibitors through the parasite membrane. Giving 
the low lipophilicity of these compounds it is indeed unlikely that they can penetrate into cells through simple 
diffusion. Results obtained in this study represent a solid base for the future development of effective inhibitors 
of TbDHCH. 
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9. Human lysophosphatidic acid acyl transferase (hLPAAT) inhibitors 
as new anti-Chlamydia agents 
In a previous work, CI-976 (182), a molecule able to inhibit the enzymes acyl-CoA:cholesterol acyl transferase 
(ACAT) and lysophosphatidic acid:acyl-CoA acyl transferase (LPAAT) was found able to inhibit the growth 
of C. trachomatis in human cells. Herein, I describe the design and synthesis of analogues of 182 with the aim 
of generating a more potent and safe compound. 
 
Figure 9. 1 Structure of the dual LPAAT and ACAT inhibitor CI-976. 
 
9.1 Correlation of hLPAAT inhibition and C. trachomatis growth inhibition [55] 
182 is a long chain saturated aryl amide that was firstly described as an ACAT inhibitor during a SAR 
campaign of related compounds. [56] Later on, this molecule showed the additional ability of inhibiting a 
human specific Golgi-associated LPAAT. [57] This membrane-associated enzyme is widely expressed and is 
involved in the Kennedy pathway (the de novo synthesis of glycerophosholipids). In humans, six isoforms (α-
ζ) of this enzyme are known. [58] LPAAT catalyzes the conversion of lysophosphatidic acid (LPA) in 
phosphatidic acid (PA), which can be further modified to other lipids (TAG, PE, PC, PS, PI, PG, CL; scheme 
9.1). [59]  
 
Scheme 9. 1 LPAAT catalyzes the conversion of LPA to PA, the key intermediate of the de novo biosynthesis of lipids. 
 
Compound 182 showed also to cause an accumulation of transferrin (Tf) in the Rab11-positive compartment 
(specific for the slow recycling pathway of Tf) in human cells. [60] The inhibition of hLPAAT was correlated 
to the ability of 182 to hamper the development of Chlamydia inclusions in human cells, observed in another 
work. Rab11 vescicles were found to be intimately associated with chlamydial inclusion, and they probably 
represent the source of iron for the parasite; the delay in the recycling pathway caused by 182 led to the 
accumulation of iron-laden vescicles around Chlamydia inclusions, with inhibition of chlamydial growth 
(probably due to iron overload, fig. 9.2). Since another dual ACAT/LPAAT inhibitor (FR179254) showed the 
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same anti-chlamydial effect, while a specific ACAT inhibitor (Sandoz 58-035) turned out to be inactive, 
LPAAT inhibition was linked with the antibacterial properties of 182, despite the biological connection 
between enzyme inhibition and Tf recycling delay are still to be elucidated. [55] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. 3 Structures of compounds used to assess the correlation of LPAAT inhibition and anti-chlamydial activity.  
 
 
 
 
 
 
  
Rab5 Rab11 
Rab4 
Plasma 
membrane 
Early 
endosome 
Chlamydial 
inclusion LPAAT 
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Figure 9. 2 Slow recycling pathway of Tf and its relationship with C. trachomatis inclusion. Rab5 positive early endosomes 
mature to Rab11 comparts that fuse with Rab4 for recycling back to the plasma membrane. Approximately the 20% of Tf is 
recycled by this pathway, which is probably used by C. trachomatis for iron supply. Several evidences linked LPAAT inhibition 
with a delay in this pathway, which results in iron overload and, lastly, growth abrogation. [55] 
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9.2 Design and synthesis of new CI-976 analogues 
The structure of 182 is quite simple, nevertheless peculiar features could be idenfied, in particular: the amide 
group, the α-methyl groups, the electron rich aromatic ring and the long saturated aliphatic chain. In order to 
generate more potent analogues, my strategy was to introduce little modifications at the groups listed above 
and then to proceed with a deeper study around the most promising compounds. Initially, I focused on the 
substitution of the α position of 182. I investigated the role of the methyl groups synthesizing analogues (±)-
183 and 184, in which one or both groups were removed. Another modification I introduced was the 
replacement of the two methyl groups with two fluorine atoms (compound 185). The CF2 group is known to 
behave as an oxygen atom, therefore compound 185 should possess properties similar to a carbamate; 
moreover, the fluorine atoms might establish an intramolecular hydrogen bond with the amide proton, resulting 
in a stable five member ring-like structure  
In order to obtain (±)-183, ethyl laurate (186) was methylated to give intermediate (±)-187 and then hydrolized. 
The resulting acid (±)-188 was condensed with aniline 189, obtained reducing the commercially available 
nitrobenzene 190. Condensation of the same aniline with lauric acid (191) gave compound 184 (scheme 9.2). 
 
 
 
 
 
 
 
 
 
Scheme 9. 2 Synthesis of (±)-183 and 184. 
Page | 63  
 
The strategy for the synthesis of 185 involved, as first step, the Reformatzky reaction between decyl aldehyde 
(192) and the bromo acetate 193 obtaining intermediate (±)-194. This reaction was already reported in 
literature [61] and allowed to efficiently introduce the 2,2-difluoro functionality. Compound (±)-194 was then 
deoxygenated following the Barton-McCombie procedure, which exploits the ability of imidazolyl 
thionocarbonates to form radicals. Tributyltin hydride, activated by exposure to high temperatures (refluxing 
toluene), was used as a source of radicals. Compound (±)-195, obtained treating (±)-194 with 1,1’-
thiocarbonyldiimidazole, was slowly added to the reaction mixture in order to prevent side reactions of the 
radical intermediates. The convertion to the α-gemdifluoro ester 196 was fast and very efficient. Rather than 
submitting ester 196 to a hydrolysis/coupling sequence, I performed a direct convertion to amide. Taking 
advantage of the absence of acidic protons in 196, I could treat it with the anion of aniline 189, generated in 
presence of a strong base (LiHMDS, specifically) obtaining the target compound 185 (scheme 9.3). 
Another approach that I followed, was the inclusion of the methyls into carbocyclic rings of variable size, 
introducing a certain degree of rigidification to the structure. In particular, I synthesized the α-carbocyclic 
derivatives 197, 198 and 199, characterized by the presence of a 4, 5 and 6-terms ring. The varying ring size 
allows the tuning of the bond angle between the alkyl chain and the aryl amide with a potential influence on 
the activity. To obtain these derivatives, different cycloalkane esters [(±)-200, (±)-201 and (±)-202] were 
alkylated with 1-bromodecane (203). The obtained esters (204-206) were converted to amides 197, 198 and 
199 following the same strategy used for the synthesis of 185. The initially designed compounds also included 
the α-cyclopropane derivative, as this represents the direct analogue of 182. Surprisingly, when 207 was 
submitted for alkylation under the same conditions used for the synthesis of the carbocyclic esters (±)-204-
206, I only obtained a product which was completely different from the expected one. After a thorough 
analysis, I concluded that the product obtained possessed the structure of 208. Indeed, it has been already 
reported in the literature that 207 characteristically undergoes subsequent Claisen-aldol reactions when 
exposed to LDA, giving the tricyclic diester product 208 (scheme 9.4). [62] Although the desired α-
Scheme 9. 3 Synthesis of the α-gemdifluoro compound 185. 
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cyclopropane analogue of 182 might been obtained following other approaches, further attempts were not 
performed, mainly because of time restraints. 
I then turned my attention to the properties of the aromatic ring of compounds 182, 184 and 185. A common 
approach in medicinal chemistry is to synthesize analogues with different substituents that modify the 
electronic properties of the ring or introduce steric biases that force the molecule to assume the desired 
conformation. Thus, I synthesized analogues in which the strongly electron rich 2,4,6-trimethoxyphenyl is 
replaced by electron deficient, neutral or electron rich phenyl rings. Methyl isobutyrate (209) was alkylated 
with 203 and the resulting intermediate 210 was converted to amides 211-213 using the desired aniline and 
LiHMDS (this strategy was possible due to the lack of acidic protons). Following the same strategy, the 
gemdifluoro ester 196 was used to obtain products 214-219. Remarkably, the phenyl rings of compounds 217 
and 219 possess ortho substituents that might have an influence on the conformation of the molecules. In 
particular, the two ortho iso-propyls of 217, due to steric strain, should force the phenyl ring to assume a 
perpendicular position in regards to the carbonyl. In compound 195, instead, the ortho methoxy group might 
establish an intramolecular hydrogen bond with the amide proton creating a stable network of 5 atoms. Lastly, 
the acid 191 was converted in the corresponding acyl chloride which was treated with the desired aniline 
obtaining compounds 220-225, analogues of 184 (scheme 9.5). 
Scheme 9. 4 Synthesis of the α-carbocyclic compounds 197, 198 and 199. 
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For the synthesis of compounds 211-225, commercially available anilines 226-232 were used. 
 
 
 
 
 
 
 
Since compound 185 showed promising activity in the cellular assay (see paragraph 9.3), I focused my 
attention on the synthesis of new analogues in which additional modifications were introduced while 
preserving both the α-gemdifluoro group and the 2,4,6-trimethoxyaniline. A first, sintetically convenient, 
modification was the introduction of a group able to establish a hydrogen bond in the β position of 185. 
Intermediate (±)-194 was converted into the β-hydroxy (H-bond donor) derivatives [(±)-233 and (±)-234] upon 
treatment with anilines 229 and 189, respectively, and LiHMDS. The two new analogues were also converted 
into β-keto derivatives upon facile oxidation with DMP (scheme 9.6). The ketone introduced in compounds 
235 and 236 may act as H-bond acceptor. 
Scheme 9. 5 Synthesis of analogues of compounds 182, 184 and 185 with differently decorated phenyl rings. 
Figure 9. 4 Anilines used for the synthesis of compounds 211-225. 
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In order to investigate the role of the amide proton for the activity, I synthesized compound 237, the N-
methylated analogue of 185. This modification abrogate the ability of the molecule to donate a hydrogen bond 
in that position and also the possibility of tautomerization of the amide is eliminated. This modification is of 
particular interest since the amide nitrogen of 185 could be easily exploited to install additional groups which 
might positively contribute to the activity, as it was done in compound 238, in which I introduced a benzyl 
group (scheme 9.7). 
 
 
 
 
Assuming that 185 might function as a false substrate of LPAAT (due to structural similarity with the acyl 
groups found in the natural substrates), I designed one analogue in which the saturated alkyl chain of 185 is 
replaced by a benzyl residue. This modification was inspired by the α-aryl-propionic acid NSAIDs (e.g. 
ibruprofen, ketoprofen), in which variously substituted phenyl rings effectively mimic the chain of arachidonic 
acid, the pro-inflammatory messenger that can be also found in one of the substrates of LPAAT (arachidonoyl-
CoA). It is indeed common that unsaturated fatty acids are linked to the 2-OH of glycerol in fatty acids. The 
synthetic strategy was analog to the one described for compound 185, but in this case benzaldehyde (239) was 
used as starting material. Compound 243 was obtained in low overall yields but still acceptable for the scope 
of the work (scheme 9.8). Distillation of benzaldehyde prior to reaction would provide a starting material of 
higher purity and potentially higher yields for the Reformatzky reaction (scheme 9.8, step a), while a possible 
explanation for the low yields of the deoxygenation reaction (scheme 9.8, step c) is the increased stability of 
the benzyl radical intermediate compared to the secondary alkyl radical generated from (±)-195. 
 
Scheme 9. 6 Synthesis of β-functionalized analogues of compounds 185 and 216. 
Scheme 9. 7 Synthesis of N-alkylated derivatives of 185. 
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Scheme 9. 8 Synthesis of compound 243. 
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9.3 Biological investigation 
The compounds were tested for the ability to halt the growth of C. trachomatis in human cells in a phenotypic 
screening. HeLa cultures were infected with C. trachomatis serovar L2 and then treated with different 
inhibitors at a 100 µM final concentration. After appropriate staining, the culture were observed with a confocal 
microscope. Some of the compounds showed cytotoxic effects on human cells and these were discarded from 
evaluation, since the bacteria needs healthy cells to develop. The only compound that showed similar activity 
to 182 (evaluating the mean inclusion size) was 185, in which the methyl groups are replaced by two fluorine 
atoms. Figure 9.5 shows the similar anti-chlamydial effect of the two compounds. 
 
a   
          b                            c   
Figure 9. 5 Images of HeLa cells cultures treated infected with C. trachomatis after preincubation with DMSO (a), 182 (b) and 185 
(c). DAPI is depicted in blue, phalloidin in green and C. trachomatis in red. 
To evaluate if the observed activity was due, as hypothesized, to an interaction with hLPAAT and not to a 
direct effect on the parasite, I used Escherichia. coli as a model bacterium, since Chlamydia trachomatis could 
not be object of many biological investigations because of its intrinsic fragility. E. coli possesses a unique form 
of LPAAT, commonly referred to as plsC. In a previous work, it was observed that non-functional mutation 
of plsC results in growth defects of the bacterium when incubated at 42 °C. [63] I then evaluated the growth 
of E. coli cultures under these conditions in presence of representing compounds at a 100 µM concentration. 
For all of them, I just recorded a non significant reduction in the optical dispersion of the cultures, which 
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excludes any involvement of the bacterial isoform. As additional confirmation, enzyme inhibition assay on E. 
coli lysates, performed published procedures, [57] [58] [64] gave negative results.  
9.4 Discussion 
In this part of my thesis, I confirmed the importance that the transferrin pathway has for the C. trachomatis 
inclusion process. However, a proper target deconvolution and the identification of the interaction between 
hLPAAT and the transferrin slow recycling pathway are still required. Unfortunately, only one of the 
synthesized analogues (185) presented significant activity, but these results may serve as guide for future 
studies, which might be aided by structural informations. These molecules may represent the starting point for 
the development of novel antibacterial or, even more generally, novel antimicrobials acting toward obligate 
intracellular parasites that exploit the transferrin pathway for iron acquisition. This approach represents a 
different strategy in the treatment of infections: rather than acting on microbial targets, the inhibition of host’s 
trafficking pathways that are fundamental for the infection but dispensable for the host will result in 
antimicrobial activity. 
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10. Conclusions 
In the present thesis, I described the rational design of new inhibitors of enzymes that play a critical role for 
parasite survival and for virulence.  
For two enzymes, PfGAPDH and TbCatL, both containing a catalytic cysteine residue, I designed covalent 
inhibitors exploiting the new 3-bromoisoxazoline warhead. This electrophilic moiety showed very interesting 
properties, most notably a balanced reactivity toward nucleophiles that results in selective reaction with 
activated cysteines. I propose that this warhead can be employed in the design of covalent inhibitors of other 
enzymes by linking it to a properly designed recognition moiety.  
Describing the first TbFolD inhibitors, I filled a gap in the pharmacological investigation of the reduced folate 
pathway of Trypanosoma brucei. Moreover, the first X-ray structure of TbFolD in the presence of NADP+ and 
an inhibitor was obtained using compound (S)-156. The obtained structural informations can certainly give a 
significant boost to the rational design of new potent TbFolD inhibitors. Further advances in this field might 
probably result in the first effective antifolates acting toward this parasite.  
Despite the low efficacy and the limited number of active compounds presented in the last chapter of this 
thesis, inhibition of LPAAT (which should be further confirmed) was confirmed to represent a general 
approach for the inhibition of the growth of different obliged intracellular parasites, more than Chlamydia 
trachomatis. More studies, such as isolation and structure determination, could prompt the description of more 
effective analogues. 
This thesis represents thus a contribution in the antiparasitic field, with a particular focus on neglected tropical 
diseases (human African trypanosomiasis, trachoma). 
Moreover, all the presented compounds could be exploited to perform structure-activity relationships studies 
on different enzyme isoforms, covering therapeutic areas currently of great interest (e.g. treatment of cancer). 
Some of the GAPDH inhibitors described in my thesis are already under valuation for their antiproliferative 
activity against tumor cell lines. 
As a general final comment, I can conclude that although the selection of a proper molecular target and the 
development of highly potent inhibitors are essential prerequisites, the development of truly effective 
antiparasitic agents is hampered by the difficulty in obtaining compounds able to efficiently permeate the 
parasite cell membrane. Therefore, phisico-chemical properties such as solubility, pKa and logP must be 
always considered and properly tuned. As an alternative, pro-drug approaches could be taken into 
consideration to improve cell penetration, and consequently the efficacy of highly potent enzymatic inhibitors 
characterized by low antiparasitic activity. 
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11. Appendix 
This appendix is an integration to chapter 5. Although a bit out of context from the whole thesis, I decided to 
include a more exhaustive analysis in order to provide a complete sight of the mechanisms of enzyme 
inhibition. Please note that the numbering of the equations follows the one started in chapter 5. 
11.1 Enzyme inhibitors 
Description of competitive mechanism of inhibition is reported in paragraph 5.2.1. 
11.1.1 Non-competitive inhibitors 
Non-competitive inhibitors binds equally to the free enzyme (with dissociation constant Ki) and to the binary 
complex ES. In the latter case the dissociation constant is modified by a factor α (αKi): when α> 1 the affinity 
is greater for the free enzyme while when α< 1 the affinity is greater for the complex ES. The effect of this 
kind of inhibitors is to lower Vmax, as we can see from the velocity equation 14 (and its simplified version, eq. 
15). 
𝑣 =  
𝑉max
(1 +
[𝐼]
α𝐾i
)
[𝑆]
[𝑆] + 𝐾M (
(1 +
[𝐼]
𝐾i
)
(1 +
[𝐼]
α𝐾i
)
)
         (eq.  14)                                𝑣 =
𝑉max[𝑆]
[𝑆] (1 +
[𝐼]
α𝐾i
) + 𝐾M (1 +
[𝐼]
𝐾i
)
        (eq. 15) 
In the case of α= 1 (when the affinity of the inhibitor is the same for E and ES) equation 15 can be further 
modified, giving equation 16. 
𝑣 =
𝑉max[𝑆]
([𝑆] + 𝐾M) (1 +
[𝐼]
𝐾i
)
        (eq. 16) 
The effect of non-competitive inhibitors on the apparent value of KM depends on the value of the correction 
factor α: for α> 1 it is increased, for α< 1 it is decreased and, finally, it is unaffected for α= 1. 
 
Figure 11. 1 Direct fit, semilog and double reciprocal plots for non-competitive inhibitors with α= 1 (highest [I] for the filled square 
curve, lowest [I] for the empty circle curve). 
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For non-competitive inhibitors a diagnostic feature of the double-reciprocal plot is that lines obtained at 
different [I] intersect at a point other than the y-axis. For α= 1, the intersection point is on the x-axis, while for 
α> 1 and α< 1 it is above or below, respectively, the x-axis. Equation 17 is the Cheng-Prusoff equation for non-
competitive inhibitors. 
IC50 =  
[𝑆] + 𝐾M
𝐾M
𝐾i
+
[𝑆]
α𝐾i
    (eq. 17) 
11.1.2 Uncompetitive inhibitors 
Uncompetitive inhibitors bind exclusively to the binary ES complex. We can then expect a decrease of the 
apparent Vmax and, because of the thermodynamic equilibrium between ES, EI and ESI, also the apparent KM is 
decreased. The reaction rate equation is then described by equation 18 that can be simplified giving equation 
19. 
𝑣 =  
𝑉max
(1 +
[𝐼]
α𝐾i
)
[𝑆]
[𝑆] +
𝐾M
(1 +
[𝐼]
α𝐾i
)
         (eq.  18)                                𝑣 =
𝑉max[𝑆]
[𝑆] (1 +
[𝐼]
α𝐾i
) + 𝐾M
        (eq. 19) 
From a double reciprocal plot of an uncompetitive inhibitor at different concentrations we will obtain a series 
of parallel lines with different y-intercept values (because of different Vmax). Recalling that the slope of the line 
in such plot is given by KM/Vmax and that both the values are equally affected by the term (1+[I]/αKi) (see eq. 
18), we can understand why the slope do not vary with different [I]. 
 
Figure 11. 2 Direct fit, semilog and double reciprocal plots for non-competitive inhibitors with α= 1 (highest [I] for the filled square 
curve, lowest [I] for the empty circle curve). 
Equation 20 is the Cheng-Prusoff equation for uncompetitive inhibitors. 
IC50 =  α𝐾i (1 +
𝐾M
[𝑆]
)    (eq. 20) 
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A recapitulatory table for the effect on enzyme parameters for different inhibition modalities is reported below. 
 
Table 11. 1 Effect of inhibitors on apparent steady-state kinetic constant and on catalytic steps. 
Parameter Inhibition modality 
Competitive Non-competitive 
α> 1 
Non-competitive 
α= 1 
Non-competitive 
α< 1 
Uncompetitive 
KM Increase 
linearly with 
increasing [I] 
Increase linearly 
with increasing [I] 
No effect Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly 
with increasing 
[I] 
Vmax No effect Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly 
with increasing 
[I] 
Vmax/KM Decrease 
curvilinearly 
with increasing 
[I] 
Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly with 
increasing [I] 
Decrease 
curvilinearly with 
increasing [I] 
No effect 
Step affected 𝐸 + 𝑆 → 𝐸𝑆 𝐸 + 𝑆 → 𝐸𝑆‡ 𝐸 + 𝑆 → 𝐸𝑆‡ 𝐸 + 𝑆 → 𝐸𝑆‡ 𝐸𝑆 → 𝐸𝑆‡ 
 
11.1.3 Slow and tight binding inhibitors 
Slow binding inhibitors need considerable time to reach the equilibrium between their dissociated and enzyme-
bound forms. Tight binding inhibitors, which often display slow binding behaviour, associate to enzyme with 
a very slow dissociation rate (the equilibrium assumption is not more valid). In both the cases, only apparent 
values of inhibition could be determined and a different analytical treatment is necessary. 
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11.2 The Hill coefficient 
In reality, enzymes might possess multiple binding sites and the binding of one ligand may influence the 
affinity of the same ligand for other binding site (as process referred to as cooperativity). When affinity is 
enhanced we have positive cooperativity while when it is decreased we have negative cooperativity. Moreover, 
it might be that inhibitor/enzyme stoichiometry is different from 1-to-1: the binding of two or more inhibitor 
molecules to one enzyme may be required for inhibition or the binding of one molecule to a binding site of an 
enzyme dimer could be sufficient for the inhibition of both the active sites in the dimer. Equations 7 and 8 are 
thus modified as equations 21 and 22 to take into account these mechanisms. 
𝑣i
𝑣0
=
1
1 + ([𝐼] IC50)⁄
ℎ        (eq. 21)                             % Inhibition =
100
1 + ([𝐼] IC50)⁄
ℎ        (eq. 22) 
The exponential term h is referred to as the Hill coefficient or Hill slope: it is related to the stoichiometry of 
inhibition and it also represents the steepness of the concentration-inhibition relationship. For a 1-to-1 
stoichiometry we have h= 1, which is the normality for the majority of the small molecule inhibitors. Situations 
in which h is significantly different from 1 may also reflect a non-ideal behaviour of the inhibitor. h>> 1 (sharp 
reduction of activity) can be seen for nonspecific inhibition (e.g. protein denaturants), compounds that inhibits 
the enzyme as micelle (and thus IC50 will be reflective of the critical micellar concentration) or tight 
binding/irreversible inhibitors. h<< 1 (very smooth reduction of activity) may be due to the presence non-
equivalent binding pockets in the same enzyme molecule (or an equilibrium of more forms of a single enzyme 
with a binding pocket with different affinity for I) or on separate enzyme molecules that contribute to activity 
(e.g. in the case of insufficient purification). Another reason may be compound aggregation or insolubility at 
high concentration, leading to a less than expected % inhibition at higher concentrations. The following plots 
represent enzyme inhibition with different Hill coefficients. 
 
  
Figure 11. 3 Effect of Hill coefficient on curve shape. 
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12. Experimental procedures 
12.1 Materials and methods 
All reagents and solvents were obtained from commercial suppliers and used without further purification. 
Merck silica gel 60 F245 plates were used as analytical TLC; flash column chromatography was performed on 
Merck silica gel (200-400 mesh). TLC were monitored at 254 nm and 365 nm and developed with a KMnO4 
or a ninhydrin solutions. NMR analysis were performed with a Varian Mercury 300 MHz or a Bruker 400 
MHz spectrometers. 1H, 13C and 19F chemical shifts (δ) are expressed in parts per million (ppm) and coupling 
costants (J) in hertz (Hz). Signal multiplicity is espressed as s (singlet), d (doublet), t (triplet), q (quartet), qui 
(quintet), sex (sextet), sep (septet), or m (multiplet). MW reactions were performed in a CEM Discover 
apparatus. MS analyses were performed on a Varian 320-MS triple quadrupole spectrometer with an electron 
spray ionization (ESI) source. Specific rotatory power was determined with a Jasco P1010 polarimeter. Melting 
points were obtained with a Büchi Melting Point B-540 apparatus. Analytical HPLC was performed using 
Jasco PU-980 pumps and a Jasco UV-975 detector. Preparative HPLC was performed with a Waters 1525 
Binary HPLC pump connected to a Waters 2489 UV/Visible detector. The wavelength used for detection was 
245 nm. 
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12.2 Chemistry 
 
Synthesis of dibromoformaldoxime (DBF) 
 
The synthesis of DBF was performed following a one-pot published procedure [65] with some modifications. 
Glyoxylic acid monohydrate (31 g, 338 mmol) was dissolved in water (200 mL). Hydroxylamine 
hydrochloride (25 g, 338 mmol) was added and the reaction mixture was stirred at room temperature for 20 h. 
NaHCO3 (58.8 g, 700 mmol) was then added portionwise. Subsequently, keeping the temperature of the 
reaction mixture below 10 °C, a solution of bromine (24.1 mL, 396 mml) in DCM (125 mL) was added 
dropwise. Reaction mixture was stirred at room temperature for 3 h. Phases were separated and the aqueous 
phase extracted with DCM (4x60 mL). The pooled organic layers were dried over Na2SO4, filtered and the 
solvent was removed under reduced pressure keeping the temperature below 40 °C. Crystallization with 
petroleum ether afforded the desired product (tipical yields around 25%) as a white solid (m.p.= 67-68 °C) (lit. 
m.p.= 65-66 °C) [65] which was used without further characterization. 
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Synthesis of (R)-tert-butyl 3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate [(R)-20] 
 
A solution of Boc2O (12.5 g, 57.1 mmol) in THF (25 mL) was added dropwise at 0 °C to a solution of (R)-18 
(5.00 g, 47.6 mmol) and NaHCO3 (11.2 g, 133.3 mmol) in water (50 mL). Reaction was stirred at room 
temperature until consumption of (R)-18. Reaction mixture was washed with Et2O (x2), the aqueous phase was 
made acid with 1 M aq. HCl and extracted with EtOAc. The organic phase was dried over anhydrous Na2SO4, 
filtered and the solvent was removed under vacuum obtaining (R)-2-(tert-butoxycarbonylamino)-3-
hydroxypropanoic acid [(R)-19] as a grey oil (9.56 g, quantitative yield) that was used in the following step 
without characterization. 
Rf= 0.39 (DCM/MeOH, 9:1) 
NMM (2.95 g, 26.8 mmol) and N,O-dimethylhydroxylamine hydrochloride (2.61 g, 26.8 mmol) were added 
at -15 °C to a solution of (R)-19 (5.00 g, 24.4 mmol) in dry DCM (95 mL). Reaction mixture was stirred at -
15 °C for 3 h then it was poured into 1 M aq. HCl and ice solution (30 mL). Phases were separated and the 
aqueous extracted with DCM (3x50 mL). The pooled organic layers were washed with brine, dried over 
anhydrous Na2SO4, filtered and the solvent was removed under vacuum obtaining (R)-tert-butyl 3-hydroxy-1-
(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate [(R)-20] as a white solid (5.30 g, 88% yield). 
Rf= 0.54 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 5.60 (d, J= 6.0 Hz, 1H), 4.78 (m, 1H), 3.81 (m, 2H), 3.77 (s, 3H), 3.22 (s, 
3H), 2.67 (m, 1H), 1.44 (s, 9H).  
These NMR data are in keeping with the literature. [66] 
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Synthesis of (R)-tert-butyl 4-(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3-carboxylate [(R)-
21] 
 
PTSA*H2O (202 mg, 1.06 mmol) and 2,2-dimethoxypropane (7.86 mL, 63.9 mmol) were added to a 
suspension of (R)-20 (5.30 g, 21.3 mmol) in benzene (115 mL). The reaction mixture was stirred under reflux 
for 30 min, then the MeOH-benzene azeotrope was distilled over 1 h. Additional 2,2-dimethoxypropane (2.88 
mL, 23.4 mmol) was added and distillation of the azeotrope was continued for 3 h. Benzene was removed 
under reduced pressure, Et2O was added and washed with 5% aq. NaHCO3 and brine. The organic layer was 
dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude product was 
purified by flash chromatography on silica gel (cyclohexane/EtOAc, 8:2 to 1:1) obtaining (R)-tert-butyl 4-
(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3-carboxylate [(R)-21] as a yellow oil (5.29 g, 86% 
yield). 
Rf= 0.25 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3, 1:1 mixture of rotamers): δ= 4.80 (m, 1H), 4.72 (m, 1H), 4.18 (m, 2H), 3.94 (m, 
2H), 3.74 (s, 3H), 3.69 (s, 3H), 3.21 (s, 6H), 1.70 (s, 3H), 1.68 (s, 3H), 1.56 (s, 3H), 1.52 (s, 3H), 1.49 (s, 9H), 
1.41 (s, 9H). Spectroscopic data were consistent with the literature data for this compound. [67] 
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Synthesis of (R)-tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate [(R)-22] 
 
LiAlH4 (347 mg, 9.15 mmol) was added portionwise at 0 °C to a solution of (R)-21 (5.29 g, 18.3 mmol) in dry 
THF (130 mL). The reaction was stirred at 0 °C for 2 h, then sat. aq. KHSO4 (100 mL) and Et2O were added 
and the mixture was stirred at room temperature for 30 min. Phases were separated and the aqueous phase was 
extracted with Et2O (2x75 mL). The pooled organic layers were dried over anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (cyclohexane/EtOAc, 8:2) obtaining (R)-tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate 
[(R)-22] as a yellow oil (3.62 g, 86% yield). 
Rf= 0.25 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3, major rotamer): δ= 9.54 (d, J= 2.1 Hz, 1H), 4.19 (m, 1H), 4.08 (m, 2H), 1.59 (s, 
3H), 1.51 (s, 3H), 1.43 (s, 9H).  
These NMR data are in keeping with the literature. [68]  
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Synthesis of (S)-tert-butyl 2,2-dimethyl-4-vinyloxazolidine-3-carboxylate [(S)-23] 
 
KHMDS (36.4 mL, 0.5 M in toluene, 18.2 mmol) was added to a suspension of methyltriphenylphosphonium 
bromide (6.97 g, 19.5 mmol) in dry THF (30 mL). After stirring at room temperature for 30 min, the reaction 
mixture was cooled at -78 °C and a solution of (R)-22 (3.00 g, 13.0 mmol) in dry THF (15.5 mL) was added. 
The reaction was stirred at room temperature for 3 h. Et2O (60 mL) and water (10 mL) were added, phases 
were separated and the aqueous phase was extracted with Et2O. The pooled organic layers were washed with 
brine, dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude product 
was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 9:1) obtaining (S)-tert-butyl 2,2-
dimethyl-4-vinyloxazolidine-3-carboxylate [(S)-23] as a yellow oil (2.74 g, 93% yield). 
Rf= 0.41 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3, major rotamer): δ= 5.81 (m, 1H), 5.30-5.18 (m, 2H), 4.45-4.20 (m, 1H), 4.04 (dd, 
J= 6.3, 8.7 Hz, 2H), 3.74 (dd, J= 2.2, 8.7 Hz, 2H), 1.60 (s, 3H), 1.51 (s, 3H), 1.44 (s, 9H).  
These NMR data are in keeping with the literature. [69] 
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Synthesis of (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate [(S)-24] 
 
PTSA*H2O (339 mg, 1.78 mmol) was added at 0 °C to a solution of (S)-23 (811 mg, 3.57 mmol) in MeOH 
(35 mL). The reaction mixture was stirred at room temperature for 6 h, then the volume was reduced under 
vacuum and EtOAc was added and washed with sat. aq. NaHCO3. The organic phase was dried over Na2SO4, 
filtered and the solvent was removed under reduced pressure obtaining (S)-tert-butyl 1-hydroxybut-3-en-2-
ylcarbamate [(S)-24] was obtained as a pale yellow oil (387 mg, 58% yield). 
Rf= 0.29 (cyclohexane/EtOAc, 6:4). 
1H-NMR (300 MHz, CDCl3): δ= 5.79 (ddd, J= 5.4, 10.5, 17.1 Hz, 1H), 5.24 (dd, J= 1.2, 17.1 Hz, 1H), 5.19 
(dd, J= 1.2, 10.5 Hz, 1H), 5.00 (d, J= 7.2 Hz, 1H), 4.20 (m, 1H), 3.68 (dd, J= 4.7, 11.3 Hz, 1H), 3.59 (dd, J= 
5.9, 11.3 Hz, 1H), 2.62 (m, 1H), 1.43 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 156.0, 135.5, 116.4, 79.8, 65.0, 54.6, 28.3. 
NMR data are in keeping with the literature. [70] 
[α]D20= - 22.4° (c= 0.55, CHCl3). (lit. – 22.4°) [70]  
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Synthesis of tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-hydroxyethylcarbamate [(S,R)-
40] 
Method A 
 
DBF (2.13 g, 10.5 mmol) and NaHCO3 (4.41 g, 52.5 mmol) were added to a solution of (S)-23 (2.38 g, 2.00 
mmol) in EtOAc (45 mL). The reaction mixture was stirred at room temperature until consumption of (S)-23. 
EtOAc was added and washed with water, dried over anhydrous Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 
9:1) obtaining the cycloadducts (S,R)-38 and (R,R)-39 in a diastereoisomeric mixture as yellow oil (3.59 g, 
98% yield). 
The mixture of (S,R)-38 and (R,R)-39 (4.36 g, 11.3 mmol) was dissolved in 5:1 AcOH/water (100 mL). The 
reaction mixture was stirred at 40 °C for 48 h. The solvent was removed under reduced pressure, EtOAc (100 
mL) was added and washed with water (2x60 mL). The crude was purified by flash chromatography on silica 
gel (cyclohexane/EtOAc, 9:1 to 1:1) obtaining tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-
hydroxyethylcarbamate [(S,R)-40] as a white solid (1.50 g, 43% yield). The calculated diastereoisomeric ratio 
for the 1,3-cycloaddition step was indirectly quantified as 1.4:1 (S,R)-38/(R,R)-39. 
Method B 
 
DBF (2.07 g, 10.2 mmol) and NaHCO3 (3.59 g, 42.7 mmol) were added to a solution of (S)-24 (1.6 g, 8.54 
mmol) in EtOAc (30 mL). The reaction mixture was stirred at room temperature until consumption of (S)-24. 
EtOAc was added and washed with water, dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 7:3) 
obtaining tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-hydroxyethylcarbamate [(S,R)-40] as a 
white solid (1.01 g, 39% yield). This 1,3-cycloaddition step showed a diastereoisomeric ratio of 1:1. 
Rf= 0.37 (cyclohexane/EtOAc, 6:4). 
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1H-NMR (300 MHz, CDCl3): δ= 5.11 (bs, 1H), 4.77 (ddd, J= 8.7, 8.7, 8.7 Hz, 1H), 3.99-3.88 (m, 1H), 3.82-
3.67 (m, 2H), 3.38-3.25 (m, 2H), 1.89 (bs, 1 H), 1.45 (s, 9 H). 
NMR data are in keeping with the literature. [38]  
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Synthesis of (S)-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-butoxycarbonylamino)acetic acid 
[(S,S)-41] 
 
PDC (10.9 g, 29.1 mmol) was added to a solution of (S,R)-40 (600 mg, 1.94 mmol) in DMF (11 mL). The 
reaction mixture was stirred at room temperature for 6 h, then water (34 mL) was added and it was extracted 
with EtOAc (3x25 mL). The organic phase was extracted with 1 M aq. NaOH (4x20 mL), then the organic 
extracts were made acid with 2 M aq. HCl and extracted with EtOAc (3x60 mL). The pooled organic extracts 
were dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure obtaining (S)-2-((S)-
3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-butoxycarbonylamino)acetic acid [(S,S)-41] as a green solid (574 
mg, 91% yield). 
Rf= 0.60 (DCM/MeOH, 9:1 + 1% AcOH). 
1H-NMR (300 MHz, CDCl3): δ= 5.45 (bs, 1H), 5.00 (ddd, J= 3.9, 7.7, 11.0 Hz, 1H), 4.52 (dd, J= 3.9, 8.0 Hz, 
1H), 3.60–3.30 (m, 2H), 1.45 (s, 9H). 
These NMR data are in keeping with the literature. [38] 
 
 
Synthesis of (S)-2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid hydrobromide [(S,S)-
1*HBr] 
 
33% HBr/AcOH (7 mL) was added to (S,S)-41 (200 mg, 0.619 mmol). The reaction mixture was stirred at 
room temperature for 5 min, then the solvent was removed under reduced pressure. The obtained solid was 
crystallized with iPrOH/Et2O. (S)-2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid 
hydrobromide [(S,S)-1*HBr] was obtained as a grey solid (112 mg, 60% yield). 
1H-NMR (300 MHz, D2O): δ= 5.10 (ddd, J= 3.3, 7.5, 11.1 Hz, 1H), 4.06 (d, J= 3.3 Hz, 1H), 3.51 (dd, J= 11.1, 
18.0 Hz, 1H), 3.39 (dd, J= 7.5, 18.0 Hz, 1H). 
13C-NMR (75 MHz, D2O): δ= 169.1, 141.0, 79.3, 55.5, 43.1. 
MS(ESI): m/z calcd for C5H879Br2N2O3: 222.0 (M-HBr); found: 223.0 [M-HBr+H]+.  
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Synthesis of (±)-2-(3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid [(±)-3] 
 
DBF (0.40 g, 2.0 mmol) and NaHCO3 (0.84 g, 10.0 mmol) were added to a solution of 3-buten-1-ol (44) (167 
µL, 2.00 mmol) in EtOAc (2.8 mL). The reaction mixture was heated in microwave reactor at 80 °C for 1 h. 
Few drops of water were added and the solvent was decanted. The organic phase was washed with water (2x10 
mL), dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 1:1) obtaining (±)-2-(3-bromo-4,5-
dihydroisoxazol-5-yl)ethanol [(±)-45] as a yellow oil (237 mg, 61% yield). 
Rf= 0.26 (cyclohexane/EtOAc, 1:1) 
1H-NMR (300 MHz, CDCl3): δ= 4.84 (dddd, J= 5.2, 8.5, 8.5, 10.2 Hz, 1H), 3.79-3.72 (m, 2H), 3.32 (dd, J= 
10.2, 17.3 Hz, 1H), 2.94 (dd, J= 8.5, 17.3 Hz, 1H), 2.59 (bs, 1H), 2.03-1.80 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 138.1, 80.2, 59.2, 47.0, 37.5. 
NaIO4 (1.04 g, 4.88 mmol) and a catalytic amount of Ru2O·H2O (2.5 mg) were added to a solution of (±)-45 
(237 mg, 1.22 mmol) in 1.5:1:1 H2O/MeCN/CCl4 (9.2 mL). The suspension was vigorously stirred at room 
temperature for 45 min, then DCM (10 mL) and water (10 mL) were added. The organic layer was separated 
and the solvent was removed under reduced pressure. The residue was dissolved in EtOAc (5 mL), extracted 
with 10% aq. K2CO3 (3x5 mL). The aqueous phase was made acidic with 2 M aq. HCl and newly extracted 
with EtOAc (3x5 mL). The organic extracts were washed with brine, dried over anhydrous Na2SO4, and the 
solvent removed under vacuum obtaining (±)-2-(3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid [(±)-3] as a 
white solid (185 mg, 73% yield) which recrystallizes from n-hexane/EtOAc as white prisms (m.p.= 82-83 °C) 
(lit. m.p.= 82-83 °C). [39] 
Rf= 0.40 (DCM/MeOH, 95:5 + 1% AcOH) 
1H-NMR (300 MHz, CDCl3): δ= 5.05 (dddd, J= 6.0, 7.3, 7.3, 10.4 Hz, 1H), 3.45 (dd, J=10.4, 17.4 Hz, 1H), 
3.00 (dd, J= 7.3, 17.4 Hz, 1H), 2.90 (dd, J= 6.0, 16.8 Hz, 1 H), 2.54 (dd, J= 7.3, 16.8 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 175.3, 137.6, 77.5, 46.8, 39.2. 
MS(ESI): m/z calcd for C5H679BrNO3: 206.9; found: 205.8 [M-H]-. 
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Synthesis of (±)-tert-butyl (3-bromo-4,5-dihydroisoxazol-5-yl)methylcarbamate [(±)-4] 
 
tert-Butyl allylcarbamate (44) was synthesized following published synthetic procedure. [71] 
DBF (2.7 g, 13.0 mmol) and NaHCO3 (4.2 g, 50.0 mmol) were added to a solution of 44 (1.8 g, 11.5 mmol) in 
EtOAc (50 mL). The reaction mixture was stirred at room temperature until consumption of 44. Water was 
added, phases were separated and the aqueous phase was extracted with EtOAc (3x15 mL). The organic 
extracts were dried over anhydrous Na2SO4 and the solvent was removed under vacuum. The crude product 
was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 85:15) obtaining (±)-tert-butyl (3-
bromo-4,5-dihydroisoxazol-5-yl)methylcarbamate [(±)-4] as a white solid (2.92 g, 91% yield) which 
recrystallizes as colourless prisms from petroleum ether/EtOAc (m.p.= 69-70 °C) (lit. m.p.= 69-70 °C). [71] 
Rf= 0.29 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 4.88 (bs, 1H), 4.83-4.74 (m, 1H), 3.44-3.38 (m, 2H), 3.27 (dd, J=10.8, 17.4 
Hz, 1H), 3.04 (dd, J= 7.5, 17.4 Hz, 1H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 156.3, 137.7, 80.9, 80.0, 43.8, 43.2, 28.4. 
MS(ESI): m/z calcd for C9H1579BrN2O3: 278.0; found: 279.1 [M+H]+. 
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Synthesis of (±)-methyl 3-bromo-4,5-dihydroisoxazole-5-carboxylate [(±)-5] 
 
DBF (200 mg, 0.986 mmol) and NaHCO3 (414 mg, 4.93 mmol) were added to a solution of methyl acrylate 
(133 µL, 1.48 mmol) in EtOAc (2.5 mL). The reaction mixture was vigorously stirred at room temperature for 
30 h. EtOAc (10 mL) was added and the organic phase was washed with water (7 mL), dried over anhydrous 
Na2SO4, filtered and evaporated to afford (±)-methyl 3-bromo-4,5-dihydroisoxazole-5-carboxylate [(±)-5] as 
a yellow oil (190 mg, 93% yield). 
Rf= 0.37 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 5.10 (dd, J= 8.2, 10.2 Hz, 1H), 3.83 (s, 3H), 3.55-3.47 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 169.6, 137.0, 78.4, 53.3, 45.0. 
MS(ESI): m/z calcd for C5H679BrNO3: 206.9; found: 207.8 [M+H]+. 
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Synthesis of (±)-tert-butyl 3-bromo-6,6a-dihydro-3aH-pyrrolo[3,4-d]isoxazole-5(4H)-carboxylate [(±)-6] 
and HPLC resolution of the racemate 
 
tert-Butyl 2,5-dihydro-1H-pyrrole-1-carboxylate (29) was obtained following published synthetic procedure. 
[40] 
DBF (3.6 g, 17.7 mmol) and NaHCO3 (3.81 g, 44.3 mmol) were added to a solution of 29 (1.5 g, 11.5 mmol) 
in EtOAc (30 mL). The reaction mixture was stirred at room temperature until consumption of 29. Water was 
added, phases were separated and the aqueous phase was extracted with EtOAc. The organic extracts were 
dried over anhydrous Na2SO4 and the solvent was removed under vacuum. The crude product was purified by 
flash chromatography on silica gel (cyclohexane/EtOAc, 9:1 to 8:2) obtaining (±)-tert-butyl 3-bromo-6,6a-
dihydro-3aH-pyrrolo[3,4-d]isoxazole-5(4H)-carboxylate [(±)-6] as a white solid (2.58 g, quantitative yield) 
which recrystallizes from iPrOH as white prisms (m.p.= 50-52 °C) (lit. m.p.= 50-52 °C). [72] 
Rf= 0.43 (cyclohexane/AcOEt, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 5.24 (ddd, J= 1.4, 5.8, 8.8 Hz, 1H), 4.02-3.86 (m, 3H), 3.52 (dd, J= 5.8, 13.2 
Hz, 1H), 3.41 (dd, J= 8.0, 12.1 Hz, 1 H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 154.2, 139.6, 85.0, 80.8, 57.4, 54.0, 48.6, 28.5. 
MS(ESI): m/z calcd for C10H1579BrN2O3: 290.0; found: 291.0 [M+H]+. 
The racemic mixture was resolved by HPLC using a Kromasil 5-AmyCoat 21.2x250 mm column and n-
hexane/iPrOH 9:1 as eluent (flux= 15 mL, λ= 220 nm, Vinjection= 1 mL; c= 100 mg/mL).  
(-)-6 tR= 8.99 min; [α]D20= - 100.5° (c= 0.60, CHCl3). 
(+)-6 tR= 10.81 min; [α]D20= + 101.0° (c= 0.64, CHCl3). 
(+)-6 was crystallized from EtOAc/n-hexane 1:20 as colourless prisms and its absolute configuration was 
determined by X-ray crystallography analysis exploiting anomalous scattering due to the presence of the heavy 
bromine atom. (+)-(S,S)-6; (-)-(R,R)-6. 
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Synthesis of (S)-2-(benzyloxycarbonylamino)-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid 
[(S,S)-7] 
 
NaHCO3 (84 mg, 1.00 mmol) was added to a solution of (S,S)-1*HBr (76 mg, 0.250 mmol) in 1:1 water/THF 
(8 mL). The reaction mixture was stirred at room temperature for 5 min, then benzyl chloroformate (39 mL, 
0.28 mmol) was added dropwise and the reaction was stirred at room temperature for 1 h. After disappearance 
of the starting material, the organic solvent was removed under reduced pressure and the aqueous phase was 
washed with Et2O (1x4 mL), made acidic with 2 M HCl and extracted with EtOAc (3x5 mL). The pooled 
organic extracts were dried over anhydrous Na2SO4, and the solvent evaporated obtaining (S)-2-
(benzyloxycarbonylamino)-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetic acid [(S,S)-7] as an hygroscopic 
white foam (83 mg, 93% yield). 
Rf= 0.35 (DCM/MeOH, 95:5 + 1% AcOH). 
1H -NMR (300 MHz, CDCl3): δ= 8.90 (bs, 1H), 7.40–7.25 (m, 5H), 5.92 (d, J=7.7 Hz, 1H), 5.12 (s, 2H), 4.98–
4.85 (m, 1H), 4.58 (dd, J=3.6, 8.2 Hz, 1H), 3.58–3.18 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.7, 156.4, 138.7, 135.9, 128.9, 128.7, 128.4, 81.9, 67.9, 56.6, 44.2. 
[α]D20= + 167° (c= 0.20, H2O). 
MS(ESI): m/z calcd for C13H1379BrN2O5: 356.0; found: 357.0 [M+H]+. 
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Synthesis of (S)-methyl 2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-butoxycarbonylamino)acetate 
[(S,S)-42] 
 
Trimethylsilyl diazomethane (155 µL, 2.0 M in hexanes, 0.310 mmol) was added at 0 °C to a solution of (S,S)-
41 (100 mg, 0.310 mmol) in 7:3 toluene/MeOH (2.0 mL). Reaction mixture was stirred at room temperature 
for 1 h, then it was quenched with few drops of AcOH. The solvent was removed under reduced pressure and 
the crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 8:2 to 7:3) 
obtaining (S)-methyl 2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-butoxycarbonylamino)acetate [(S,S)-
42] as a yellow oil (71 mg, 68% yield). 
Rf= 0.44 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 5.50 (d, J= 8.0, 1H), 4.92 (ddd, J= 3.3, 7.2, 10.5 Hz, 1H), 4.42 (dd, J= 3.3, 
8.0 Hz, 1H), 3.78 (s, 3H), 3.44 (dd, J= 7.2, 17.3 Hz, 1H), 3.36 (dd, J= 10.5, 17.3 Hz, 1H), 1.42 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 169.3, 155.3, 138.2, 82.2, 80.9, 56.6, 53.2, 44.5, 28.4. 
[α]D20= + 158.1° (c= 0.50, CHCl3). 
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Synthesis of (S)-methyl 2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetate [(S,S)-8] 
 
TFA (163 µL, 2.11 mmol) was added at 0 °C to a solution of (S,S)-42 (71 mg, 0.211 mmol) in DCM (380 µL). 
Reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was quenched 
with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The pooled 
organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel using 100% EtOAc as eluent, 
obtaining (S)-methyl 2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetate [(S,S)-8] as a red oil (26 mg, 
52% yield). 
Rf= 0.40 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 5.00 (ddd, J= 3.5, 8.0, 10.7 Hz, 1H), 3.92 (d, J = 3.5 Hz, 1H), 3.75 (s, 3H), 
3.33 (dd, J= 8.0, 17.3 Hz, 1H), 3.20 (dd, J= 10.7, 17.3 Hz, 1H), 1.90 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 172.0, 138.2, 82.7, 56.2, 52.8, 42.5.  
[α]D20= + 95.7° (c= 0.34, CHCl3). 
MS(ESI): m/z calcd for C6H979BrN2O3: 236.0; found: 236.9 [M+H]+.  
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Synthesis of (S)-benzyl 2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-butoxycarbonylamino)acetate 
[(S,S)-43] 
 
Benzyl bromide (66.2 µL, 0.557 mmol) was added to a solution of (S,S)-41 (150 mg, 0.464 mmol) in DMF 
(1.5 mL). Reaction mixture was stirred at 50 °C for 1 h, then EtOAc was added and washed with 1 M aq. HCl, 
5% aq. NaHCO3 and brine. The organic phase was dried over anhydrous Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 95:5 to 8:2) obtaining (S)-benzyl 2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(tert-
butoxycarbonylamino)acetate [(S,S)-43] as a yellow oil (160 mg, 83% yield). 
Rf= 0.51 (cyclohexane/EtOAc, 3:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.40−7.30 (m, 5H), 5.55 (d, J= 6.0 Hz, 1H), 5.22 (d, J = 12.0 Hz, 1H), 5.14 
(d, J= 12.0 Hz, 1H), 4.83 (ddd, J = 3.6, 7.4, 11.0 Hz, 1H), 4.50 (m, 1H), 3.42 (dd, J = 6.9, 17.6 Hz, 1H), 3.30 
(dd, J = 11.3, 17.6 Hz, 1H), 1.42 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 168.7, 155.3, 138.1, 134.9, 128.9, 128.9, 82.3, 80.9, 68.3, 56.6, 44.4, 28.5. 
[α]D20= + 132.0° (c= 0.50, CHCl3). 
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Synthesis of (S)-benzyl 2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetate [(S,S)-9] 
 
TFA (300 µL, 13.7 mmol) was added at 0 °C to a solution of (S,S)-43 (116 mg, 0.281 mmol) in DCM (1.0 
mL). Reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel using 100% EtOAc as eluent, 
obtaining (S)-benzyl 2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetate [(S,S)-9] as an orange oil (45 
mg, 51% yield). 
Rf= 0.65 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 7.40−7.30 (m, 5H), 5.21 (d, J = 12.0 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 4.98 
(ddd, J = 3.9, 8.0, 10.7 Hz, 1H), 3.94 (d, J = 3.9 Hz, 1H), 3.33 (dd, J= 8.0, 17.3 Hz, 1H), 3.10 (dd, J= 10.7, 
17.3 Hz, 1H), 1.70 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.4, 138.1, 135.3, 129.0, 128.9, 128.7, 82.8, 67.6, 56.3, 42.4.  
[α]D20= + 63.4° (c= 0.72, CHCl3). 
MS(ESI): m/z calcd for C12H1379BrN2O3: 312.0; found: 312.9 [M+H]+.  
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Synthesis of (±)-3-bromo-5-phenyl-4,5-dihydroisoxazole [(±)-10] 
 
DBF (1.00 g, 4.93 mmol) and NaHCO3 (2.07 g, 24.6 mmol) were added to a solution of styrene (48) (0.85 mL, 
7.40 mmol) in EtOAc (16 mL). The reaction mixture was vigorously stirred at room temperature until 
consumption of DBF. EtOAc was added and the organic phase was washed with water, dried over anhydrous 
Na2SO4, filtered and evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 95:5) obtaining (±)-3-bromo-5-phenyl-4,5-dihydroisoxazole [(±)-10] as a colorless oil 
(960 mg, 86% yield). 
Rf= 0.50 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.42-7.31 (m, 5H), 5.67 (dd, J= 8.9, 11.0 Hz, 1H), 3.62 (dd, J= 11.0, 17.3 
Hz, 1H), 3.21 (dd, J= 8.9, 17.3, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 139.5, 137.0, 129.2, 129.0, 126.2, 83.5, 49.4. 
MS(ESI): m/z calcd for C9H879BrNO: 225.0; found: 225.9 [M+H]+. 
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Synthesis of 1-nitro-4-vinylbenzene (34) 
 
KHMDS (5.46 mL, 0.5 M in toluene, 2.73 mmol) was added to a suspension of methyltriphenylphosphonium 
bromide (1.06 g, 2.98 mmol) in dry THF (6 mL). The reaction mixture was vigorously stirred at room 
temperature for 30 min, then a solution of 4-nitrobenzaldehyde (31) (300 µL, 1.95 mmol) in dry THF (2 mL) 
was added. The reaction mixture was stirred at room temperature for 2.5 h, then it was quenched with 25% aq 
NH4Cl (10 mL), phases were separated and the aqueous phase was extracted with Et2O (2x15 mL). The 
combined organic phases were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and 
evaporated. The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 99:1 
to 9:1) obtaining 1-nitro-4-vinylbenzene (34) as a yellow oil (130 mg, 48% yield). 
Rf= 0.51 (cyclohexane/EtOAc, 95:5). 
1H-NMR (300 MHz, CDCl3): δ= 8.19 (m, 2H), 7.54 (m, 2H), 6.68 (dd, J= 8.4, 13.2 Hz, 1H), 5.93 (d, J= 13.2 
Hz, 1H), 5.50 (d, J= 8.4 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 147.1, 143.8, 134.9, 126.8, 123.9, 118.6. 
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Synthesis of (±)-3-bromo-5-(4-nitrophenyl)-4,5-dihydroisoxazole [(±)-11] 
 
DBF (176 mg, 0.872 mmol) and NaHCO3 (366 mg, 4.36 mmol) were added to a solution of 34 (130 mg, 0.872 
mmol) in EtOAc (2.6 mL). The reaction mixture was vigorously stirred at room temperature until consumption 
of 34. EtOAc (10 mL) was added and the organic phase was washed with water (7 mL), dried over anhydrous 
Na2SO4, filtered and evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 9:1) obtaining (±)-3-bromo-5-(4-nitrophenyl)-4,5-dihydroisoxazole [(±)-11] as a white 
solid (190 mg, 80 % yield) which recrystallizes as white needles (m.p.= 101.1-101.5 °C). 
Rf= 0.41 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 8.26 (m, 2H), 7.53 (m, 2H), 5.78 (dd, J= 8.2, 11.1 Hz, 1H), 3.74 (dd, J= 11.1, 
17.3 Hz, 1H), 3.17 (dd, J= 8.2, 17.3 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 148.2, 146.8, 136.9, 126.9, 124.4, 81.9, 49.6. 
MS(ESI): m/z calcd for C9H779BrN2O3: 270.0; found: 270.8 [M+H]+. 
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Synthesis of (±)-3-bromo-5-(pyridin-4-yl)-4,5-dihydroisoxazole [(±)-12] 
 
DBF (194 mg, 0.955 mmol) and NaHCO3 (160 mg, 1.91 mmol) were added to a solution of 4-vinylpyridine 
(50) (103 µL, 0.955 mmol) in EtOAc (1.9 mL). The reaction mixture was vigorously stirred at room 
temperature until consumption of 50. EtOAc was added and the organic phase was washed with water, dried 
over anhydrous Na2SO4, filtered and evaporated. The crude product was purified by flash chromatography on 
silica gel (cyclohexane/EtOAc, 2:8) obtaining (±)-3-bromo-5-(pyridin-4-yl)-4,5-dihydroisoxazole [(±)-12] as 
a white solid (87 mg, 40% yield) which recrystallizes as colorless prisms from n-hexane/EtOAc (decomposes 
at T> 72 °C). 
Rf= 0.40 (EtOAc). 
1H-NMR (300 MHz, CDCl3): δ= 8.60 (d, J= 6.0 Hz, 2H), 7.22 (d, J= 6.0 Hz, 2H), 5.65 (dd, J= 8.0, 11.0 Hz, 
1H), 3.70 (dd, J= 11.0, 17.3 Hz, 1H), 3.12 (dd, J= 8.0, 17.3 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 150.5, 148.7, 137.0, 120.6, 81.3, 49.2. 
MS(ESI): m/z calcd for C8H779BrN2O 226.0; found 227.1 [M+H]+. 
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Synthesis of (±)-3-bromo-5-(4-fluorophenyl)-4,5-dihydroisoxazole [(±)-13] 
 
DBF (150 mg, 0.739 mmol) and NaHCO3 (310 mg, 3.69 mmol) were added to a solution of 4-fluorostyrene 
(49) (132 µL, 1.11 mmol) in EtOAc (3 mL). The reaction mixture was vigorously stirred at room temperature 
for 24 h. EtOAc (10 mL) was added and the organic phase was washed with water (7 mL), dried over anhydrous 
Na2SO4, filtered and evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 98:2) obtaining (±)-3-bromo-5-(4-fluorophenyl)-4,5-dihydroisoxazole [(±)-13] as a 
white solid (154 mg, 93% yield) which recrystallizes as white needles from n-hexane (m.p.= 59.2-59.9 °C). 
Rf= 0.37 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.33 (m, 2H), 7.08 (m, 2H), 5.66 (dd, J= 9.1, 10.7 Hz, 1H), 3.61 (dd, J= 10.7, 
17.3 Hz, 1H), 3.18 (dd, J= 9.1, 17.3 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 163.1 (d, JC-F= 247.9 Hz), 136.9, 135.3 (d, JC-F= 3.1 Hz), 128.1 (d, JC-F= 8.3 
Hz), 116.1 (d, JC-F= 21.7 Hz), 82.8, 49.4. 
MS(ESI): m/z calcd for C9H779BrFNO: 243.0; found: 243.9 [M+H]+. 
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Synthesis of (±)-4-(3-bromo-4,5-dihydroisoxazol-5-yl)aniline [(±)-14] 
 
DBF (200 mg, 0.986 mmol) and NaHCO3 (414 mg, 4.93 mmol) were added to a solution of 4-vinylaniline (36) 
(115 µL, 0.986 mmol) in EtOAc (2.3 mL). The reaction mixture was vigorously stirred at room temperature 
for 20 h. EtOAc (10 mL) was added and the organic phase was washed with water, dried over anhydrous 
Na2SO4, filtered and evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 8:2 to 7:3) obtaining (±)-4-(3-bromo-4,5-dihydroisoxazol-5-yl)aniline [(±)-14] as a 
brown oil (85 mg, 36% yield). 
Rf= 0.26 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.15 (m, 2H), 6.71 (m, 2H), 5.56 (dd, J= 9.6, 10.7 Hz, 1H), 3.51 (dd, J= 10.7, 
17.3 Hz, 1H), 3.18 (dd, J= 9.6, 17.3 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 147.3, 137.0, 128.6, 127.9, 115.4, 83.9, 48.9. 
MS(ESI): m/z calcd for C9H979BrN2O: 240.0; found: 241.0 [M+H]+. 
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Synthesis of 4-vinylphenol (33) 
 
KHMDS (6.9 mL, 0.5 M in toluene, 3.44 mmol) was added to a suspension of methyltriphenylphosphonium 
bromide (1.32 g, 3.69 mmol) in dry THF (9 mL). The reaction mixture was vigorously stirred at room 
temperature for 30 min, then a solution of 4-hydroxybenzaldehyde (30) (300 mg, 2.46 mmol) in dry THF (3 
mL) was added. The reaction mixture was stirred at room temperature for 2.5 h, then it was quenched with 
25% aq. NH4Cl (10 mL), phases were separated and the aqueous phase was extracted with Et2O. The pooled 
organic phases were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and evaporated. The 
crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 85:5) obtaining 4-
vinylphenol (33) as a grey solid (140 mg, 48% yield) (m.p.= 71.9-72.6 °C) (lit. m.p.= 71-72 °C). [73] 
Rf= 0.59 (cyclohexane/EtOAc, 7:3) 
1H-NMR (300 MHz, CD3OD): δ= 7.25 (m, 2H), 6.72 (m, 2H), 6.68 (dd, J= 10.8, 17.8 Hz, 1H), 5.55 (dd, J= 
0.9, 17.8 Hz, 1H), 5.02 (dd, J= 0.9, 10.8 Hz, 1H). 
These NMR data are in keeping with the literature. [73] 
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Synthesis of (±)-4-(3-bromo-4,5-dihydroisoxazol-5-yl)phenol [(±)-15] 
 
DBF (108 mg, 0.530 mmol) and NaHCO3 (223 mg, 2.65 mmol) were added to a solution of 33 (63 mg, 0.530 
mmol) in EtOAc (2.0 mL). The reaction mixture was vigorously stirred at room temperature until consumption 
of 33. EtOAc (10 mL) was added and the organic phase was washed with water, dried over anhydrous Na2SO4, 
filtered and evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 8:2) obtaining (±)-4-(3-bromo-4,5-dihydroisoxazol-5-yl)phenol [(±)-15] as a yellow oil 
(99 mg, 77% yield). 
Rf= 0.44 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.18 (m, 2H), 6.84 (m, 2H), 6.51 (bs, 1H) 5.59 (dd, J= 9.6, 10.7 Hz, 1H), 
3.55 (dd, J= 10.7, 17.4 Hz, 1H), 3.19 (dd, J= 9.6, 17.4 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 156.8, 137.5, 130.7, 128.1, 116.1, 83.7, 49.0. 
MS(ESI): m/z calcd for C9H879BrNO2: 241.0; found: 241.8 [M+H]+.  
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Synthesis of N-(4-vinylphenyl)acetamide (37) 
 
Sodium acetate (34 mg, 0.513 mmol) and acetic anhydride (157 µL, 1.76 mmol) were added to a solution of 
4-vinylaniline (36) (200 µL, 1.71 mmol) in glacial acetic acid (0.5 mL). The reaction mixture was stirred at 
room temperature for 30 min, then it was cooled, filtered on a hirsch and washed with water. N-(4-
Vinylphenyl)acetamide (37) was obtained as a white solid (215 mg, 78% yield) (m.p.= 132.3-133.8 °C). [74] 
Rf= 0.21 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.46 (m, 2H), 7.36 (m, 2H), 7.25 (bs, 1H), 6.66 (dd, J= 10.7, 17.6 Hz, 1H), 
5.67 (d, J= 17.6 Hz, 1H), 5.02 (d, J= 10.7 Hz, 1H), 2.17 (s, 3H). 
These NMR data are in keeping with the literature. [74] 
 
 
Synthesis of (±)-N-(4-(3-bromo-4,5-dihydroisoxazol-5-yl)phenyl)acetamide [(±)-16] 
 
DBF (201 mg, 0.993 mmol) and NaHCO3 (417 mg, 5.10 mmol) were added to a solution of 37 (160 mg, 0.993 
mmol) in DCM (4.2 mL). The reaction mixture was vigorously stirred at room temperature until consumption 
of 37. 5% MeOH/DCM was added and solid NaHCO3 was filtered off. The crude product was purified by flash 
chromatography on silica gel (cyclohexane/EtOAc, 6:4 to 4:6) obtaining (±)-N-(4-(3-bromo-4,5-
dihydroisoxazol-5-yl)phenyl)acetamide [(±)-16] as a white solid (232 mg, 82% yield) (m.p.= 165.5-166.1 °C 
then decomposes). 
Rf= 0.27 (cyclohexane/EtOAc, 1:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.52 (m, 2H), 7.30 (m, 2H), 7.21 (bs, 1H), 5.63 (dd, J=  Hz, 2H), 4.77 (ddd, 
J= 9.2, 10.7 Hz, 1H), 3.59 (dd, J= 10.7, 17.3 Hz, 1H), 3.18 (dd, J= 9.2, 17.3 Hz, 1H), 2.18 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 168.8, 138.7, 137.1, 135.0, 127.0, 120.4, 83.2, 49.2 24.8. 
MS(ESI): m/z calcd for C11H1179BrN2O2: 282.0; found: 282.8 [M+H]+.  
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Synthesis of 1-methoxy-4-vinylbenzene (35) 
 
KHMDS (6.16 mL, 0.5 M in toluene, 3.08 mmol) was added to a suspension of methyltriphenylphosphonium 
bromide (1.18 g, 3.30 mmol) in dry THF (6 mL).The reaction mixture was stirred at room temperature for 30 
min, then a solution of 4-methoxybenzaldehyde (32) (268 µL, 2.20 mmol) in dry THF (2 mL) was added. The 
reaction mixture was stirred at room temperature for 2.5 h, it was quenched with 25% aq. NH4Cl (10 mL), 
phases were separated and the aqueous phase was extracted with Et2O (2 x 15 mL). The combined organic 
phases were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and evaporated. The crude 
product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 99:1) obtaining 1-methoxy-
4-vinylbenzene (35) as a yellow oil (200 mg, 68% yield). 
Rf= 0.72 (cyclohexane/EtOAc, 95:5). 
1H-NMR (300 MHz, CDCl3): δ= 7.35 (m, 2H), 6.86 (m, 2H), 6.67 (dd, J= 10.8, 17.7 Hz, 1H), 5.62 (d, J= 17.7, 
1H), 5.13 (d, J= 10.8, 1H), 3.82 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 159.3, 136.2, 130.4, 127.3, 113.9, 111.5, 55.3. 
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Synthesis of (±)-3-bromo-5-(4-methoxyphenyl)-4,5-dihydroisoxazole [(±)-17] 
 
DBF (287 mg, 1.42 mmol) and NaHCO3 (596 mg, 7.10 mmol) were added to a solution of 35 (190 mg, 1.41 
mmol) in EtOAc (3.8 mL). The reaction mixture was vigorously stirred at room temperature until consumption 
of 35. EtOAc (10 mL) was added and the organic phase was washed with water (7 mL), dried over anhydrous 
Na2SO4, filtered and the solvent was removed under vacuum. The crude product was purified by flash 
chromatography on silica gel (cyclohexane/EtOAc, 9:1) obtaining (±)-3-bromo-5-(4-methoxyphenyl)-4,5-
dihydroisoxazole [(±)-17] as a yellow solid (276 mg, 76% yield) which recrystallizes from diisopropylether as 
yellow scales (m.p.= 59.4-60.8 °C) (lit. m.p.= 62-63 °C). [75] 
Rf= 0.49 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.28 (m, 2H), 6.91 (m, 2H), 5.62 (dd, J= 9.4, 10.7 Hz, 1H), 3.81 (s, 3H), 3.56 
(dd, J= 10.7, 17.3 Hz, 1H), 3.20 (dd, J= 9.4, 17.3 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 160.2, 137.0, 131.2, 127.8, 114.5, 83.4, 55.6, 49.1. 
MS(ESI): m/z calcd for C10H1079BrNO2: 255.0; found: 255.8 [M+H]+. 
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Synthesis of (±)-3-chloro-5-phenyl-4,5-dihydroisoxazole [(±)-51] 
 
(±)-10 (452 mg, 2.0 mmol) was dissolved in 10 M HCl in THF (5 mL). The reaction mixture was stirred at 
room temperature for 4 h, then the solvent was evaporated, water (5 mL) added, and the aqueous phase 
extracted with EtOAc (2x5 mL). The pooled organic layers were dried over anhydrous Na2SO4, filtered and 
the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (cyclohexane/EtOAc, 95:5) obtaining (±)-3-chloro-5-phenyl-4,5-dihydroisoxazole [(±)-51] as a 
colorless oil (327 mg, 90% yield).  
Rf= 0.46 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.42-7.35 (m, 5H), 5.67 (dd, J= 9.1, 10.7 Hz, 1H), 3.62 (dd, J= 10.7, 17.0 
Hz, 1H), 3.18 (dd, J= 9.1, 17.0 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 148.8, 139.5, 129.2, 129.0, 126.2, 84.1, 46.4. 
MS(ESI): m/z calcd for C9H835ClNO: 181.0; found: 182.0 [M+H]+. 
  
Page | 106 
 
Synthesis of (±)-5-phenylpyrazolidin-3-one [(±)-55] 
 
Methyl (E)-cinnamate (54) (1.00 g, 6.17 mmol) was added to a solution of hydrazine monohydrate (329 µL, 
6.79 mmol) in EtOH (6.2 mL). Reaction mixture was stirred under reflux for 50 h. The solvent was removed 
under vacuum and the crude product was purified by flash chromatography on silica gel (CHCl3/MeOH, 15:1) 
obtaining (±)-5-phenylpyrazolidin-3-one [(±)-55] as a white solid (620 mg, 62% yield) (m.p.= 100.8-101.7 °C) 
(lit. m.p.= 100-102 °C). [76] 
Rf= 0.32 (DCM/MeOH, 95:5). 
1H-NMR (300 MHz, CDCl3): δ= 7.43-7.30 (m, 5H), 4.83 (dd, J= 7.7, 9.2 Hz, 1H), 2.84 (dd, J= 7.7, 16.2 Hz, 
1H), 2.76 (dd, J= 9.2, 16.2 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 176.9, 138.9, 129.1, 128.5, 126.8, 61.8, 38.7. 
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Synthesis of (±)-1-ethyl-5-phenylpyrazolidin-3-one [(±)-56] 
 
Acetaldehyde (108 µL, 1.91 mmol) was added to a solution of (±)-55 (200 mg, 1.23 mmol) in MeOH (28 mL). 
Reaction mixture was stirred at room temperature for 30 min, then NaBH4 (84 mg, 1.85 mmol) was added and 
the reaction mixture was stirred for 1 h. The solvent was removed under vacuum, the residue was dissolved in 
EtOAc (15 mL) and washed with 10% aq. NH4Cl (3x15 mL). The organic phase was dried over anhydrous 
Na2SO4, filtered and the solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (cyclohexane/EtOAc, 3:8) obtaining (±)-1-ethyl-5-phenylpyrazolidin-3-one [(±)-
56] as a white solid (130 mg, 55% yield) which recrystallizes from diisopropyl ether as white needles (m.p.= 
113.0-113.6 °C). 
Rf= 0.39 (cyclohexane/EtOAc, 2:8). 
1H-NMR (300 MHz, CDCl3): δ= 8.25 (bs, 1H), 7.46-7.26 (m, 5H), 4.12 (dd, J= 8.4, 8.7 Hz, 1H), 3.02 (dd, J= 
8.4, 16.8 Hz, 1H), 2.86 (dq, J= 7.3, 12.0 Hz, 1H), 2.67 (dq, J= 6.9, 12.0 Hz, 1H), 2.56 (dd, J= 8.7, 16.8 Hz, 
1H), 1.14 (dd, J= 6.9, 7.3 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 173.1, 140.3, 128.9, 128.2, 127.3, 67.8, 53.0, 39.9, 13.1. 
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Synthesis of (±)-3-chloro-1-ethyl-5-phenyl-4,5-dihydro-1H-pyrazole [(±)-52] 
 
POCl3 (1.25 mL, 12.5 mmol) was added to a solution of (±)-56 (237 mg, 1.25 mmol) in MeCN (60 mL).The 
reaction was stirred under reflux for 3 h. The solvent was removed under vacuum, the residue was dissolved 
in EtOAc (50 mL) and the solution was added dropwise to an ice and water solution (30 mL). The organic 
layer was separated and washed with H2O (50 mL) and brine (50 mL). The organic phase was dried over 
anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography on silica gel (cyclohexane/EtOAc, 98:2) obtaining (±)-3-chloro-1-ethyl-5-
phenyl-4,5-dihydro-1H-pyrazole [(±)-52] as a yellow oil (64 mg, 25% yield). 
Rf= 0.48 (cyclohexane/EtOAc, 95:5). 
1H-NMR (300 MHz, CDCl3): δ= 7.45-7.28 (m, 5H), 4.28 (dd, J= 10.2, 14.3 Hz, 1H), 3.15 (dd, J= 10.2, 16.6 
Hz, 1H), 2.94 (dd, J= 14.3, 16.6 Hz, 1H), 2.90 (dq, J= 7.3, 12.6 Hz, 1H), 2.80 (dd, J= 7.0, 12.6 Hz, 1H), 1.17 
(dt, J= 7.0, 7.3 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 141.2, 139.7, 128.9, 128.4, 127.8, 72.1, 49.1, 47.6, 12.9, 10.3 
MS(ESI): m/z calcd for C11H1335ClN2: 208.1; found: 209.0 [M+H]+. 
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Synthesis of (±)-1-benzyl-5-phenylpyrazolidin-3-one [(±)-57] 
 
Benzyl bromide (147 µL, 1.23 mmol), K2CO3 (170 mg, 1.23 mmol) and NaI (18 mg, 0.12 mmol) were added 
to a solution of (±)-55 (200 mg, 1.23 mmol) in MeCN (23 mL). The reaction mixture was stirred under reflux 
for 3 h. The solvent was removed under vacuum and the residue was diluted with EtOAc (25 mL). The organic 
layer was washed with 3% aq. NH4Cl (25 mL), dried over anhydrous Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 6:4 to 1:1) obtaining (±)-1-benzyl-5-phenylpyrazolidin-3-one [(±)-57] as a white solid 
(200 mg, 64% yield) which recrystallizes from diisopropyl ether as white needles (m.p.= 110.8-112.4 °C). 
Rf= 0.46 (cyclohexane/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.51-7.27 (m, 10H), 6.76 (bs, 1H), 4.23 (dd, J= 8.2, 9.6 Hz, 1H), 4.04 (d, J= 
12.8 Hz, 1H), 3.58 (d, J= 12.8 Hz, 1H), 2.98 (dd, J= 8.2, 16.8 Hz, 1H), 2.58 (dd, J= 9.6, 9.6 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 172.9, 139.8, 136.4, 129.3, 129.1, 129.0, 128.3, 128.3, 127.4, 67.3, 62.3, 39.7. 
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Synthesis of (±)-1-benzyl-3-chloro-5-phenyl-4,5-dihydro-1H-pyrazole [(±)-53] 
 
POCl3 (793 µL, 7.93 mmol) was added to a solution of (±)-57 (200 mg, 0.793 mmol) in MeCN (34 mL).The 
reaction mixture was stirred under reflux for 3 h. The solvent was removed under vacuum, the residue was 
dissolved in EtOAc (50 mL) and the solution was added dropwise to an ice and water solution (30 mL). The 
organic layer was separated and washed with H2O (50 mL) and brine (50 mL). The organic phase was dried 
over anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography on silica gel (cyclohexane/EtOAc, 99:1) obtaining (±)-1-benzyl-3-chloro-5-
phenyl-4,5-dihydro-1H-pyrazole [(±)-53] as a yellow oil (100 mg, 46% yield). 
Rf= 0.54 (cyclohexane/EtOAc, 95:5). 
1H-NMR (300 MHz, CDCl3): δ= 7.47-7.22 (m, 10H), 4.30 (dd, J= 10.2, 14.3 Hz, 1H), 4.28 (d, J= 14.0 Hz, 
1H), 3.83 (d, J= 14.0 Hz, 1H), 3.09 (dd, J= 10.2, 16.5 Hz, 1H), 2.94 (dd, J= 14.3, 16.5 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 141.3, 139.2, 136.4, 129.7, 129.0, 128.5, 128.0, 127.6, 70.5, 57.4, 47.6. 
MS(ESI): m/z calcd for C16H1535ClN2: 270.1; found: 271.5 [M+H]+.  
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Synthesis of tert-butyl (R)-2-(benzyloxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate 
[(S,R)-60] 
 
Freshly prepared Ag2O (115 mg, 0.498 mmol) and benzyl bromide (395 µL, 3.32 mmol) were added to a 
solution of (S,R)-40 (100 mg, 0.332 mmol) in DCM (4.0 mL). Reaction mixture was stirred at room 
temperature overnight, then it was filtered over celite and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 9:1 to 8:2) 
obtaining tert-butyl (R)-2-(benzyloxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate [(S,R)-60] as 
a yellow oil (48 mg, 36% yield). 
Rf= 0.50 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 7.41-7.25 (m, 5H), 5.06 (d, J= 7.1 Hz, 2H), 4.77 (ddd, J= 7.2, 8.4, 10.2 Hz, 
1H), 4.52 (s, 2H), 3.85 (m, 1H), 3.79 (dd, J= 2.5, 9.6 Hz, 1H), 3.55 (dd, J= 3.7, 9.6 Hz, 1H), 3.34 (dd, J= 7.2, 
17.7 Hz, 1H), 3.22 (dd, J= 10.2, 17.7 Hz, 1H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.6, 138.0, 137.7, 128.5, 127.9, 127.7, 80.6, 80.1, 73.5, 68.6, 52.4, 44.3, 
28.3. 
[α]D20= + 48.0° (c= 0.95, CHCl3). 
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Synthesis of (R)-2-(benzyloxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine [(S,R)-58] 
 
TFA (86 µL, 1.13 mmol) was added at 0 °C to a solution of (S,R)-60 (45 mg, 0.113 mmol) in DCM (487 µL). 
The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was quenched 
with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The pooled 
organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (DCM/MeOH, 96:4) obtaining 
(R)-2-(benzyloxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine [(S,R)-58] as a yellow oil (19 mg, 
56% yield). 
Rf= 0.32 (DCM/MeOH, 96:4). 
1H-NMR (300 MHz, CDCl3): δ= 7.40-7.25 (m, 5H), 4.69 (ddd, J= 5.3, 8.7, 10.8 Hz, 1H), 4.51 (s, 2H), 3.50 
(dd, J= 4.5, 9.3 Hz, 1H), 3.40 (dd, J= 5.7, 9.3 Hz, 1H), 3.34 (dd, J= 8.7, 17.7 Hz, 1H), 3.28 (ddd, J= 4.5, 5.3, 
5.7 Hz, 1H), 3.10 (dd, J= 10.8, 17.7 Hz, 1H), 1.38 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 138.0, 137.8, 128.5, 127.8, 127.7, 83.3, 73.5, 71.3, 52.5, 42.3. 
[α]D20= + 58.3° (c= 0.75, CHCl3). 
MS(ESI): m/z calcd for C12H1579BrN2O2: 298.0; found: 298.8 [M+H]+.  
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Synthesis of tert-butyl (S)-2-(benzylamino)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-
oxoethylcarbamate [(S,S)-61] 
 
Benzylamine (18.2 µL, 0.167 mmol), EDC hydrochloride (32 mg, 0.167 mmol) and HOBt (11 mg, 0.0835 
mmol) were added to a solution of (S,S)-41 (54 mg, 0.167 mmol) in dry THF (6 mL). The reaction mixture 
was stirred at room temperature for 2 h, then the solvent was removed under reduced pressure and the crude 
product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 7:3) obtaining tert-butyl (S)-
2-(benzylamino)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-oxoethylcarbamate [(S,S)-61] as a colourless oil 
(48 mg, 70% yield). 
Rf= 0.32 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.38-7.22 (m, 5H), 6.54 (t, J= 5.7 Hz, 1H), 5.48 (d, J= 7.8 Hz, 1H), 4.74 (ddd, 
J= 6.6, 8.3, 10.5 Hz, 1H), 4.48 (d, J= 5.7 Hz, 2H), 4.26 (dd, J= 7.8, 8.3 Hz, 1H), 3.52 (dd, J= 6.6, 17.7 Hz, 
1H), 3.32 (dd, J= 10.5, 17.7 Hz, 1H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 168.4, 155.9, 138.8, 137.4, 128.7, 127.6, 127.6, 81.8, 80.8, 55.7, 44.3, 43.8, 
28.2. 
[α]D20= + 141.3° (c= 1.0, CHCl3). 
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Synthesis of (S)-2-amino-N-benzyl-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetamide [(S,S)-59] 
 
TFA (185 µL, 2.42 mmol) was added at 0 °C to a solution of (S,S)-61 (100 mg, 0.242 mmol) in DCM (1 mL). 
The reaction mixture was stirred at room temperature for 4 h, then it was diluted with DCM and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (S)-
2-amino-N-benzyl-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetamide [(S,S)-59] as a colourless solid (55 
mg, 73% yield) which recrystallizes from 1:3 iPrOH/n-hexane as colourless needles (m.p.= 90.6-91.3 °C). 
Rf= 0.28 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 7.41-7.23 (m, 6H), 5.09 (dt, J= 4.8, 9.6 Hz, 1H), 4.44 (d, J= 6.3 Hz, 2H), 3.80 
(d, J= 4.8 Hz, 1H), 3.22 (d, J= 9.6 Hz, 2H), 1.49 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 170.5, 138.1, 137.8, 128.8, 127.7, 127.6, 82.8, 56.4, 43.3, 41.8. 
[α]D20= + 80.9° (c= 1.0, CHCl3). 
MS(ESI): m/z calcd for C12H1479BrN3O2: 311.0; found: 311.9 [M+H]+. 
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Synthesis of tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-
nitrobenzyloxy)ethylcarbamate [(S,R)-72] 
 
Freshly prepared Ag2O (749 mg, 3.23 mmol) and 4-nitrobenzyl bromide (69) (1.40 g, 6.47 mmol) were added 
to a solution of (S,R)-40 (200 mg, 0.647 mmol) in DCM (6.7 mL). Reaction mixture was stirred at room 
temperature overnight, then it was filtered over celite and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 9:1 to 8:2) 
obtaining tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-nitrobenzyloxy)ethylcarbamate 
[(S,R)-72] as a brown oil (98 mg, 32% yield). 
Rf= 0.25 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 8.21 (d, J= 8.7 Hz, 2H), 7.47 (d, J= 8.7 Hz, 2H), 5.00 (d, J= 8.1 Hz, 1H), 
4.78 (q, J= 8.7 Hz, 1H), 4.63 (m, 2H), 3.89 (m, 1H), 3.84 (dd, J= 2.6, 9.3 Hz, 1H), 3.61 (dd, J= 3.6, 9.3 Hz, 
1H), 3.35 (dd, J= 7.5, 17.6 Hz, 1H), 3.27 (dd, J= 10.6, 17.6 Hz, 1H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.5, 147.5, 145.1, 138.1, 127.8, 123.7, 80.5, 80.4, 72.2, 69.3, 52.4, 44.5, 
28.3. 
[α]D20= + 48.9° (c= 0.112, CHCl3). 
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Synthesis of (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-nitrobenzyloxy)ethanamine [(S,R)-62] 
 
TFA (132 µL, 1.73 mmol) was added at 0 °C to a solution of (S,R)-72 (77 mg, 0.173 mmol) in DCM (0.8 mL). 
The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was quenched 
with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The pooled 
organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (R)-
1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-nitrobenzyloxy)ethanamine [(S,R)-62] as a white solid (26 mg, 
43% yield) which recrystallizes from 1:3 iPrOH/n-hexane as colourless needles (m.p.= 86.8-87.5 °C). 
Rf= 0.30 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 8.20 (m, 2H), 7.47 (m, 2H), 4.70 (ddd, J= 5.7, 8.4, 10.8 Hz, 1H), 4.62 (s, 2H), 
3.58 (dd, J= 4.5, 9.5 Hz, 1H), 3.52 (dd, J= 5.7, 9.5 Hz, 1H), 3.34 (dd, J= 8.4, 17.1 Hz, 1H), 3.28 (m, 1H), 3.17 
(dd, J= 10.8, 17.1 Hz, 1H), 1.66 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 147.5, 145.3, 137.9, 127.7, 123.7, 82.9, 72.2, 72.0, 52.7, 42.8. 
[α]D20= + 54.5° (c= 0.326, CHCl3). 
MS(ESI): m/z calcd for C12H1479BrN3O4: 343.0; found 344.0 [M+H]+.  
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Synthesis of tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-
fluorobenzyloxy)ethylcarbamate [(S,R)-73] 
 
Freshly prepared Ag2O (749 mg, 3.23 mmol) and 4-fluorobenzyl bromide (70) (722 µL, 6.47 mmol) were 
added to a solution of (S,R)-40 (100 mg, 0.332 mmol) in DCM (6.7 mL). Reaction mixture was stirred at room 
temperature overnight, then it was filtered over celite and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 9:1 to 8:2) 
obtaining tert-butyl (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-fluorobenzyloxy)ethylcarbamate 
[(S,R)-73] as a yellow oil (127 mg, 47% yield). 
Rf= 0.55 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.28 (m, 2H), 7.03 (t, J= 9.0 Hz, 2H), 5.01 (d, J= 6.9 Hz, 1H), 4.76 (dd, J= 
8.6, 17.6 Hz, 1H), 4.47 (s, 2H), 3.85 (m, 1H), 3.77 (dd, J= 2.3, 9.6 Hz, 1H), 3.53 (dd, J= 3.7, 9.6 Hz, 1H), 3.33 
(dd, J= 7.2, 17.7 Hz, 1H), 3.23 (dd, J= 10.5, 17.7 Hz, 1H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 162.4 (d, JC-F= 245.1 Hz), 155.6, 138.1, 133.4, 129.5 (d, JC-F= 8.0 Hz), 115.4 
(d, JC-F= 21.7 Hz), 80.6, 80.2, 72.8, 68.6, 52.4, 44.4, 28.3. 
This intermediate was not pure enough to provide an accurate absolute value of specific optical rotation. 
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Synthesis of (R)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-fluorobenzyloxy)ethanamine [(S,R)-63] 
 
TFA (187 µL, 2.44 mmol) was added at 0 °C to a solution of (S,R)-73 (102 mg, 0.244 mmol) in DCM (1.1 
mL). The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (R)-
1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-fluorobenzyloxy)ethanamine [(S,R)-63] as a yellow oil (38 
mg, 49% yield). 
Rf= 0.35 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 7.30 (m, 2H), 7.04 (m, 2H), 4.76 (ddd, J= 5.1, 8.7, 11.1 Hz, 1H), 4.49 (s, 2H), 
3.56 (dd, J= 4.6, 9.6 Hz, 1H), 3.49 (dd, J= 5.5, 9.6 Hz, 1H), 3.38 (dd, J= 8.7, 17.7 Hz, 1H), 3.34 (ddd, J= 4.6, 
5.1, 5.5 Hz, 1H), 3.17 (dd, J= 11.1, 17.7 Hz, 1H). 
13C-NMR (75 MHz, CDCl3): δ= 162.4 (d, JC-F= 245.0 Hz), 138.0, 133.5 (d, JC-F= 2.6 Hz), 129.5 (d, JC-F= 8.0 
Hz), 115.4 (d, JC-F= 20.6 Hz), 80.0, 72.8, 71.1, 52.6, 42.5. 
[α]D20= + 59.0° (c= 0.50, CHCl3). 
MS(ESI): m/z calcd for C12H1479BrFN2O2: 316.0; found 316.9 [M+H]+.  
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Synthesis of tert-butyl (R)-2-(biphenyl-4-ylmethoxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-
yl)ethylcarbamate [(S,R)-74] 
 
Freshly prepared Ag2O (749 mg, 3.23 mmol) and 4-bromomethylbiphenyl bromide (71) (1.60 g, 6.47 mmol) 
were added to a solution of (S,R)-40 (200 mg, 0.647 mmol) in DCM (6.7 mL). Reaction mixture was stirred at 
room temperature overnight, then it was filtered over celite and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 9:1 to 
8:2) obtaining tert-butyl (R)-2-(biphenyl-4-ylmethoxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-
yl)ethylcarbamate [(S,R)-74] as a yellow oil (98 mg, 32% yield). 
Rf= 0.47 (cyclohexane/EtOAc, 8:2). 
1H-NMR (300 MHz, CDCl3): δ= 7.59 (m, 4H), 7.48-7.32 (m, 5H), 5.06 (d, J= 8.1 Hz, 1H), 4.80 (m, 1H), 4.57 
(s, 2H), 3.88 (m, 1H), 3.83 (dd, J= 2.5, 9.4 Hz, 1H), 3.59 (dd, J= 3.7, 9.4 Hz, 1H), 3.36 (dd, J= 7.2, 17.2 Hz, 
1H), 3.24 (dd, J= 10.5, 17.2 Hz, 1H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.6, 140.9, 140.8, 138.1, 136.7, 128.8, 128.2, 127.4, 127.2, 127.1, 80.6, 
80.1, 73.3, 68.7, 52.4, 44.4, 28.3. 
[α]D20= + 34.1° (c= 0.90, CHCl3). 
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Synthesis of (R)-2-(biphenyl-4-ylmethoxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine [(S,R)-
64] 
 
TFA (157 µL, 2.06 mmol) was added at 0 °C to a solution of (S,R)-74 (98 mg, 0.206 mmol) in DCM (0.9 mL). 
The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was quenched 
with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The pooled 
organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 2:8 to 
EtOAc, 100%) obtaining (R)-2-(biphenyl-4-ylmethoxy)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine 
[(S,R)-64] as a yellow oil (28 mg, 36% yield). 
Rf= 0.39 (cyclohexane/EtOAc, 2:8). 
1H-NMR (300 MHz, CDCl3): δ= 7.58 (m, 4H), 7.48-7.32 (m, 5H), 4.73 (ddd, J= 5.1, 8.7, 11.1 Hz, 1H), 4.56 
(s, 2H), 3.56 (dd, J= 4.2, 9.4 Hz, 1H), 3.49 (dd, J= 6.0, 9.4 Hz, 1H), 3.37 (dd, J= 8.7, 17.7 Hz, 1H), 3.33 (ddd, 
J= 4.2, 5.1, 6.0 Hz, 1H), 3.14 (dd, J= 11.1, 17.7 Hz, 1H), 1.77 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 140.8, 140.7, 138.0, 136.8, 128.8, 128.2, 127.4, 127.2, 127.1, 83.3, 73.2, 71.4, 
52.6, 42.4. 
[α]D20= + 189.9° (c= 0.35, CHCl3). 
MS(ESI): m/z calcd for C18H1979BrN2O2: 374.1; found: 375.1 [M+H]+. 
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Synthesis of tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-nitrobenzylamino)-2-
oxoethylcarbamate [(S,S)-79] 
 
4-Nitrobenzylamine hydrochloride (75) (58 mg, 0.309 mmol), triethylamine (43 µL, 0.309 mmol), EDC 
hydrochloride (59 mg, 0.309 mmol) and HOBt (21 mg, 0.154 mmol) were added to a solution of (S,S)-41 (100 
mg, 0.309 mmol) in dry THF (12 mL). The reaction mixture was stirred at room temperature for 2 h, then the 
solvent was removed under reduced pressure and the crude product was purified by flash chromatography on 
silica gel (cyclohexane/EtOAc, 7:3) obtaining tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-
nitrobenzylamino)-2-oxoethylcarbamate [(S,S)-79]as a yellow solid (90 mg, 64% yield) which recrystallizes 
from 1:4 iPrOH/n-hexane as colorless needles (m.p.= 140.8-141.5 °C). 
Rf= 0.26 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 8.18 (d, J= 8.5 Hz, 2H), 7.45 (d, J= 8.5 Hz, 2H), 6.92 (t, J= 5.7 Hz, 1H), 5.48 
(d, J= 7.5 Hz, 1H), 4.77 (ddd, J= 6.0, 6.3, 10.5 Hz, 1H), 4.61 (dd, J= 6.6, 15.9 Hz, 1H), 4.54 (dd, J= 6.0, 15.9 
Hz, 1H), 4.33 (dd, J= 6.0, 7.5 Hz, 1H), 3.52 (dd, J= 6.3, 18.1 Hz, 1H), 3.34 (dd, J= 10.5, 18.1 Hz, 1H), 1.44 
(s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 169.1, 155.9, 147.2, 145.2, 138.8, 128.0, 123.8, 81.6, 81.0, 55.8, 44.2, 42.9, 
28.2. 
[α]D20= + 102.6° (c= 0.50, CHCl3). 
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Synthesis of (S)-2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-nitrobenzyl)acetamide [(S,R)-
65] 
 
TFA (150 µL, 1.96 mmol) was added at 0 °C to a solution of (S,R)-79 (87 mg, 0.196 mmol) in DCM (0.85 
mL). The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (S)-
2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-nitrobenzyl)acetamide [(S,S)-65] as a colourless 
solid (51 mg, 76% yield) which recrystallizes from 1:3 iPrOH/n-hexane as white needles (m.p.= 138.8-139.3 
°C). 
Rf= 0.30 (EtOAc, 100%). 
1H-NMR (300 MHz, CD3OD): δ= 8.18 (m, 2H), 7.54 (m, 2H), 4.85 (dt, J= 6.0, 9.6 Hz, 1H), 4.56 (d, J= 16.0 
Hz, 1H), 4.48 (d, J= 16.0 Hz, 1H), 3.57 (d, J= 6.0 Hz, 1H), 3.36 (d, J= 9.6 Hz, 1H). 
13C-NMR (75 MHz, CD3OD): δ= 172.7, 147.1, 146.2, 138.1, 127.9, 123.2, 83.1, 56.8, 42.6, 42.0. 
[α]D20= + 112.0° (c= 0.33, MeOH). 
MS(ESI): m/z calcd for C12H1379BrN4O4: 356.0; found: 357.0 [M+H]+. 
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Synthesis of tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-fluorobenzylamino)-2-
oxoethylcarbamate [(S,S)-80] 
 
4-Fluorobenzylamine (76) (35 µL, 0.309 mmol), EDC hydrochloride (59 mg, 0.309 mmol) and HOBt (21 mg, 
0.154 mmol) were added to a solution of (S,S)-41 (100 mg, 0.309 mmol) in dry THF (12 mL). The reaction 
mixture was stirred at room temperature for 2 h, then the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 7:3) obtaining tert-
butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-fluorobenzylamino)-2-oxoethylcarbamate [(S,S)-80] 
as a brown oil (103 mg, 77% yield). 
Rf= 0.27 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.24 (m, 2H), 7.01 (m, 2H), 6.55 (t, J= 5.7 Hz, 1H), 5.46 (d, J= 6.6 Hz, 1H), 
4.73 (m, 1H), 4.44 (d, J= 5.7 Hz, 2H), 4.25 (t, J= 7.9 Hz, 1H), 3.52 (dd, J= 5.8, 17.7 Hz, 1H), 3.32 (dd, J= 
10.9, 17.7 Hz, 1H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 168.5, 162.2 (d, JC-F= 243.9 Hz), 155.8, 138.7, 133.3 (d, JC-F= 2.8 Hz), 129.3 
(d, JC-F= 9.1 Hz), 115.5 (d, JC-F= 21.7 Hz), 81.7, 80.8, 55.7, 44.2, 43.0, 28.2. 
[α]D20= + 94.9° (c= 0.50, CHCl3). 
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Synthesis of (S)-2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-fluorobenzyl)acetamide [(S,S)-
66] 
 
TFA (192 µL, 2.51 mmol) was added at 0 °C to a solution of (S,S)-80 (108 mg, 0.251 mmol) in DCM (1.1 
mL). The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (S)-
2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-fluorobenzyl)acetamide [(S,S)-66] as colourless 
solid (46 mg, 55% yield) which recrystallizes from 1:4 iPrOH/n-hexane as white needles (m.p.= 86.2-86.6 °C). 
Rf= 0.44 (EtOAc, 100%). 
1H-NMR (300 MHz, CDCl3): δ= 7.38, (t, J= 6.0 Hz, 1H), 7.24 (m, 2H), 7.02 (m, 2H), 5.07 (dt, J= 4.5, 10.0 
Hz, 1H), 4.41 (d, J= 6.0 Hz, 2H), 3.80 (d, J= 4.5 Hz, 1H), 3.23 (d, J= 10.0 Hz, 1H), 1.73 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 170.7, 162.2 (d, JC-F= 245.0 Hz), 138.1, 133.7 (d, JC-F= 3.0 Hz), 129.4 (d, JC-
F= 8.0 Hz), 115.6 (d, JC-F= 20.6 Hz), 82.7, 56.4, 42.6, 42.0. 
[α]D20= + 86.1° (c= 0.50, CHCl3). 
MS(ESI): m/z calcd for C12H1379BrFN3O2: 329.0; found: 329.9 [M+H]+. 
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Synthesis of tert-butyl (S)-2-(biphenyl-4-ylmethylamino)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-
oxoethylcarbamate [(S,S)-81] 
 
4-Phenylbenzylamine (77) (59 mg, 0.322 mmol), EDC hydrochloride (62 mg, 0.322 mmol) and HOBt (22 mg, 
0.161 mmol) were added to a solution of (S,S)-41 (104 mg, 0.322 mmol) in dry THF (12 mL). The reaction 
mixture was stirred at room temperature for 2 h, then the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 8:2) obtaining tert-
butyl (S)-2-(biphenyl-4-ylmethylamino)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-oxoethylcarbamate 
[(S,S)-81] as a brown oil (127 mg, 81% yield). 
Rf= 0.42 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.55 (m, 4H), 7.43 (t, J= 7.3 Hz, 2H), 7.34 (m, 3H), 6.70 (t, J= 5.4 Hz, 1H), 
5.53 (d, J= 6.9 Hz, 1H), 4.77 (ddd, J= 6.6, 7.8, 10.5 Hz, 1H), 4.50 (d, J= 5.4 Hz, 2H), 4.31 (dd, J= 6.9, 7.8 Hz, 
1H), 3.52 (dd, J= 6.6, 17.7 Hz, 1H), 3.31 (dd, J= 10.5, 17.7 Hz, 1H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 168.7, 155.9, 140.7, 140.3, 138.5, 136.7, 128.8, 128.0, 127.4, 127.0, 81.8, 
80.7, 55.8, 44.0, 43.4, 20.3. 
[α]D20= + 150.9° (c= 0.50, CHCl3). 
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Synthesis of (S)-2-amino-N-(biphenyl-4-ylmethyl)-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetamide 
[(S,S)-67] 
 
TFA (296 µL, 2.60 mmol) was added at 0 °C to a solution of (S,S)-81 (127 mg, 0.260 mmol) in DCM (1.3 
mL). The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (S)-
2-amino-N-(biphenyl-4-ylmethyl)-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)acetamide [(S,S)-67] as a pink 
solid (84 mg, 83% yield) (decomposes at T> 155 °C). 
Rf= 0.43 (EtOAc, 100%). 
1H-NMR (300 MHz, DMSO-d6): δ= 8.53 (t, J= 6.0 Hz, 1H), 7.60 (m, 4H), 7.42 (t, J= 7.6 Hz, 2H), 7.33 (m, 
3H), 4.77 (dt, J= 5.7, 9.3 Hz, 1H), 4.30 (d, J= 6.0 Hz, 2H), 3.45 (d, J= 5.7 Hz, 1H), 3.29 (d, J=9.3 Hz, 2H), 
2.23 (bs, 2H) 
13C-NMR (75 MHz, DMSO-d6): δ= 171.9, 140.4, 139.2, 138.9, 138.7, 129.4, 128.2, 127.8, 127.0, 83.6, 56.8, 
42.5, 42.2. 
[α]D20= + 84.2° (c= 0.55, CHCl3). 
MS(ESI): m/z calcd for C18H1879BrN3O2: 387.1; found: 388.2 [M+H]+. 
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Synthesis of tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-methoxybenzylamino)-2-
oxoethylcarbamate [(S,S)-82] 
 
4-Methoxybenzylamine (78) (34 µL, 0.309 mmol), EDC hydrochloride (59 mg, 0.309 mmol) and HOBt (21 
mg, 0.154 mmol) were added to a solution of (S,S)-41 (100 mg, 0.309 mmol) in dry THF (12 mL). The reaction 
mixture was stirred at room temperature for 2 h, then the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 8:2 to 7:3) obtaining 
tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-(4-methoxybenzylamino)-2-oxoethylcarbamate 
[(S,S)-82] as a white foam (93 mg, 68% yield). 
Rf= 0.30 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.20 (m, 2H), 6.86 (m, 2H), 6.47 (t, J= 5.7 Hz, 1H), 5.47 (d, J= 8.4 Hz, 1H), 
4.72 (ddd, J= 6.6, 7.5, 10.5 Hz, 1H), 4.40 (d, J= 5.7 Hz, 2H), 4.24 (dd, J= 7.5, 8.4 Hz, 1H), 3.79 (s, 3H), 3.51 
(dd, J= 6.6, 17.6 Hz, 1H), 3.31 (dd, J= 10.5, 17.6 Hz, 1H), 1.43 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 168.4, 159.0, 155.8, 138.6, 129.6, 129.0, 114.1, 81.8, 80.7, 55.7, 55.3, 44.1, 
43.2, 28.2. 
[α]D20= + 135.8° (c= 0.50, CHCl3). 
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Synthesis and (S)-2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-methoxybenzyl)acetamide 
[(S,S)-68] 
 
TFA (154 µL, 2.01 mmol) was added at 0 °C to a solution of (S,S)-82 (89 mg, 0.201 mmol) in DCM (0.87 
mL). The reaction mixture was stirred at room temperature for 4 h, then DCM was added and the acid was 
quenched with 5% aq. NaHCO3. Phases were separated and the aqueous phase was extracted with DCM. The 
pooled organic layers were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (EtOAc, 100%) obtaining (S)-
2-amino-2-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-N-(4-methoxybenzyl)acetamide [(S,S)-82] as a colourless 
solid (58 mg, 84% yield) which recrystallizes from 1:3 iPrOH/n-hexane as colourless needles (m.p.= 118.0-
118.8 °C). 
Rf= 0.31 (EtOAc, 100%). 
1H-NMR (300 MHz, CD3OD): δ= 7.22 (d, J= 8.1 Hz, 2H), 6.86 (d, J= 8.1 Hz, 2H), 4.32 (s, 2H), 3.76 (s, 3H), 
3.55 (d, J= 5.7 Hz, 1H). 
13C-NMR (75 MHz, CD3OD): δ= 171.9, 159.0, 138.0, 130.1, 128.5, 113.5, 83.0, 56.5, 54.3, 42.2. 
[α]D20= + 143.0° (c= 0.50, MeOH). 
MS(ESI): m/z calcd for C13H1679BrN3O3: 341.1; found: 342.1 [M+H]+. 
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Synthesis of (S)-2-(tert-butoxycarbonylamino)but-3-enyl methanesulfonate [(S)-85] 
 
MsCl (83 µL, 1.07 mmol) was added at 0 °C to a solution of (S)-24 (200 mg, 1.07 mmol) was dissolved in dry 
DCM (2 mL). TEA (194 µL, 1.39 mmol) and DMAP (13 mg, 0.107 mmol). The reaction mixture was stirred 
at 0 °C for 15 min, then it was diluted with DCM, washed with 1 M aq. HCl and sat. aq. NaHCO3. The organic 
phase was dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure, 
obtaining (S)-2-(tert-butoxycarbonylamino)but-3-enyl methanesulfonate [(S)-85] as a yellow oil (256 mg, 90% 
yield). 
Rf= 0.51 (cyclohexane/EtOAc, 6:4). 
1H-NMR (300 MHz, CDCl3): δ= 5.80 (ddd, J= 6.0, 10.5, 17.1 Hz, 1H), 5.31 (d, J= 17.1 Hz, 1H), 5.27 (d, J= 
10.5 Hz, 1H), 4.82 (m, 1H), 4.45 (m, 1H), 4.29 (dd, J= 4.5, 10.2 Hz, 1H), 4.21 (dd, J= 5.3, 10.2 Hz, 1H), 3.02 
(s, 3H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.0, 133.6, 117.8, 80.2, 70.5, 51.7, 37.5, 28.3. 
[α]D20= - 33.7° (c= 0.50, CHCl3). 
 
  
Page | 130 
 
Synthesis of (S)-tert-butyl 1-(benzylthio)but-3-en-2-ylcarbamate [(S)-86] 
 
Phenylmethanethiol (113 µL, 0.965 mmol) and DBU (217 µL, 1.45 mmol) were added to a solution of (S)-86 
(256 mg, 0.965 mmol) in benzene (1.2 mL). Reaction mixture was stirred at room temperature for 1 h and 
additional phenylmethanethiol (23 µL, 0.193 mmol) was added. The reaction mixture was stirred for 30 min 
then Et2O was added and washed two times with 0.2 M aq. NaOH. The aqueous phase was extracted with Et2O 
and the pooled organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and the solvent 
was removed under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 95:5 to 9:1) obtaining (S)-tert-butyl 1-(benzylthio)but-3-en-2-ylcarbamate [(S)-86] as a 
colourless oil (226 mg, 80% yield). 
Rf= 0.32 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3,): δ= 7.35-7.19 (m, 5H), 5.78 (ddd, J= 5.4, 11.1, 17.1 Hz, 1H), 5.19 (d, J= 17.1 
Hz, 1H), 5.14 (d, J= 11.1 Hz, 1H), 4.74 (m, 1H), 4.33 (m, 1H), 3.73 (s, 2H), 2.59 (d, J= 6.3 Hz, 2H), 1.45 (s, 
9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.2, 138.0, 137.4, 128.9, 128.5, 127.1, 115.5, 79.6, 51.7, 36.7, 36.4, 28.4. 
[α]D20= - 11.8° (c= 1.00, CHCl3). 
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Synthesis of tert-butyl (S)-2-(benzylthio)-1-((R)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate 
[(R,S)-87] and tert-butyl (S)-2-(benzylthio)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate 
[(S,S)-88] 
DBU (187 mg, 0.924 mmol) and NaHCO3 (388 mg, 4.62 mmol) were added to a solution of (S)-GC86 (226 
mg, 0.770 mmol) in EtOAc (4 mL). The reaction mixture was vigorously stirred at room temperature until 
consumption of (S)-86. EtOAc was added, washed with water, dried over anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (cyclohexane/EtOAc, 9:1 to 85:15). 
 
tert-Butyl (S)-2-(benzylthio)-1-((R)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate [(R,S)-87] was 
obtained as a white solid (164 mg, 51% yield) which recrystallizes from diisopropylether as white needles 
(m.p.= 106.5-107.3 °C). 
Rf= 0.22 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.37-7.20 (m, 5H), 4.98 (ddd, J= 1.8, 8.4, 11.1 Hz, 1H), 4.66 (d, J= 9.9 Hz, 
1H), 3.87 (dt, J= 7.8, 8.4 Hz, 1H), 3.73 (s, 2H), 3.25 (dd, J= 11.1, 17.4 Hz, 1H), 3.10 (dd, J= 8.4, 17.4 Hz, 
1H), 2.57 (d, J= 7.8 Hz, 2H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 156.0, 138.2, 137.8, 129.0, 128.5, 127.2, 81.0, 80.2, 52.2, 44.0, 36.1, 33.0, 
28.3. 
[α]D20= - 85.5° (c= 1.00, CHCl3). 
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tert-Butyl (S)-2-(benzylthio)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate [(S,S)-88] was 
obtained as a green oil (138 mg, 43% yield) which solidifies upon cooling at - 20 °C. 
Rf= 0.15 (cyclohexane/EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 7.35-7.20 (m, 5H), 4.79 (d, J= 9.3 Hz, 1H), 4.65 (ddd, J= 7.6, 7.8, 10.2 Hz, 
1H), 3.83 (m, 1H), 3.73 (s, 2H), 3.23 (dd, J= 10.2, 17.7 Hz, 1H), 3.11 (dd, J= 7.6, 17.7 Hz, 1H), 2.67 (d, J= 
5.7 Hz, 2H), 1.45 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.5, 137.7, 137.7, 129.0, 128.6, 127.3, 82.3, 80.2, 52.3, 44.4, 36.8, 32.2, 
28.3. 
[α]D20= + 84.6° (c= 1.05, CHCl3). 
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Synthesis of tert-butyl (S)-2-(benzylsulfonyl)-1-((R)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate 
[(R,S)-89] 
 
mCPBA (131 mg, ≥77% purity, 0.583 mmol) was added at 0 °C to a solution of (R,S)-87 (110 mg, 0.265 mmol) 
in CHCl3 (3.3 mL). Reaction mixture was stirred at room temperature for 10 min then DCM was added and 
washed with sat. aq. NaHCO3. The organic phase was dried over anhydrous Na2SO4, filtered and the solvent 
was removed under reduced pressure, obtaining tert-butyl (S)-2-(benzylsulfonyl)-1-((R)-3-bromo-4,5-
dihydroisoxazol-5-yl)ethylcarbamate [(R,S)-89] as a white solid (118 mg, quantitative yield) which 
recrystallizes from 1:3 CHCl3/EtOH as white needles (decomposes at T> 180 °C). 
Rf= 0.39 (cyclohexane/EtOAc, 7:3). 
1H-NMR (300 MHz, CDCl3): δ= 7.46-7.37 (m, 5H), 5.00 (t, J= 9.4 Hz, 1H), 4.80 (d, J= 10.2 Hz, 1H), 4.42 (m, 
1H), 4.34 (d, J= 14.2 Hz, 1H), 4.27 (d, J= 14.2 Hz, 1H), 3.33 (dd, J= 10.8, 17.7 Hz, 1H), 3.19-3.02 (m, 3H), 
1.46 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ= 155.5, 138.3, 130.7, 129.2, 129.1, 127.5, 81.9, 81.0, 60.1, 52.4, 48.4, 43.8, 
28.2. 
[α]D20= - 108.5° (c= 0.55, CHCl3). 
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Synthesis of (S)-2-(benzylsulfonyl)-1-((R)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine [(R,S)-83] 
 
TFA (432 µL, 5.64 mmol) was added at 0 °C to a solution of (R,S)-89 (126 mg, 0.282 mmol) in DCM (2.4 
mL). Reaction mixture was stirred at room temperature for 1 h then it was diluted with DCM and sat. aq. 
NaHCO3 was added. Phases were separated and the organic phase was dried over anhydrous Na2SO4, filtered 
and the evaporated. The crude product was purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 3:7) obtaining (S)-2-(benzylsulfonyl)-1-((R)-3-bromo-4,5-dihydroisoxazol-5-
yl)ethanamine [(R,S)-83] as a white solid (67 mg, 68% yield) which recrystallizes from iPrOH as colorless 
needles (m.p.= 144.6-145.5 °C). 
Rf= 0.46 (cyclohexane/EtOAc, 3:7). 
1H-NMR (300 MHz, CD3OD): δ= 7.49-7.38 (m, 5H), 4.73 (ddd, J= 4.0, 8.2, 10.5 Hz, 1H), 4.51 (s, 2H), 3.42 
(ddd, J= 3.9, 4.0, 8.7 Hz, 1H), 3.34 (dd, J= 10.5, 17.4 Hz, 1H), 3.21 (dd, J= 8.6, 17.4 Hz, 1H), 3.21 (dd, J= 
3.9, 14.7 Hz, 1H), 3.12 (dd, J= 8.7, 14.7 Hz, 1H). 
13C-NMR (75 MHz, CD3OD): δ= 138.0, 130.9, 128.5, 128.4, 128.0, 83.8, 59.7, 54.4, 48.8, 42.8. 
[α]D20= - 111.9° (c= 0.50, MeOH). 
MS(ESI): m/z calcd for C12H1579BrN2O3S: 346.0; found: 347.0 [M+H]+. 
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Synthesis of tert-butyl (S)-2-(benzylsulfonyl)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate 
[(S,S)-90] 
 
mCPBA (214 mg, ≥77% purity, 0.953 mmol) was added at 0 °C to a solution of [(S,S)-88] (180 mg, 0.433 
mmol) in CHCl3 (5.3 mL). Reaction mixture was stirred at room temperature for 10 min then DCM was added 
and washed with sat. aq. NaHCO3. The organic phase was dried over anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude was decanted from 1:1 cyclohexane/EtOAc as eluent, 
obtaining tert-butyl (S)-2-(benzylsulfonyl)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethylcarbamate [(S,S)-
90] as a white solid (127 mg, 65% yield) (decomposes at T> 170 °C). 
Rf= 0.54 (cyclohexane/EtOAc, 6:4). 
1H-NMR (300 MHz, DMSO-d6): δ= 7.45-7.33 (m, 5H), 7.20 (d, J= 9.0 Hz, 1H), 4.59 (m, 1H), 4.46 (s, 2H), 
4.14 (m, 1H), 3.41 (dd, J= 10.5, 17.4 Hz, 1H), 3.27-3.16 (m, 2H), 3.10 (dd, J= 6.4, 17.4 Hz, 1H), 1.36 (s, 9H). 
13C-NMR (75 MHz, DMSO-d6): δ= 155.6, 138.8, 131.5, 129.0, 128.9, 128.6, 82.4, 79.1, 59.2, 52.1, 47.6, 43.1, 
28.6. 
[α]D20= + 101.5° (c= 0.55, DMSO). 
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Synthesis of (S)-2-(benzylsulfonyl)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)ethanamine [(S,S)-84] 
 
TFA (341 µL, 4.46 mmol) was added at 0 °C to a suspension of [(S,S)-90] (100 mg, 0.223 mmol) in DCM (1.9 
mL). Reaction mixture was stirred at room temperature for 1 h, then it was diluted with DCM and sat. aq. 
NaHCO3 was added. Phases were separated and the organic phase was dried over anhydrous Na2SO4, filtered 
and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography 
on silica gel (cyclohexane/EtOAc, 4:6) obtaining (S)-2-(benzylsulfonyl)-1-((S)-3-bromo-4,5-dihydroisoxazol-
5-yl)ethanamine [(S,S)-84] as a pale orange solid (54 mg, 70% yield) (m.p.= 132.8-134.0 °C). 
Rf= 0.38 (cyclohexane/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.42-7.38 (m, 5H), 4.55 (m, 1H), 4.33 (s, 2H), 3.55 (m, 1H), 3.25 (dd, J= 9.9, 
17.4 Hz, 1H), 3.20 (dd, J= 8.1, 17.4 Hz, 1H), 3.13 (dd, J= 1.8, 14.1 Hz, 1H), 2.86 (dd, J= 9.3, 14.1 Hz, 1H), 
2.18 (bs, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 137.9, 130.8, 129.2, 129.2, 127.5, 83.7, 60.9, 53.7, 49.0, 43.3. 
[α]D20= + 116.3° (c= 0.50, CHCl3). 
MS(ESI): m/z calcd for C12H1579BrN2O3S: 346.0; found: 347.1 [M+H]+. 
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Synthesis of tert-butyl 5-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)pentanamido) 
pentylcarbamate [(S,S,R)-94] 
 
 
EDC hydrochloride (88.6 mg, 0.462 mmol), HOBt (62.4 mg, 0.462 mmol) and TEA (114 µL, 0.818 mmol) 
were added at 0 °C to a suspension of (S,S,R)-93 (100 mg, 0.409 mmol) in dry DMF (2.2 mL). The mixture 
was stirred at 0 °C for 10 min then 92 (85.3 µL, 0.409 mmol) was added at 0 °C. The reaction mixture was 
stirred at room temperature for 24 h protected from light. DMF was removed under reduced pressure, water 
was added and the precipitate filtered and washed with water (10 mL) and n-hexane (8 ml). The obtained white 
solid was purified by flash chromatography on silica gel (DCM/MeOH, 9:1) as eluent, obtaining tert-butyl 5-
(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)pentanamido)pentylcarbamate [(S,S,R)-
94] as a white solid (135 mg, 80% yield) (m.p.= 134.6-135.5 °C). 
Rf= 0.43 (DCM/MeOH, 9:1). 
1H-NMR (300 MHz, CD3OD): δ= 4.48 (dd, J= 4.8, 7.8 Hz, 1H), 4.29 (dd, J= 4.4, 7.8 Hz, 1H), 3.20 (m, 1H), 
3.16 (t, J= 7.0 Hz, 2H), 3.02 (t, J= 6.7 Hz, 2H), 2.92 (dd, J= 4.8, 12.3 Hz, 1H), 2.92 (d, J= 12.3 Hz, 1H), 2.19 
(t, J= 7.4 Hz, 2H), 1.80-1.26 (m, 21H). 
13C-NMR (75 MHz, CD3OD): δ= 175.8, 175.7, 165.7, 158.2, 79.8, 79.3, 78.8, 78.4, 63.1, 61.4, 56.8, 41.1, 
41.0, 40.3, 40.2, 36.7, 30.4, 29.9, 29.6, 29.2, 28.9, 26.7, 25.0. 
[α]D20= + 44.9° (c= 0.55, CH3OH). 
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Synthesis of tert-butyl (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-oxo-2-(5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentylamino)ethylcarbamate [(S,S,S,S,R)-
96] 
 
30% TFA/DCM (1.80 mL) was added at 0 °C to (S,S,R)-94 (135 mg, 0.315 mmol). Reaction mixture was 
stirred at room temperature for 16 h. Solvent was evaporated and the residue was dissolved in 1:1 
CHCl3/MeOH (6.5 mL) and neutralized with solid KHCO3. The solid was filtered and the filtrate was 
evaporated, obtaining N-(5-aminopentyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide [(S,S,R)-95] as a white fluffy solid (103 mg, quantitative yield) that was subsequently used 
without characterization. 
EDC hydrochloride (66.1 mg, 0.345 mmol), HOBt (46.6 mg, 0.345 mmol) and TEA (131 µL, 0.942 mmol) 
were added at 0 °C to a solution of (S,S)-41 (101 mg, 0.314 mmol) in dry DCM (1 mL). The mixture was 
stirred at 0 °C for 10 min, then a solution of (S,S,R)-95 (103 mg, 0.314 mmol) in dry DMF (3.3 mL) was added 
at 0 °C. The reaction mixture was stirred at room temperature for 24 h. Water (5 mL) was added and it was 
extracted with 1:1 CHCl3/MeOH (10 mL). The organic layer was washed with brine, dried over anhydrous 
Na2SO4, filtered and the solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (DCM/MeOH, 95:5 to 9:1) obtaining tert-butyl (S)-1-((S)-3-bromo-4,5-
dihydroisoxazol-5-yl)-2-oxo-2-(5-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)pentylamino)ethylcarbamate [(S,S,S,S,R)-96] as a yellow solid (31 mg, 16% yield) 
(decomposes at T> 70 °C). 
Rf= 0.36 (DCM/MeOH, 9:1). 
1H-NMR (300 MHz, CD3OD): δ= 4.87 (m, 1H), 4.49 (dd, J= 4.8, 7.8 Hz, 1H), 4.30 (dd, J= 4.8, 7.8 Hz, 1H), 
4.22 (d, J= 6.6 Hz, 1H), 3.41 (dd, J= 10.5, 17.7 Hz, 1H), 3.26-3.12 (m, 5H), 2.92 (dd, J= 4.8, 12.3 Hz, 1H), 
2.70 (d, J= 12.3 Hz, 1H), 2.19 (t, J= 7.1 Hz, 2H), 1.80-1.26 (m, 12H), 1.44 (s, 9H). 
13C-NMR (75 MHz, CD3OD): δ= 174.5, 169.7, 164.7, 156.2, 138.0, 81.2, 79.7, 62.0, 60.2, 55.6, 53.4, 43.3, 
39.6, 38.9, 38.8, 35.4, 28.6, 28.5, 28.4, 28.1, 27.2, 25.5, 23.7. 
[α]D20= + 60.9° (c= 0.30, CH3OH). 
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Synthesis of (S)-1-((S)-3-bromo-4,5-dihydroisoxazol-5-yl)-2-oxo-2-(5-(5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamido)pentylamino)ethanaminium 2,2,2-trifluoroacetate 
[(S,S,S,S,R)-91*TFA] 
 
30% TFA/DCM (1.1 mL) was added at 0 °C to (S,S,S,S,R)-96 (31 mg, 0.0489 mmol). The reaction mixture 
was stirred at room temperature for 3.5 h. The solvent was removed at reduced pressure, obtaining (S)-1-((S)-
3-bromo-4,5-dihydroisoxazol-5-yl)-2-oxo-2-(5-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)pentylamino)ethanaminium 2,2,2-trifluoroacetate [(S,S,S,S,R)-91*TFA] as a red solid (31 
mg, quantitative yield) (decomposes at T> 70 °C). 
1H-NMR (300 MHz, CD3OD): δ= 5.11 (ddd, J= 4.5, 8.7, 10.5 Hz, 1H), 4.49 (dd, J= 4.8, 8.0 Hz, 1H), 4.30 (dd, 
J= 4.3, 8.0 Hz, 1H), 4.18 (d, J=4.8 Hz, 1H), 3.50 (dd, J= 10.5, 18.3 Hz, 1H), 3.40 (dd, J= 8.7, 18.3 Hz, 1H),  
3.27-3.11 (m, 5H), 2.93 (dd, J= 4.8, 12.9 Hz, 1H), 2.70 (d, J= 12.9 Hz, 1H), 2.20 (t, J= 7.2 Hz, 2H), 1.81-1.26 
(m, 12H). 
13C-NMR (75 MHz, CD3OD): δ= 174.6, 164.7, 164.5, 138.5, 79.0, 62.0, 60.2, 55.6, 53.8, 41.6, 39.6, 39.3, 
38.7, 35.4, 28.6, 28.3, 28.3, 28.1, 25.5, 23.7 (TFA signals are too low to detect). 
[α]D20= + 53.1° (c= 0.54, CH3OH). 
MS(ESI): m/z calcd for C22H3479BrF3N6O6S: 532.1 (M-TFA); found: 533.3 [M-TFA+H]+. 
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Synthesis of (±)-3-bromo-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole [(±)-148] 
 
TFA (264 µL, 3.43 mmol) was added at 0 °C to a solution of (±)-6 (100 mg, 0.343 mmol) in DCM (0.88 mL). 
The reaction was stirred at room temperature for 4 h, then the solvent was removed under reduced pressure. 
The residue was dissolved in EtOAc and washed with 5% aq. NaHCO3. The organic phase was dried over 
anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude product was purified by 
flash chromatography on silica gel (EtOAc/MeOH, 9:1) obtaining (±)-3-bromo-4,5,6,6a-tetrahydro-3aH-
pyrrolo[3,4-d]isoxazole [(±)-148] as a white solid (55 mg, 84% yield). 
Rf= 0.22 (EtOAc/MeOH, 9:1). 
1H-NMR (300 MHz, CDCl3): δ= 5.25 (dd, J= 3.8, 8.2 Hz, 1H), 3.82 (dd, J= 7.4, 8.2 Hz, 1H), 3.48 (d, J= 13.5 
Hz, 1H), 3.36 (d, J= 12.6 Hz, 1H), 2.88 (dd, J= 7.4, 12.6 Hz, 1H), 2.84 (dd, J= 3.8, 13.5 Hz, 1H), 1.84 (bs, 
1H). 
13C-NMR (75 MHz, CDCl3): δ= 139.5, 88.2, 60.1, 57.4, 52.3. 
 
Following the same procedure starting from (R,R)-6 or (S,S)-6 the single enantiomers were obtained. 
 
(3aR,6aR)-3-bromo-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole [(R,R)-148] 
[α]D20= - 179.8° (c= 0.60, CHCl3). 
(3aS,6aS)-3-bromo-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole [(S,S)-148] 
[α]D20= + 180.0° (c= 0.61, CHCl3). 
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General procedure for carbamates (S)-100-111 synthesis 
Method A 
The required chloroformate (1.5 eq.) was added dropwise at 0 °C to a solution of compound (S)-97, (S)-98 or 
(S)-99 (1 eq.) in 7:3 sat. aq. NaHCO3/dioxane (30 mL). The reaction mixture was stirred at room temperature 
for 12 h. Dioxane was evaporated and the reaction mixture was diluted with EtOAc, washed with 3 M aq. HCl, 
dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography on silica gel (light petroleum/EtOAc, 6:4) to afford pure 
carbamates. 
Method B 
TEA (1.5 eq.) and (Boc)2O (1.2 eq.) were added at 0 °C to a solution of compound (S)-97, (S)-98 or (S)-99 (1 
equiv) in dry DCM. The reaction mixture was stirred at room temperature for 12 h, then it was diluted with 
EtOAc, washed with 3 M aq. HCl, dried over anhydrous Na2SO4, filtered and the solvent was removed under 
reduced pressure. The crude product was purified by flash column chromatography on silica gel (light 
petroleum/EtOAc, 6:4) to afford pure carbamates. 
The products have been used in the following step without characterization. 
 
General procedure for esters (S)-100-123 hydrolysis 
The synthesis of compounds (S)-100-123 was performed following the reported procedure [48] which is 
reported below. 
 LiOH (2 eq.) was added at 0 °C to a solution carbamate (1 eq.) in 1:1 methanol/water. The reaction mixture 
was stirred at room temperature until disappearance of the starting material. The reaction mixture was 
concentrated under vacuum, treated with 10% aq. citric acid and extracted with EtOAc. The pooled organic 
extracts were dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure to 
afford the pure carboxylic acids [(S)-112-123]. 
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General procedure for the coupling of acids (S)-112-123 and amine (±)-148 
HOBt (1.2 eq.), EDC (1.2 eq.), amine (±)-148, (R,R)-148 or (S,S)-148, (1 eq.) and DIPEA (1.5 eq.) were added 
at 0 °C to a solution of the desired acid (1 eq.) in 1:1 DMF/DCM (1:1). The reaction mixture was stirred at 
room temperature for 15 h, then it was diluted with EtOAc and washed with sat. aq. NaHCO3. The organic 
phase dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude product 
was purified by flash column chromatography on silica gel (light petroleum/EtOAc, 4:6) to afford the desired 
product. When racemic (±)-148 was used, the product was obtained as a mixture of diastereoisomers. When 
enantiopure amines (R,R)-148 or (S,S)-148 were used, the product was obtained as a single diastereoisomer. 
The following characterizations are in keeping with the literature. [48] 
 
Synthesis of n-propyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-
methyl-1-oxopentan-2-ylcarbamate [(S,S,S)-124] and n-propyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-methyl-1-oxopentan-2-ylcarbamate [(S,R,R)-125] 
 
86% yield. Rf= 0.50 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 5.44-5.19 (m, 2H), 4.61-4.39 (m, 1H), 4.21 (d, J= 13.4 Hz, 1H), 4.15-3.87 
(m, 4H), 3.84-3.47 (m, 2H), 1.80-1.48 (m, 5H), 1.02 (t, J= 7.4 Hz, 3H), 0.96 (d, J= 7.3 Hz, 3H), 0.91 (d, J= 
7.5 Hz, 3H). 
MS(ESI): m/z calcd for C15H2479BrN3O4: 389.1; found: 390.1 [M+H]+. 
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Synthesis of allyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-methyl-
1-oxopentan-2-ylcarbamate [(S,S,S)-126] 
 
87% yield. Rf= 0.48 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 5.99-5.82 (m, 1H), 4.63-4.51 (m, 2H), 5.51–5.32 (m, 2H), 5.25 (m, 2H), 4.50-
4.39 (m, 1H), 4.28–4.15 (m, 1H), 4.19 (d, J= 12.2 Hz, 1H), 4.03-3.90 (m, 1H), 3.99 (d, J= 12.2 Hz, 1H), 3.51 
(m, 1H), 1.77–1.63 (m, 1H), 1.62–1.38 (m, 2H), 0.99 (d, J= 6.1 Hz, 3H), 0.94 (d, J= 6.5 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 172.1, 157.4, 139.6, 134.9, 119.1, 84.1, 65.9, 57.9, 53.7, 51.6, 47.9, 44.2, 
26.5, 23.8, 21.7. 
[α]D20= + 62.2° (c= 0.36, DCM). 
MS(ESI): m/z calcd for C15H2279BrN3O4: 387.1; found: 388.3 [M+H]+. 
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Synthesis of allyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-methyl-
1-oxopentan-2-ylcarbamate [(S,R,R)-127] 
 
93% yield. Rf= 0.48 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 5.98-5.82 (m, 1H), 5.49 (d, J= 8.1 Hz, 1H), 5.42-5.24 (m, 1H), 5.24 (m, 2H), 
4.62-4.50 (m, 2H), 4.50-4.41 (m, 1H), 4.17 (d, J= 14.1 Hz, 1H), 4.11-3.96 (m, 1H), 4.00 (d, J= 14.1 Hz, 1H), 
3.82-3.67 (m, 1H), 3.58 (m, 1H), 1.81-1.64 (m, 1H), 1.62-1.44 (m, 1H), 1.45-1.31 (m, 1H), 1.01 (d, J= 6.7 Hz, 
3H), 0.94 (d, J= 6.5 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ= 172.2, 157.4, 139.7, 134.9, 119.1, 84.1, 65.9, 58.0, 53.7, 51.6, 47.9, 44.2, 
26.5, 23.8, 21.7. 
[α]D20= - 79.3° (c= 0.75, DCM); 
MS(ESI): m/z calcd for C15H2279BrN3O4: 387.1; found: 388.3 [M+H]+.  
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Synthesis of tert-butyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-
methyl-1-oxopentan-2-ylcarbamate [(S,S,S)-128] and tert-butyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-methyl-1-oxopentan-2-ylcarbamate [(S,R,R)-129] 
 
93% yield. Rf= 0.58 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 5.20 (d, J= 7.9 Hz, 1H), 5.20-5.06 (m, 1H), 4.55-4.36 (m, 1H), 4.21 (d, J= 
14.9 Hz, 1H), 4.12-3.91 (m, 3H), 3.69-3.59 (m, 0.5H), 3.59-3.46 (m, 0.5H), 1.79-1.66 (m, 1H), 1.67-1.54 (m, 
2H), 1.45 (s, 9H), 1.00 (d, J= 7.4 Hz, 3H), 0.96 (d, J= 6.7 Hz, 3H). 
MS(ESI): m/z calcd for C16H2679BrN3O4: 403.1; found: 404.1 [M+H]+. 
 
 
Synthesis of benzyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-
methyl-1-oxopentan-2-ylcarbamate [(S,S,S)-130] and benzyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-4-methyl-1-oxopentan-2-ylcarbamate [(S,R,R)-131] 
 
83% yield. Rf= 0.56 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.47-7.30 (m, 5H), 5.52-5.27 (m, 2H), 5.11 (s, 2H), 4.63-4.42 (m, 1H), 4.21 
(d, J= 13.8 Hz, 1H), 4.13-3.86 (m, 2H), 3.84-3.71 (m, 1H), 3.68-3.55 (m, 0.5H), 3.54-3.42 (m, 0.5H), 1.80-
1.66 (m, 1H), 1.59-1.46 (m, 2H), 1.01 (d, J= 6.7 Hz, 3H), 0.96 (d, J= 6.5 Hz, 3H). 
MS(ESI): m/z calcd for C19H2479BrN3O4: 437.1; found: 438.1 [M+H]+. 
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Synthesis of n-propyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-
3-phenylpropan-2-ylcarbamate [(S,S,S)-132] and n-propyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-phenylpropan-2-ylcarbamate [(S,R,R)-133] 
 
84% yield. Rf= 0.39 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.33-7.11 (m, 5H), 5.42 (d, J= 7.4 Hz, 1H), 5.26-5.17 (m, 1H), 4.68-4.52 (m, 
1H), 4.17 (d, J= 13.8 Hz, 0.5H), 4.10 (d, J= 13.8 Hz, 0.5H), 4.09-3.99 (m, 1H), 3.97 (t, J= 7.0 Hz, 2H), 3.84-
3.61 (m, 2H), 3.56-3.46 (m, 0.5H), 3.46-3.37 (m, 0.5H), 3.15-3.02 (m, 1H), 3.02-2.88 (m, 1H), 1.68-1.55 (m, 
2H), 0.93 (t, J= 8.0 Hz, 3H). 
MS(ESI): m/z calcd for C18H2279BrN3O4: 423.1; found: 424.1 [M+H]+. 
 
Synthesis of allyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-
phenylpropan-2-ylcarbamate [(S,S,S)-134] 
 
92% yield. Rf= 0.40 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.36-7.13 (m, 5H), 6.00-5.82 (m, 1H), 5.51 (d, J= 7.6 Hz, 1H), 5.37-5.19 (m, 
3H), 4.72-4.51 (m, 3H), 4.07 (d, J= 12.3 Hz, 1H), 3.96-3.73 (m, 2H), 3.54 (m, 1H), 3.34 (d, J= 12.3 Hz, 1H), 
3.16-2.83 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.8, 155.8, 137.2, 136.1, 134.1, 129.5, 129.1, 128.8, 118.4, 85.4, 66.8, 57.5, 
55.8, 53.4, 48.7, 40.4. 
[α]D20= + 42.7° (c= 0.18, DCM). 
MS(ESI): m/z calcd for C18H2079BrN3O4: 421.1; found: 422.2 [M+H]+.  
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Synthesis of allyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-
phenylpropan-2-ylcarbamate [(S,R,R)-135] 
 
89% yield. Rf= 0.40 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.38-7.13 (m, 5H), 6.00-5.81 (m, 1H), 5.58 (d, J= 8.8 Hz, 1H), 5.30 (m, 1H), 
5.22 (m, 2H), 4.69-4.51 (m, 3H), 4.19 (d, J= 11.8 Hz, 1H), 4.03-3.88 (m, 1H), 3.85-3.67 (m, 1H), 3.38 (d, J= 
11.8 Hz, 1H), 3.27 (m, 1H), 3.19-2.86 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.8, 155.8, 137.2, 136.0, 134.0, 129.5, 129.0, 128.8, 118.4, 85.4, 66.8, 57.5, 
55.9, 53.4, 48.7, 40.4. 
[α]D20= - 51.2° (c= 0.40, DCM). 
MS(ESI): m/z calcd for C18H20BrN3O4: 421.1; found: 422.2 [M+H]+. 
 
Synthesis of tert-butyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-
3-phenylpropan-2-ylcarbamate [(S,S,S)-136] and tert-butyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-phenylpropan-2-ylcarbamate [(S,R,R)-137] 
 
90% yield. Rf= 0.46 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.41-7.12 (m, 5H), 5.37 (bs, 1H), 5.31-5.19 (m, 1H), 4.69-4.50 (m, 1H), 4.19 
(d, J= 15.3 Hz, 0.5H), 4.06 (d, J= 15.3 Hz, 0.5H), 4.00-3.62 (m, 3H), 3.54 (m, 0.5H), 3.49-3.38 (m, 0.5H), 
3.17-2.86 (m, 2H), 1.44 (s, 9H). 
MS(ESI): m/z calcd for C19H2479BrN3O4: 437.1; found: 438.1 [M+H]+. 
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Synthesis of benzyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-
phenylpropan-2-ylcarbamate [(S,S,S)-138] and benzyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-3-phenylpropan-2-ylcarbamate [(S,R,R)-139] 
 
92% yield. Rf= 0.42 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.46-7.10 (m, 10H), 5.54 (d, J= 7.4 Hz, 1H), 5.29-5.18 (m, 0.5H), 5.14 (s, 
2H), 5.12-5.05 (m, 0.5H), 4.73-4.57 (m, 1H), 4.19 (d, J= 12.1 Hz, 0.5H), 4.07 (d, J= 12.1 Hz, 0.5H), 3.99-3.86 
(m, 1H), 3.84-3.66 (m, 1H), 3.60-3.46 (m, 0.5H), 3.38 (d, J= 12.1 Hz, 0.5H), 3.30 (d, J= 12.1 Hz, 0.5H), 3.34-
3.23 (m, 0.5H), 3.18-2.89 (m, 2H). 
MS(ESI): m/z calcd for C22H2279BrN3O4: 471.1; found: 472.1 [M+H]+. 
 
 
Synthesis of n-propyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-
4-phenylbutan-2-ylcarbamate [(S,S,S)-140] and n-propyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-phenylbutan-2-ylcarbamate [(S,R,R)-141] 
 
88% yield. Rf= 0.45 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.39-7.17 (m, 5H), 5.41 (bs, 1H), 5.34-5.22 (m, 1H), 4.49-4.33 (m, 1H), 4.30-
4.16 (m, 1H), 4.03 (t, J= 7.5 Hz, 2H), 3.99-3.90 (m, 1H), 3.76-3.59 (m, 2H), 3.52-3.42 (m, 0.5H), 3.42-3.31 
(m, 0.5H), 2.77-2.65 (m, 2H), 2.07-1.89 (m, 2H), 1.71-1.59 (m, 2H), 0.96 (t, J= 8.0 Hz, 3H). 
MS(ESI): m/z calcd for C19H2479BrN3O4: 437.1; found: 438.1 [M+H]+. 
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Synthesis of allyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-
phenylbutan-2-ylcarbamate [(S,S,S)-142] 
 
85% yield. Rf= 0.46 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.38-7.15 (m, 5H), 6.01-5.85 (m, 1H), 5.60 (d, J= 7.7 Hz, 1H), 5.39-5.20 (m, 
3H), 4.63-4.55 (m, 2H), 4.45-4.33 (m, 1H), 4.21 (d, J= 13.0 Hz, 1H), 3.94 (m, 1H), 3.72-3.60 (m, 2H), 3.46 
(m, 1H), 2.78-2.63 (m, 2H), 2.13-1.88 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.8, 156.6, 141.3, 139.2, 133.1, 129.4, 128.6, 125.8, 117.3, 84.5, 66.1, 55.7, 
53.1, 51.4, 47.9, 31.8, 29.6. 
[α]D20= + 60.4° (c= 0.22, DCM). 
MS(ESI): m/z calcd for C19H2279BrN3O4: 435.1; found: 436.1 [M+H]+. 
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Synthesis of allyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-
phenylbutan-2-ylcarbamate [(S,R,R)-143] 
 
81% yield. Rf= 0.46 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.38-7.17 (m, 5H), 6.01-5.85 (m, 1H), 5.62 (d, J= 8.1 Hz, 1H), 5.32-5.20 (m, 
1H), 5.28 (m, 2H), 4.66-4.54 (m, 2H), 4.55-4.39 (m, 1H), 4.13 (d, J= 13.4 Hz, 1H), 4.05-3.88 (m, 1H), 3.77-
3.57 (m, 1H), 3.68 (d, J= 13.4 Hz, 1H), 3.42 (m, 1H), 2.82-2.60 (m, 2H), 2.06-1.87 (m, 2H). 
13C-NMR (75 MHz, CDCl3): δ= 171.8, 156.6, 141.3, 139.2, 133.1, 129.3, 128.7, 125.9, 117.2, 84.4, 66.1, 55.6, 
53.1, 51.4, 47.9, 31.7, 29.5. 
[α]D20= - 70.5° (c= 0.39, DCM); 
MS(ESI): m/z calcd for C19H2279BrN3O4: 435.1; found: 436.1 [M+H]+. 
 
Synthesis of tert-butyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-
4-phenylbutan-2-ylcarbamate [(S,R,R)-144] and tert-butyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-phenylbutan-2-ylcarbamate [(S,R,R)-145] 
 
96% yield. Rf= 0.48 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.37-7.17 (m, 5H), 5.37 (bs, 1H), 5.33-5.18 (m, 1H), 4.53-4.26 (m, 1H), 4.26-
4.11 (m, 1H), 4.06-3.88 (m, 1H), 3.79-3.56 (m, 2H), 3.54-3.42 (m, 0.5H), 3.42-3.32 (m, 0.5H), 2.84-2.61 (m, 
2H), 2.11-1.83 (m, 2H), 1.46 (s, 9H). 
MS(ESI): m/z calcd for C20H2679BrN3O4: 451.1; found: 452.1 [M+H]+. 
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Synthesis of benzyl (S)-1-((3aS,6aS)-3-bromo-3a,4,6,6a-tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-
phenylbutan-2-ylcarbamate [(S,S,S)-146] and benzyl (S)-1-((3aR,6aR)-3-bromo-3a,4,6,6a-
tetrahydropyrrolo[3,4-d]isoxazol-5-yl)-1-oxo-4-phenylbutan-2-ylcarbamate [(S,R,R)-147] 
 
87% yield. Rf= 0.42 (light petroleum/EtOAc, 4:6). 
1H-NMR (300 MHz, CDCl3): δ= 7.46–7.16 (m, 10H), 5.52 (bs, 1H), 5.33-5.22 (m, 1H), 5.14 (s, 2H), 4.60-4.36 
(m, 1H), 4.26-4.10 (m, 1H), 4.04-3.86 (m, 1H), 3.74-3.59 (m, 2H), 3.53-3.42 (m, 0.5H), 3.42-3.30 (m, 0.5H), 
2.87-2.62 (m, 2H), 2.13-1.88 (m, 2H). 
MS(ESI): m/z calcd for C23H2479BrN3O4: 485.1; found: 486.1 [M+H]+. 
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Synthesis of ethyl 4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)ureido)benzoate (153) 
 
1 M aq. NaOH (11.4 mL) was added to a suspension of 4-hydroxy-2,5,6-triaminopyrimidine sulfate salt 
(150*H2SO4) (910 mg, 3.80 mmol) in water (2.0 mL). A solution of ethyl 4-isocyanatebenzoate (151) (726 
mg, 3.80 mmol) in MeCN (6.0 mL) was slowly added. The reaction mixture was vigorously stirred at room 
temperature for 2.5 h, then it was neutralized with 1 M aq. HCl (11.4 mL). The precipitate was filtered, washed 
with water (50 mL), ethanol (30 mL) and Et2O (30 mL) obtaining ethyl 4-(3-(2,4-diamino-6-
hydroxypyrimidin-5-yl)ureido)benzoate (153) as a pale orange solid (950 mg, 75% yield) (decomposes at T> 
180 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 10.0 (bs, 1H), 8.98 (bs, 1H), 7.84 (d, J= 8.4 Hz, 2H), 7.57 (d., J= 8.4 Hz, 
2H), 6.76 (s, 1H), 6.16 (bs, 2H), 5.96 (bs, 2H), 4.26 (q, J= 7.0 Hz, 2H), 1.31 (t, J= 7.0 Hz, 3H). 
13C-NMR (75 MHz, DMSO-d6): δ= 166.2, 162.4, 161.0, 155.3, 154.0, 145.9, 130.9, 122.6, 117.6, 89.9, 60.8, 
14.9. 
 
 
 
Synthesis of 4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)ureido)benzoic acid (154) 
 
1 M aq. NaOH (28.6 mL) was added to a suspension of 153 (950 mg, 2.86 mmol) in water (25 mL). The 
reaction mixture was stirred at room temperature for 3 h, then it was neutralized with 1 M aq. HCl (28.6 mL). 
The precipitate was centrifuged (5000 rpm, 3 min) and washed with water (20 mL), ethanol (20 mL) and Et2O 
(20 mL) obtaining 4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)ureido)benzoic acid (154) as a pale orange 
solid (800 mg, 92% yield) (decomposes at T> 240 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.50 (bs, 1H), 9.98 (bs, 1H), 8.90 (bs, 1H), 7.80 (d, J= 7.6 Hz, 2H), 7.52 
(d, J= 7.6 Hz, 2H), 6.71 (s, 1H), 6.18 (bs, 2H), 5.88 (bs, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 167.8, 162.2, 160.9, 155.3, 154.0, 145.6, 131.1, 123.5, 117.5, 90.0.  
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General procedure for the esterification of amino acids 
SOCl2 (2.2 eq.) was added dropwise at 0 °C to a suspension of amino acid in methanol or ethanol (0.75 mol/L). 
The reaction mixture was stirred at room temperature for 24 h, then the solvent was removed under reduced 
pressure obtaining the diester hydrochloride product. 
 
Synthesis (S)-1,5-diethoxy-1,5-dioxopentan-2-aminium chloride [(S)-158] 
 
The product was synthesized following the general procedure for the esterification of amino acids, and it was 
obtained as a white solid (99% yield) (m.p.= 108-110 °C) (lit. m.p.= 109-110 °C). [77] 
1H-NMR (300 MHz, D2O): δ= 4.20 (q, J= 7.3 Hz, 2H), 4.13-4.04 (m, 3H), 2.53 (dt, J= 1.8, 7.3 Hz, 2H), 2.25-
2.05 (m, 2H), 1.21 (t, J= 7.3 Hz, 3H), 1.16 (t, J= 7.3 Hz, 3H). 
13C-NMR (75 MHz, D2O): δ= 174.6, 169.9, 63.9, 62.3, 52.3, 29.8, 25.0, 13.5, 13.4. 
 
 
Synthesis of (S)-1,4-dimethoxy-1,4-dioxobutan-2-aminium chloride [(S)-162] 
 
The product was synthesized following the general procedure for the esterification of amino acids, and it was 
obtained as a white solid (98% yield) (m.p.= 115.7-116.5 °C) (lit. m.p.= 115-116 °C). [78] 
1H-NMR (300 MHz, DMSO-d6): δ= 8.68 (bs, 3H), 4.33 (t, J= 6.2 Hz, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 2.99 (m, 
2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 169.6, 168.7, 53.0, 52.2, 48.4, 34.0. 
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Synthesis of (S)-1,6-dimethoxy-1,6-dioxohexan-2-aminium chloride [(S)-163] 
 
The product was synthesized following the general procedure for the esterification of amino acids, and it was 
obtained as a colourless oil (quantitative yield). 
1H-NMR (300 MHz, D2O): δ= 4.05 (t, J= 6.3 Hz, 1H), 3.74 (s, 3H), 3.58 (s, 3H), 2.36 (t, J= 7.1, 7.7 Hz, 2H), 
1.97-1.75 (m, 2H), 1.73-1.48 (m, 2H). 
13C-NMR (75 MHz, D2O): δ= 169.6, 168.7, 53.0, 52.2, 48.4, 34.0. 
 
 
 
Synthesis of 4-methoxy-4-oxobutan-1-aminium chloride (164) 
 
The product was synthesized following the general procedure for the esterification of amino acids, and it was 
obtained as a white solid (90% yield) (m.p.= 122.5-123.2 °C) (lit. m.p.= 120.0 °C). [79] 
1H-NMR (300 MHz, CD3OD): δ= 3.68 (s, 3H), 2.98 (t, J= 7.7 Hz, 2H), 2.48 (t, J= 7.1 Hz, 2H), 1.93 (tt, J= 
7.1, 7.7 Hz, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 174.5, 52.3, 40.0, 31.4, 23.7. 
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General procedure for the coupling of 154 with amino esters 
NMM (4 eq.) and CDMT (4 eq.) were added to a suspension of 154 (1 eq.) in dry DMF (47 mmol/L). The 
reaction mixture was stirred at 35 °C for 5 h, then the amino ester hydrochloride (4 eq.) and NMM (4 eq.) were 
added. The reaction mixture was stirred at 30 °C for 18 h, then the solvent was removed at reduced pressure, 
ethanol was added and the precipitate was filtered, washed with ethanol and Et2O, obtaining the desired 
product. 
 
Synthesis of (S)-diethyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)pentanedioate [(S)-155] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (65% yield) (decomposes at T> 180 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.95 (bs, 1H), 8.82 (bs, 1H), 8.48 (d, J= 7.0 Hz, 1H), 7.80 (d, J= 8.8 Hz, 
2H), 7.50 (d, J= 8.8 Hz, 2H), 6.70 (s, 1H), 6.18 (bs, 2H), 5.88 (bs, 2H), 4.40-4.37 (m, 1H), 4.07 (q, J= 7.3 Hz, 
2H), 4.00 (q, J= 7.3 Hz, 2H), 2.45-2.38 (m, 2H), 2.17-1.95 (m, 2H), 1.17 (t, J= 7.3 Hz, 3H), 1.13 (t, J= 7.3 Hz, 
3H). 
13C-NMR (75 MHz, DMSO-d6): δ= 172.9, 172.7, 167.0, 162.2, 160.9, 155.4, 153.9, 144.4, 129.1, 126.6, 117.4, 
90.1, 61.2, 60.6, 52.6, 30.9, 26.5, 14.8. 
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Synthesis of (S)-dimethyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)succinate [(S)-168] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (72% yield) (decomposes at T> 178 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 10.06 (bs, 1H), 8.82 (bs, 1H), 8.70 (d, J= 7.7 Hz, 1H), 7.75 (d, J= 8.8 Hz, 
2H), 7.51 (d, J= 8.8 Hz, 2H), 6.72 (s, 1H), 6.25 (bs, 2H), 5.96 (bs, 2H), 4.79 (ddd, J= 6.3, 7.7, 7.9 Hz, 1H), 
3.62 (s, 3H), 3.60 (s, 3H), 2.93 (dd, J= 6.3, 16.5 Hz, 1H), 2.79 (dd, J= 7.9, 16.5Hz, 1H). 
13C-NMR (75 MHz, DMSO-d6): δ= 172.2, 171.3, 166.5, 161.8, 160.9, 155.3, 153.8, 144.5, 129.0, 126.3, 117.4, 
90.0, 52.9, 52.4, 49.8, 36.1. 
  
Page | 157  
 
Synthesis of (S)-dimethyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)hexanedioate [(S)-169] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (61% yield) (decomposes at T> 190 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.96 (bs, 1H), 8.82 (bs, 1H), 8.50 (d, J= 7.4 Hz, 1H), 7.77 (d, J= 8.8 Hz, 
2H), 7.50 (d, J= 8.8 Hz, 2H), 6.69 (s, 1H), 6.14 (bs, 2H), 5.88 (bs, 2H), 4.38 (dt, 1H, J = 6.9, 7.4 Hz, 1H), 3.62 
(s, 3H), 3.56 (s, 3H), 2.32 (t, J= 7.3 Hz, 2H), 1.89-1.72 (m, 2H), 1.68-1.53 (m, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.8, 173.4, 166.9, 162.3, 160.9, 155.4, 154.0, 144.4, 129.1, 126.5, 117.3, 
90.0, 53.0, 52.5, 51.9, 33.5, 30.5, 22.0. 
 
 
 
Synthesis of methyl 4-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)butanoate (170) 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (63% yield) (decomposes at T> 210 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.98 (bs, 1H), 8.77 (bs, 1H), 8.26 (t, J= 5.5 Hz, 1H), 7.71 (d, J= 8.5 Hz, 
2H), 7.47 (d, J= 8.5 Hz, 2H), 6.69 (s, 1H), 6.16 (bs, 2H), 5.88 (bs, 2H), 3.56 (s, 3H) 3.23 (dt, J= 5.5, 6.6 Hz, 
2H), 2.34 (t, J= 7.1 Hz, 2H), 1.75 (tt, J= 6.6, 7.1 Hz, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.9, 166.6, 162.3, 160.9, 155.4, 154.0, 143.9, 128.6, 127.5, 117.4, 90.1, 
51.9, 39.1, 31.5, 25.3. 
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Synthesis of (S)-methyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)propanoate [(S)-171] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (69% yield) (decomposes at T> 172 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.98 (bs, 1H), 8.82 (bs, 1H,), 8.55 (d, J= 6.9 Hz, 1H), 7.77 (d, J= 8.7 Hz, 
2H), 7.50 (d, J= 8.7 Hz, 2H), 6.70 (s, 1H), 6.17 (bs, 2H), 5.89 (bs, 2H), 4.43 (dq, J= 6.9, 7.1 Hz, 1H), 3.62 (s, 
3H), 1.37 (d, J= 7.1 Hz, 3H). 
13C-NMR (75 MHz, DMSO-d6): δ= 174.1, 166.5, 162.2, 160.9, 155.4, 153.9, 144.3, 129.0, 126.5, 117.3, 90.0, 
52.5, 48.9, 17.5. 
 
 
 
Synthesis of methyl 3-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-
yl)ureido)benzamido)propanoate (172) 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (63% yield) (decomposes at T> 180 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.98 (bs, 1H), 8.77 (bs, 1H), 8.33 (t, J= 5.5 Hz, 1H), 7.70 (d, J= 8.8 Hz, 
2H), 7.47 (d, J= 8.8 Hz, 2H), 6.69 (s, 1H), 6.16 (bs, 2H), 5.89 (bs, 2H), 3.59 (s, 3H), 3.44 (dt, J= 5.5, 6.9 Hz, 
2H), 2.56 (t, J= 6.9 Hz, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 172.5, 166.6, 162.3, 160.9, 155.4, 154.0, 144.1, 128.7, 127.2, 117.4, 90.1, 
52.1, 36.1, 34.4. 
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Synthesis of (S)-methyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)-3-
phenylpropanoate [(S)-173] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (58% yield) (decomposes at T> 180 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.98 (bs, 1H), 8.81 (bs, 1H), 8.61 (d, J= 7.0 Hz,1H), 7.70 (d, J= 8.8 Hz, 
2H), 7.48 (d, J= 8.8 Hz, 2H), 7.30-7.21 (m, 4H), 7.20-7.13 (m, 1H), 6.70 (s, 1H), 6.16 (bs, 2H), 5.89 (bs, 2H), 
4.60 (ddd, J= 6.0, 8.0, 9.1 Hz, 1H), 3.61 (s, 3H) 3.17-3.04 (m, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.1, 166.7, 162.3, 160.9, 155.3, 154.0, 144.4, 138.5, 129.7, 129.0, 128.9, 
127.1, 126.5, 117.3, 90.0, 54.7, 52.6, 37.0. 
 
 
 
Synthesis of (S)-methyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)-3-(4-
hydroxyphenyl)propanoate [(S)-174] 
 
The product was synthesized following the general procedure for the coupling of 154 with amino esters, and 
it was obtained as a pale orange solid (59% yield) (decomposes at T> 175 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 9.97 (bs, 1H), 9.19 (s, 1H), 8.83 (bs, 1H), 8.55 (d, J= 7.8 Hz, 1H), 7.70 
(d, J= 8.7 Hz, 2H), 7.48 (d, J= 8.7 Hz, 2H), 7.06 (d, J= 8.4 Hz, 2H), 6.71 (s, 1H), 6.63 (d, J= 8.4 Hz, 2H), 6.15 
(bs, 2H), 5.89 (bs, 2H), 4.56−4.45 (m, 1H), 3.60 (s, 3H), 3.05−2.87 (m, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.3, 166.7, 162.3, 160.9, 156.6, 155.4, 154.0, 144.3, 130.7, 129.0, 128.4, 
126.5, 117.3, 115.7, 90.0, 55.4, 52.5, 36.3.  
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General procedure for the synthesis of (S)-156 and analogues 
The coupling product (1 eq.) was dissolved in 1 M aq. NaOH (2 or 4 eq.). The reaction mixture was stirred at 
room temperature for 5 h, then it was neutralized with 1 M aq. HCl (2 or 4 eq.). The precipitate was filtered 
and washed with water, ethanol and Et2O, obtaining the desired product. 
 
Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)pentanedioic 
acid [(S)-156] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (88% yield) (decomposes at T> 190 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.35 (bs, 2H), 9.98 (bs, 1H), 8.82 (bs, 1H), 8.38 (d, J= 6.6 Hz, 1H), 7.79 
(d, J = 8.0 Hz, 2H), 7.50 (d, J= 8.0 Hz, 2H), 6.68 (s, 1H), 6.18 (bs, 2H), 5.90 (bs, 2H), 4.40-4.30 (m, 1H), 2.38-
2.30 (m, 2H), 2.10-2.00 (m, 1H), 2.00-1.90 (m, 1H). 
13C-NMR (75 MHz, DMSO-d6): δ= 174.6, 174.3, 166.8, 162.3, 160.9, 155.4, 154.0, 144.3, 129.0, 126.8, 117.4, 
90.1, 52.5, 31.1, 26.7. 
MS(ESI): m/z calcd for C17H19N7O7: 433.1; found: 434.1 [M+H]+. 
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Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)succinic acid 
[(S)-175] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (80% yield) (decomposes at T> 230 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.48 (bs, 2H), 9.96 (bs, 1H), 8.81 (bs, 1H), 8.48 (d, J= 7.4 Hz, 1H), 7.74 
(d, J= 8.5 Hz, 2H), 7.50 (d, J= 8.5 Hz, 2H), 6.69 (s, 1H), 6.14 (bs, 2H), 5.88 (bs, 2H), 4.70 (ddd, J= 6.1, 7.4, 
7.8 Hz, 1H), 2.81 (dd, J= 6.1, 16.4 Hz, 1H), 2.66 (dd, J= 7.8, 16.4 Hz, 1H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.5, 172.6, 166.3, 162.3, 160.9, 155.4, 154.0, 144.3, 128.9, 126.7, 117.4, 
90.0, 49.9, 36.9. 
MS(ESI): m/z calcd for C16H17N7O7: 419.1; found: 420.1 [M+H]+. 
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Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)hexanedioic 
acid [(S)-176] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (79% yield) (decomposes at T> 205 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.26 (bs, 2H), 9.97 (bs, 1H), 8.80 (bs, 1H), 8.35 (d, J= 7.7 Hz, 1H), 7.78 
(d, J= 8.7 Hz, 2H), 7.50 (d, J= 8.7 Hz, 2H), 6.69 (s, 1H), 6.14 (bs, 2H), 5.87 (bs, 2H), 4.31 (dt, J= 5.1, 7.7 Hz, 
1H), 2.22 (t, J= 7.4 Hz, 2H), 1.89-1.68 (m, 2H), 1.68-1.49 (m, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 175.0, 174.5, 166.7, 162.3, 160.9, 155.4, 154.0, 144.2, 129.0, 126.9, 117.3, 
90.1, 53.1, 34.0, 30.9, 22.1. 
MS(ESI): m/z calcd for C18H21N7O7: 447.1; found: 448.1 [M+H]+. 
 
 
Synthesis of 4-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)butanoic acid 
(177) 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (79% yield) (dec. T> 205 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.02 (bs, 1H), 9.97 (bs, 1H), 8.78 (bs, 1H), 8.25 (t, J= 5.8 Hz, 1H), 7.72 
(d, J= 8.8 Hz, 2H), 7.47 (d, J= 8.8 Hz, 2H), 6.68 (s, 1H), 6.13 (bs, 2H), 5.86 (bs, 2H), 3.23 (dt, J= 5.8, 6.6 Hz, 
2H), 2.25 (t, J= 7.4 Hz, 2H), 1.72 (tt, J= 5.8, 6.6 Hz, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 175.0, 166.6, 162.2, 160.9, 155.4, 154.0, 143.9, 128.6, 127.6, 117.4, 90.2, 
39.2, 31.9, 25.4. 
MS(ESI): m/z calcd for C16H19N7O5: 389.1; found: 390.1 [M+H]+.  
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Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)propanoic 
acid [(S)-178] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (70% yield) (decomposes at T> 195 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.44 (bs, 1H), 9.98 (bs, 1H), 8.82 (bs, 1H), 8.40 (d, J= 7.1 Hz, 1H), 7.77 
(d, J= 8.8 Hz, 2H), 7.49 (d, J= 8.8 Hz, 2H), 6.69 (s, 1H), 6.13 (bs, 2H), 5.87 (bs, 2H), 5.74 (s, 1H), 4.37 (dq, 
J= 7.1, 7.4 Hz, 1H), 1.36 (d, J= 7.4 Hz, 3H). 
13C-NMR (75 MHz, DMSO-d6): δ= 175.1, 166.3, 162.3, 160.9, 155.4, 154.0, 144.2, 128.9, 126.9, 117.3, 90.1, 
48.8, 17.8. 
MS(ESI): m/z calcd for C15H17N7O5: 375.1; found: 376.1 [M+H]+. 
 
 
Synthesis of 3-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)propanoic acid 
(179) 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (82% yield) (dec. T> 220 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.19 (bs, 1H), 9.97 (bs, 1H), 8.78 (bs, 1H), 8.30 (t, J= 5.3 Hz, 1H), 7.71 
(d, J= 8.8 Hz, 2H), 7.47 (d, J= 8.8 Hz, 2H), 6.69 (s, 1H), 6.14 (bs, 2H), 5.87 (bs, 2H), 3.41 (dt, J= 5.3, 6.7 Hz, 
2H), 2.43 (t, J= 6.7 Hz, 2H). 
13C-NMR (75 MHz, DMSO-d6): δ= 173.6, 166.6, 162.3, 160.9, 155.4, 154.0, 144.0, 128.7, 127.3, 117.4, 90.1, 
36.2, 34.6. 
MS(ESI): m/z calcd for C15H17N7O5: 375.1; found: 376.1 [M+H]+.  
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Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)-3-
phenylpropanoic acid [(S)-180] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (72% yield) (decomposes at T> 180 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.76 (bs, 1H), 9.97 (bs, 1H), 8.79 (bs, 1H), 8.46 (d, J= 8.2 Hz,1H), 7.69 
(d, J= 8.8 Hz, 2H), 7.48 (d, J= 8.8 Hz, 2H), 7.33-7.21 (m, 4H), 7.19-7.12 (m, 1H), 6.69 (s, 1H), 6.14 (bs, 2H), 
5.87 (bs, 2H), 4.56 (ddd, J= 4.6, 8.2, 10.5 Hz, 1H), 3.15 (dd, J= 4.6, 13.8 Hz, 1H), 3.04 (dd, J= 10.5, 13.8 Hz, 
1H). 
13C-NMR (75 MHz, DMSO-d6): δ= 174.1, 166.6, 162.3, 160.9, 155.3, 154.0, 144.2, 139.0, 129.7, 128.9, 128.8, 
127.0, 126.8, 117.3, 90.1, 54.9, 37.0. 
MS(ESI): m/z calcd for C21H21N7O5: 451.2; found: 452.2 [M+H]+. 
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Synthesis of (S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)ureido)benzamido)-3-(4-
hydroxyphenyl)propanoic acid [(S)-181] 
 
The product was synthesized following the general procedure for the synthesis of (S)-156 and analogues, and 
it was obtained as a pale orange solid (76% yield) (decomposes at T> 198 °C). 
1H-NMR (300 MHz, DMSO-d6): δ= 12.61 (bs, 1H), 9.96 (bs, 1H), 9.16 (s, 1H), 8.81 (bs, 1H), 8.39 (d, J= 8.2 
Hz, 1H), 7.69 (d, J= 8.8 Hz, 2H), 7.47 (d, J= 8.8 Hz, 2H), 7.07 (d, J= 8.4 Hz, 2H), 6.69 (s, 1H), 6.62 (d, J= 8.4 
Hz, 2H), 6.15 (bs, 2H), 5.89 (bs, 2H), 4.53−4.41 (m, 1H), 3.02 (dd, 1H, J= 4.5, 13.8 Hz, 1H), 2.91 (dd, J= 
10.1, 13.8 Hz, 1H). 
13C-NMR (75 MHz, DMSO-d6): δ= 174.2, 166.6, 162.3, 160.9, 156.5, 155.4, 154.0, 144.2, 130.7, 129.0, 126.9, 
126.8, 117.3, 115.6, 90.0, 55.2, 36.2. 
MS(ESI): m/z calcd for C21H21N7O6: 467.2; found: 468.2 [M+H]+.  
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Synthesis of (±)-ethyl 2-methyldodecanoate [(±)-187] 
 
Ethyl laurate (186) (174 µL, 0.657 mmol) was added at -78 °C to a freshly prepared solution of LDA [nBuLi 
(341 µL, 2.5 M in hexanes, 0.854 mmol) was added to diisopropylamine (138 µL, 0.985 mmol) in 1.0 mL of 
dry THF at -78 °C, then the reaction mixture was stirred at 0 °C for 15 min]. The solution was stirred for 1 h, 
then MeI (82 µL, 1.31 mmol) was added. The reaction mixture was stirred at -78 °C for 1 h, then the solution 
was allowed to warm to room temperature and stirred overnight. The reaction was quenched with water and 
extracted twice with Et2O. The pooled organic phases were dried over anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude product was purified by column chromatography on 
silica gel (n-hexane/EtOAc, 20:1) obtaining (±)-ethyl 2-methyldodecanoate [(±)-187] as colourless oil (152 
mg, 96% yield).  
Rf= 0.37 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 4.11 (q, J= 7.1 Hz, 2H), 2.40 (sex, J= 7.0 Hz, 1H), 1.68-1.58 (m, 1H), 1.43-
1.34 (m, 1H), 1.32-1.21 (m, 19H), 1.12 (d, J= 7.0 Hz, 3H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 177.0, 60.0, 39.6, 33.8, 31.9, 29.6, 29.5, 29.5, 29.3, 27.2, 22.7, 17.1, 14.3, 
14.1. 
 
Synthesis of (±)-2-methyldodecanoic acid [(±)-188] 
 
(±)-187 (152 mg, 0.627 mmol) was added to 1.25 M aq. LiOH (1 mL) and the reaction mixture was stirred 
under reflux for 24 h. The reaction was quenched with 1 M aq. HCl and it was extracted twice with Et2O. The 
pooled organic extracts were dried over anhydrous Na2SO4, filtered and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography on silica gel (n-hexane/EtOAc, 
20:1 to 5:1) obtaining (±)-2-methyldodecanoic acid [(±)-188] as colourless oil (80 mg, 60% yield). 
Rf= 0.25 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 11.74 (bs, 1H), 2.45 (sex, J= 7.0 Hz, 1H), 1.74-1.62 (m, 1H), 1.48-1.37 (m, 
1H), 1.36-1.21 (m, 18H), 1.17 (d, J= 7.0 Hz, 3H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 183.8, 39.4, 33.5, 31.9, 29.6, 29.5, 29.5, 29.3, 27.1, 22.7, 16.8, 14.1.  
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Synthesis of 2,4,6-trimethoxyaniline (189) 
 
1,3,5-Trimethoxy-2-nitrobenzene (190) (500 mg, 2.34 mmol) and zinc dust (765 mg, 11.7 mmol) were 
suspended in ethanol (2.5 mL). The reaction mixture was cooled to 0 °C and acetic acid (2.5 mL) was slowly 
added. The reaction was stirred at room temperature overnight, then it was quenched with sat. aq. NaHCO3. 
Et2O was added, phases were separated and the aqueous phase was extracted with Et2O. The pooled organic 
phases were dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude 
product was purified by column chromatography on silica gel (n-hexane/EtOAc, 1:1) obtaining 2,4,6-
trimethoxyaniline(189) as a brown oil (429 mg, quantitative yield).  
Rf= 0.37 (n-hexane/EtOAc, 2:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.17 (s, 2H), 3.83 (s, 6H), 3.77 (s, 3H), 3.49 (bs, 2H). 
13C-NMR (100 MHz, CDCl3): δ= 152.5, 148.1, 119.0, 91.4, 55.8. 
MS (ESI): m/z calcd for C9H13NO3: 183.1; found: 184.1 [M+H]+. 
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Synthesis of (±)-2-methyl-N-(2,4,6-trimethoxyphenyl)dodecanamide [(±)-183] 
 
1,1’-Carbonyldiimidazole (92 mg, 0.559 mmol) was added at 0 °C to a suspension of (±)-188 (80 mg, 0.373 
mmol) in dry THF (1.5 mL) and the reaction mixture was stirred at room temperature for 1 h. A solution of 
189 (102 mg, 0.559 mmol) in dry THF (1 mL) was added and the reaction mixture was stirred at 45 °C 
overnight. Et2O was added and washed with water. The organic phase was dried over anhydrous Na2SO4, 
filtered and the solvent was removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc, 2:1 to 1:1) obtaining 2-methyl-N-(2,4,6-
trimethoxyphenyl)dodecanamide [(±)-183] as a white amorphous solid (81 mg, 57% yield).  
Rf= 0.34 (n-hexane-EtOAc, 1:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.41 (bs, 1H), 6.13 (s, 2H), 3.80 (m, 3H), 3.78 (s, 6H), 2.45-2.32 (m, 1H), 
1.79-1.65 (m, 1H), 1.50-1.35 (m, 1H), 1.34-1.15 (m, 18H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 175.6, 159.7, 156.4, 107.7, 91.1, 55.9, 55.5, 41.7, 34.7, 31.9, 29.8, 29.7, 
29.6, 29.3, 27.4, 22.7, 18.1, 14.1. 
MS (ESI): m/z calcd for C22H37NO4: 379.3; found: 380.2 [M+H]+. 
HRMS (ESI): m/z calcd for C22H38NO4+: 380.2795; found: 380.2793 (Δ= - 0.6 ppm). 
  
Page | 169  
 
Synthesis of (±)-N-(2,4,6-trimethoxyphenyl)dodecanamide [(±)-184] 
 
1,1’-Carbonyldiimidazole (121 mg, 0.748 mmol) was added at 0 °C to a suspension of lauric acid (191) (100 
mg, 0.499 mmol) in dry THF (2.0 mL) and the reaction mixture was stirred at room temperature for 1 h. A 
solution of 189 (137 mg, 0.748 mmol) in dry THF (1.0 mL) was added and the reaction mixture was stirred at 
45 °C for 4 h. Et2O was added and washed with water. The organic phase was dried over anhydrous Na2SO4, 
filtered and the solvent was removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc, 2:1 to 3:7) obtaining (±)-N-(2,4,6-
trimethoxyphenyl)dodecanamide [(±)-184] as a white solid (160 mg, 88% yield). 
Rf= 0.28 (n-hexane/EtOAc, 1:1). 
1H-NMR (400 MHz, CDCl3, mixture of conformers): δ= 6.43 (bs, 1H), 6.13 (s, 2H), 3.78 (s, 9H), 2.41-2.30 
(m, 2H), 1.78-1.66 (m, 2H), 1.45-1.14 (m, 16H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 172.3, 159.8, 156.4, 107.7, 91.1, 56.0, 55.5, 36.8, 31.9, 29.7, 29.6, 29.6, 
29.4, 29.3, 29.2, 25.9, 22.7, 14.1. 
MS (ESI): m/z calcd for C21H35NO4: 365.3; found: 366.3 [M+H]+. 
HRMS (ESI): m/z calcd for C21H36NO4+: 366.2639; found: 366.2638 (Δ= - 0.2 ppm). 
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Synthesis of (±)-ethyl 2,2-difluoro-3-hydroxydodecanoate [(±)-194] 
 
TMSCl (113 µL, 0.891 mmol) was added to a suspension of zinc dust (583 mg, 8.91 mmol) in dry THF (10 
mL) and the mixture was gently heated for 5 min. After additional 15 min, decyl aldehyde (192) (500 µL, 2.65 
mmol) and ethyl bromodifluoroacetate (193) (680 µL, 5.30 mmol) were added. The reaction mixture was 
vigorously stirred at room temperature for 3 h, then it was quenched with sat. aq. NH4Cl. EtOAc was added, 
the phases were separated and the aqueous phase was extracted with ethyl acetate. The pooled organic extracts 
were washed with brine, dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by column chromatography on silica gel (n-hexane/EtOAc, 10:1) 
obtaining (±)-ethyl 2,2-difluoro-3-hydroxydodecanoate [(±)-194] as a colourless oil (734 mg, 99% yield).  
Rf= 0.50 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 4.37 (q, J= 7.7 Hz, 2H), 4.08-3.97 (m, 1H), 2.13 (d, J= 7.1 Hz, 1H), 1.72-
1.49 (m, 2H), 1.36 (t, J= 7.7 Hz, 3H), 1.40-1.25 (m, 14H), 0.88 (m, 3H). 
These NMR data are in keeping with the literature. [61] 
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Synthesis of (±)-ethyl 3-(1H-imidazole-1-carbonothioyloxy)-2,2-difluorododecanoate [(±)-195]  
 
DMAP (19 mg, 0.159 mmol) and 1,1’-thiocarbonyldiimidazole (453 mg, 2.54 mmol) were added at 0 °C to a 
solution of (±)-194 (446 mg, 1.59 mmol) in dry DCM (7.0 mL). The reaction mixture was stirred at room 
temperature for 1 h. The solvent was removed under reduced pressure and the crude product was purified by 
column chromatography on silica gel (n-hexane/EtOAc, 5:1) obtaining (±)-ethyl 3-(1H-imidazole-1-
carbonothioyloxy)-2,2-difluorododecanoate [(±)-195] as a colourless oil (572 mg, 92% yield). 
Rf= 0.25 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.31 (1H, m), 7.60 (1H, m), 7.04 (m, 1H), 6.13 (m, 1H), 4.28 (q, J= 7.1 Hz, 
2H), 1.93 (m, 2H), 1.49-1.18 (m, 17H), 0.85 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 183.1, 162.1 (t, JC-F= 31.3 Hz), 137.1, 131.2, 118.1, 112.6 (dd, JC-F= 253.7, 
257.5 Hz), 79.4 (dd, JC-F= 25.2, 30.0 Hz), 63.6, 31.8, 29.4, 29.2, 29.2, 27.5, 24.6, 22.6, 14.0, 13.8. 
19F-NMR (376.45 MHz, CDCl3): δ= - 113.1 (dd, J= 7.9, 266.2 Hz, 1F), - 117.4 (dd, J= 13.7, 266.2 Hz, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 113.1 (d, J= 266.2 Hz, 1F), - 117.4 (d, J= 266.2 Hz, 1F). 
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Synthesis of ethyl 2,2-difluorododecanoate (196) 
 
(±)-195 (685 mg, 1.75 mmol) in dry toluene (5.0 mL) was added dropwise to a refluxing solution of tributyltin 
hydride (941 µL, 3.50 mmol) in toluene (18 mL). The reaction mixture was stirred under reflux for 30 min, 
then the solvent was removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (n-hexane, 100% to n-hexane/EtOAc, 20:1) obtaining ethyl 2,2-
difluorododecanoate (196) as a colourless oil (430 mg, 93% yield). 
Rf= 0.25 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 4.32 (q, J= 7.2 Hz, 2H), 2.04 (m, 2H), 1.51-1.40 (m, 2H), 1.39-1.19 (m, 17H), 
0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 164.4 (t, JC-F= 32.9 Hz), 116.4 (t, JC-F= 248.3 Hz), 62.6, 34.5 (t, JC-F= 23.0 
Hz), 31.9, 29.5, 29.4, 29.3, 29.2, 29.0, 22.6, 21.4 (t, JC-F= 4.3 Hz), 14.0, 13.9. 
19F-NMR (376.45 MHz, CDCl3): δ = - 105.9 (t, JF-H= 16.8 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ = - 105.9 (s, 2F). 
MS (ESI): m/z calcd for C14H26F2O2: 264.2; found: 287.1 [M+Na]+. 
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Synthesis of 2,2-difluoro-N-(2,4,6-trimethoxyphenyl)dodecanamide (185) 
 
LiHMDS (568 µL, 1.0 M in THF) was added at 0 °C to a solution of 196 (75 mg, 0.284 mmol) and 189 (78 
mg, 0.426 mmol) in dry THF (2.6 mL). The reaction mixture was stirred at room temperature for 1 h and then 
quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. The organic phase 
was washed with 1 M aq. HCl, 5% aq. NaHCO3, dried over anhydrous Na2SO4, filtered and the solvent was 
removed under vacuum. The crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc, 10:1) obtaining 2,2-difluoro-N-(2,4,6-trimethoxyphenyl)dodecanamide (185) as a brown solid 
(92 mg, 81% yield) which recrystallizes as brown needles from n-hexane (m.p.= 63.3-63.9 °C).  
Rf= 0.27 (n-hexane/EtOAc, 3:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.27 (bs, 1H), 6.16 (s, 2H), 3.81 (s, 3H), 3.81 (s, 6H), 2.23-2.08 (m, 2H), 
1.60-1.49 (m, 2H), 1.41-1.20 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 163.0 (t, JC-F= 28.3 Hz), 160.5, 156.2, 118.9 (t, JC-F= 251.0 Hz), 105.2, 91.0, 
55.9, 55.4, 34.4 (t, JC-F= 23.0 Hz), 31.9, 29.6, 29.4, 29.4, 29.3, 29.2, 22.7, 21.7 (t, JC-F= 4.2 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.6 (dt, JF-H = 2.4, 17.0 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 105.6 (s, 2F). 
MS (ESI): m/z calcd for C21H33F2NO4: 401.2; found: 402.2 [M+H]+. 
HRMS (ESI): m/z calcd for C21H34F2NO4+: 402.2450; found: 402.4422 (Δ= - 2.1 ppm). 
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General procedure for the alkylation of cycloalkane esters 200-202 
The desired cycloalkane ester (1.0 eq.) was added at -78 °C to a freshly prepared solution of LDA [nBuLi (1.3 
eq.) was added to diisopropylamine (1.5 eq.) in dry THF (1.0 mL/mmol of cycloalkane ester) at -78 °C, then 
the reaction mixture was stirred at 0 °C for 15 min]. The reaction mixture was stirred at -78 °C for 1 h, then 1-
bromodecane (203) (3.0 eq.) was added. After another hour at -78 °C, the solution was allowed to warm to 
room temperature and was stirred overnight. The reaction mixture was quenched with water and extracted 
twice with Et2O. The pooled organic extracts were dried over anhydrous Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography on silica gel (n-
hexane, 100% to n-hexane/EtOAc, 20:1) obtaining the desired product. 
 
Synthesis of ethyl 1-decylcyclobutanecarboxylate (204) 
 
The product was synthesized following the general procedure for the alkylation of cycloalkane esters 200-202, 
and it was obtained as colourless oil (43% yield).  
Rf= 0.39 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 4.14 (q, J= 7.1 Hz, 2H), 2.43-2.34 (m, 2H), 1.91-1.82 (m, 4H), 1.77-1.70 (m, 
2H), 1.33-1.21 (m, 17H), 1.20-1.11 (m, 2H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 177.4, 60.1, 47.7, 38.1, 31.9, 30.0, 29.9, 29.6, 29.6, 29.5, 29.3, 24.8, 22.7, 
15.6, 14.3, 14.1. 
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Synthesis of methyl 1-decylcyclopentanecarboxylate (205)  
 
The product was synthesized following the general procedure for the alkylation of cycloalkane esters 200-202, 
and it was obtained as a yellow oil (63% yield).  
Rf= 0.38 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 3.66 (s, 3H), 2.15-2.05 (m, 2H), 1.64-1.54 (m, 6H), 1.50-1.41 (m, 2H), 1.33-
1.12 (m, 16H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 178.5, 54.2, 51.6, 39.4, 36.0, 31.9, 30.1, 29.6, 29.6, 29.5, 29.3, 26.0, 24.9, 
22.7, 14.1. 
 
 
 
Synthesis of methyl 1-decylcyclohexanecarboxylate(206) 
 
The product was synthesized following the general procedure for the alkylation of cycloalkane esters 200-202, 
and it was obtained as a yellow oil (48% yield). 
Rf= 0.42 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 3.66 (s, 3H), 2.09-2.00 (m, 2H), 1.60-1.50 (m, 3H), 1.48-1.41 (m, 2H), 1.36-
1.11 (m, 21H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 177.5, 51.3, 47.1, 40.7, 34.2, 31.9, 30.1, 29.6, 29.5, 29.3, 26.0, 24.0, 23.3, 
22.7, 14.1. 
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General procedure for the synthesis of compounds 197-199 
LiHMDS (1.0 M in THF, 2.0 eq.) was added at 0 °C to a solution of compound 204, 205 or 206 (1.0 eq.) and 
189 (1.5 eq.) in dry THF (8.0 mL/mmol of ester). The reaction mixture was stirred at room temperature 
overnight, then it was quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. 
The organic phase was washed with 1 M aq. HCl, 5% aq. NaHCO3, dried over anhydrous Na2SO4, filtered and 
the solvent was removed under vacuum. The crude product was purified by column chromatography on silica 
gel (n-hexane/EtOAc) obtaining the desired product. 
 
Synthesis of 1-decyl-N-(2,4,6-trimethoxyphenyl)cyclobutanecarboxamide (197)  
 
The product was synthesized following the general procedure for the synthesis of compounds 197-199, and it 
was obtained as an orange solid (56% yield) which recrystallizes as orange needles from n-hexane (m.p.= 94.3-
95.5 °C).  
Rf= 0.44 (n-hexane/EtOAc, 1:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.36 (bs, 1H), 6.14 (s, 2H), 3.79 (s, 3H), 3.78 (s, 6H), 2.55-2.46 (m, 2H), 
1.97-1.78 (m, 6H), 1.43-1.20 (m, 16H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 176.3, 159.6, 156.3, 107.7, 91.1, 55.9, 55.5, 48.8, 39.6, 31.9, 30.2, 30.2, 
29.7, 29.7, 29.4, 24.6, 22.7, 15.3, 14.1. 
MS (ESI): m/z calcd for C24H39NO4: 405.3; found: 428 [M+Na]+. 
HRMS (ESI): m/z calcd for C24H40NO4+: 406.2952; found: 406.2944 (Δ= - 1.9 ppm). 
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Synthesis of 1-decyl-N-(2,4,6-trimethoxyphenyl)cyclopentanecarboxamide (198)  
 
The product was synthesized following the general procedure for the synthesis of compounds 197-199, and it 
was obtained as a purple solid (55% yield) which recrystallizes as colourless needles from n-hexane (m.p.= 
77.4-78.6 °C).  
Rf= 0.29 (n-hexane/EtOAc, 2:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.53 (bs, 1H), 6.13 (s, 2H), 3.79 (s, 3H), 3.77 (s, 6H), 2.26-2.17 (m, 2H), 
1.76-1.61 (m, 2H), 1.58-1.48 (m, 2H), 1.47-1.37 (m, 2H), 1.34-1.19 (m, 14H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 176.3, 159.6, 156.3, 108.0, 91.0, 55.9, 55.5, 55.1, 40.6, 36.2, 31.9, 30.4, 
29.7, 29.7, 29.7, 29.3, 25.7, 24.6, 22.7, 14.1. 
MS (ESI): m/z calcd for C25H41NO4: 419.3; found: 442 [M+Na]+. 
HRMS (ESI): m/z calcd for C25H42NO4+: 420.3108; found: 420.3100 (Δ= - 2.0 ppm). 
 
  
Page | 178 
 
Synthesis of 1-decyl-N-(2,4,6-trimethoxyphenyl)cyclohexanecarboxamide (199) 
 
The product was synthesized following the general procedure for the synthesis of compounds 197-199, and it 
was obtained as an orange solid (57% yield) which recrystallizes as colourless scales from n-hexane (m.p.= 
74.8-76.0 °C). 
Rf= 0.31 (n-hexane/EtOAc, 2:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.63 (bs, 1H), 6.13 (s, 2H), 3.78 (s, 3H), 3.76 (s, 6H), 2.14-2.06 (m, 2H), 
1.64-1.54 (m, 5H), 1.54-1.47 (m, 2H), 1.45-1.35 (m, 2H), 1.35-1.19 (m, 17H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 175.1, 159.6, 156.3, 108.0, 91.0, 55.9, 55.5, 46.9, 41.9, 35.0, 31.9, 30.5, 
29.8, 29.7, 29.7, 29.3, 26.4, 23.8, 23.0, 22.7, 14.1. 
MS (ESI): m/z calcd for C26H43NO4: 433.3; found: 456 [M+Na]+. 
HRMS (ESI): m/z calcd for C26H44NO4+: 434.3265; found: 434.3258 (Δ= - 1.6 ppm).  
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Synthesis of methyl 2,2-dimethyldodecanoate (210) 
 
Methyl isobutyrate (209) (236 µL, 2.06 mmol) was added at -78 °C to a freshly prepared solution of LDA 
[nBuLi (1.07 µL, 2.5 M in hexanes, 2.68 mmol) was added to diisopropylamine (433 µL, 3.09 mmol) in 3 mL 
of dry THF at -78 °C and the reaction mixture was stirred at 0 °C for 15 min]. The reaction mixture was stirred 
for 1 h, then 1-bromodecane (203) (1.28 µL, 6.18 mmol) was added. After another hour at -78 °C, the reaction 
mixture was allowed to warm to room temperatur and stirred overnight. The reaction was quenched with water 
and extracted twice with Et2O. The pooled organic extracts were dried over anhydrous Na2SO4, filtered and 
the solvent was removed under reduced pressure. The crude product was purified by column chromatography 
on silica gel (n-hexane, 100% to n-hexane/EtOAc, 10:1) obtaining methyl 2,2-dimethyldodecanoate (210) as 
a colourless oil (500 mg, quantitative yield).  
Rf= 0.32 (n-hexane/EtOAc, 20:1). 
1H-NMR (400 MHz, CDCl3): δ= 3.65 (s, 3H), 1.52-1.46 (m, 2H), 1.33-1.17 (m, 16H), 1.15 (s, 6H), 0.87 (m, 
3H). 
13C-NMR (100 MHz, CDCl3): δ= 178.6, 51.6, 42.3, 40.8, 31.9, 30.1, 29.6, 29.5, 29.3, 25.2, 24.9, 22.7, 14.1. 
MS (ESI): m/z calcd for C15H30O2: 242.2; found: 265.2 [M+Na]+. 
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General procedure for the synthesis of 182 analogues 
LiHMDS 1.0 M in THF (2.0 eq.) was added at 0 °C to a solution of 210 (1.0 eq.) and desired aniline (1.5 eq.) 
in dry THF (12 mL/mmol of ester). The reaction mixture was stirred at room temperature until consumption 
of 210, then it was quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. 
The organic phase was washed with 1 M aq. HCl, 5% aq. NaHCO3, dried over Na2SO4, filtered and the solvent 
was removed under vacuum. The crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc, 10:1) obtaining the desired product. 
 
Synthesis of N-(4-chloro-3-fluorophenyl)-2,2-dimethyldodecanamide (211) 
 
The product was synthesized following the general procedure for the synthesis of 182 analogues, and it was 
obtained as a colourless solid (80% yield) (m.p.= 73.3-73.7 °C).  
Rf= 0.32 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.64 (dd, J= 2.0, 11.1 Hz, 1H), 7.38 (bs, 1H), 7.27 (t, J= 8.3 Hz, 1H), 7.09 
(ddd, J= 1.0, 2.2, 8.7 Hz, 1H), 1.61-1.53 (m, 2H), 1.32-1.18 (m, 22H), 0.86 (m, 3H). 
13C-NMR (CDCl3): δ= 176.3, 158.0 (d, JC-F= 245.8 Hz), 138.0 (d, JC-F= 9.9 Hz), 130.3, 115.9 (m), 115.5 (d, 
JC-F= 18.1 Hz), 108.7 (d, JC-F= 25.9 Hz), 43.2, 41.4, 31.9, 30.1, 29.6, 29.6, 29.5, 29.3, 25.4, 24.8, 22.7, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= -113.4 (m, 1F). 
MS (ESI): m/z calcd for C20H3135ClFNO: 355.2; found: 356.2[M+H]+. 
HRMS (ESI): m/z calcd for C20H3235ClFNO+: 356.2151; found: 356.2151 (Δ= 0.0 ppm). 
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Synthesis of 2,2-dimethyl N-phenyldodecanamide (212)  
 
The product was synthesized following the general procedure for the synthesis of 182 analogues, and it was 
obtained as a colourless solid (62% yield) (m.p.= 58.7-59.3 °C);  
Rf= 0.39 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.52 (m, 2H), 7.36 (bs, 1H), 7.30 (m, 2H), 7.09 (m, 1H), 1.62-1.55 (m, 2H), 
1.33-1.21 (m, 22H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 176.1, 138.0, 128.9, 124.1, 120.1, 43.0, 41.6, 31.9, 30.2, 29.6, 29.6, 29.5, 
29.3, 25.5, 24.9, 22.7, 14.1. 
MS (ESI): m/z calcd for C20H33NO: 303.3; found: 304.2 [M+H]. 
HRMS (ESI): m/z calcd for C20H34NO+: 304.2635; found: 304.2629 (Δ= - 1.9 ppm). 
 
 
Synthesis of N-(4-methoxyphenyl)-2,2-dimethyldodecanamide (213) 
 
The product was synthesized following the general procedure for the synthesis of 182 analogues, and it was 
obtained as an orange solid (98% yield) (m.p.= 79.5-80.7 °C). 
Rf= 0.30 (n-hexane-EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.41 (m, 2H), 7.20 (bs, 1H), 6.85 (m, 2H), 3.78 (s, 3H), 1.61-1.53 (m, 2H), 
1.32-1.19 (m, 22H), 0.87 (m, 3H). 
13C-NMR (CDCl3): δ= 175.9, 156.4, 131.1, 121.9, 114.1, 55.5, 42.8, 41.6, 31.9, 30.2, 29.6, 29.6, 29.5, 29.3, 
25.5, 24.9, 22.7, 14.1. 
MS (ESI): m/z calcd for C21H35NO2: 333.3; found: 334.3 [M+H]. 
HRMS (ESI): m/z calcd for C21H36N2O+: 334.2741; found: 334.2737 (Δ= - 1.1 ppm).  
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General procedure for the synthesis of 185 analogues 
LiHMDS (568 µL, 1.0 M in THF) was added at 0 °C to a solution of 196 (1.0 eq) and desired aniline (1.5 eq.) 
in dry THF (10 mL/mmol of ester). The reaction mixture was stirred at room temperature for 1 h and then 
quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated separated. The organic 
phase was washed with 1 M aq. HCl, 5% aq. NaHCO3, dried over Na2SO4, filtered and the solvent was removed 
under vacuum. The crude product was purified by column chromatography on silica gel (n-hexane/EtOAc, 
10:1) obtaining the desired product. 
 
Synthesis of N-(4-chloro-3-fluorophenyl)-2,2-difluorododecanamide (214) 
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as a white solid (85% yield). 
Rf= 0.36 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.03 (bs, 1H), 7.66 (dd, J= 2.5, 10.6 Hz, 1H), 7.37 (dd, J= 8.1, 8.6 Hz, 1H), 
7.20 (ddd, J= 1.2, 2.5, 8.6 Hz, 1H), 2.24-2.08 (m, 2H), 1.54-1.44 (m, 2H), 1.40-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.4 (t, JC-F= 29.2 Hz), 158.1 (d, JC-F= 247.0 Hz), 135.9 (d, JC-F= 9.6 Hz), 
130.8, 118.3 (t, JC-F= 251.8 Hz), 117.4 (d, JC-F= 17.8 Hz), 116.2 (d, JC-F= 3.6 Hz), 109.0 (d, JC-F= 26.1 Hz), 
33.7 (t, JC-F= 22.7 Hz), 31.9, 29.5, 29.4, 29.3, 29.2, 29.1, 22.7, 21.5 (t, JC-F= 4.1 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.4 (dt, JF-H= 2.9, 17.5 Hz, 2F), - 112.3 (m, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 112.3 (s, 1F), - 105.4 (s, 2F). 
MS (ESI): m/z calcd for C18H2535ClF3NO: 363.2; found: 386.1 [M+Na]+. 
HRMS (ESI): m/z calcd for C18H2635ClF3NO+: 364.1650; found: 364.1653 (Δ= 1.0 ppm). 
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Synthesis of N-(4-chlorophenyl)-2,2-difluorododecanamide (215)  
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as a yellow solid (85% yield). 
Rf= 0.36 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.11 (bs, 1H), 7.53 (m, 2H), 7.31 (m, 2H), 2.23-2.07 (m, 2H), 1.54-1.43 (m, 
2H), 1.39-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.4 (t, JC-F= 29.0 Hz), 134.7, 130.7, 129.2, 121.6, 118.4 (t, JC-F= 251.7 
Hz), 33.8 (t, JC-F= 22.9 Hz), 31.9, 29.5, 29.4, 29.3, 29.2, 29.1, 22.7, 21.5 (t, JC-F= 4.1 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.4 (dt, JF-H= 3.1, 17.5 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 105.4 (s, 2F). 
MS (ESI): m/z calcd for C18H2635ClF2NO: 345.2; found: 368.1 [M+Na]+. 
HRMS (ESI): m/z calcd for C18H2735ClF2NO+: 346.1744; found: 346.1743 (Δ= - 0.2 ppm). 
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Synthesis of 2,2-difluoro-N-phenyldodecanamide (216) 
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as a white solid (87% yield) (m.p.= 71.8-72.4 °C). 
Rf= 0.41 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.94 (bs, 1H), 7.58 (m, 2H), 7.38 (m, 2H), 7.20 (m, 1H), 2.26-2.10 (m, 2H), 
1.56-1.45 (m, 2H), 1.41-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.3 (t, JC-F= 28.6 Hz), 136.1, 129.2, 125.5, 120.3, 118.5 (t, JC-F= 251.7 
Hz), 33.8 (t, JC-F= 23.0 Hz), 31.9, 29.5, 29.4, 29.3, 29.3, 29.2, 22.7, 21.6 (t, JC-F= 4.2 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.5 (dt, JF-H= 3.1, 17.4 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 105.5 (s, 2F). 
MS (ESI): m/z calcd for C18H27F2NO: 311.2; found: 334.1 [M+Na]+. 
HRMS (ESI): m/z calcd for C18H28F2NO+: 312.2133; found: 312.2134 (Δ= 0.2 ppm). 
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Synthesis of N-(2,6-diisopropylphenyl)-2,2-difluorododecanamide (217) 
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as an orange solid (84% yield) (m.p.= 93.9-95.5 °C). 
Rf= 0.45 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.60 (bs, 1H), 7.34 (t, J= 7.7 Hz, 1H), 7.21 (d, J= 7.7 Hz, 2H), 3.03 (sep, J= 
6.8 Hz, 2H), 2.29-2.14 (m, 2H), 1.63-1.51 (m, 2H), 1.47-1.16 (m, 26H), 0.91 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 163.8 (t, JC-F= 28.6 Hz), 146.1, 129.0, 129.0, 123.7, 119.0 (t, JC-F= 251.1 
Hz), 33.8 (t, JC-F= 22.8 Hz), 31.9, 29.6, 29.4, 29.4, 29.3, 29.2, 28.8, 23.5, 22.7, 21.6 (t, JC-F= 4.1 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 104.4 (dt, JF-H= 2.2, 17.3 Hz, 2F). 
19F-NMR (376.45 MHz, CDCl3): δ= - 104.4 (s, 2F). 
MS (ESI): m/z calcd for C24H39F2NO: 395.3; found: 396.2 [M+H]+. 
HRMS (ESI): m/z calcd for C24H40F2NO+: 396.3072; found: 396.3070 (Δ= - 0.6 ppm). 
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Synthesis of 2,2-difluoro-N-(4-methoxyphenyl)dodecanamide(218) 
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as a white solid (75% yield) (m.p.= 100.4-101.1 °C). 
Rf= 0.26 (n-hexane/EtOAc, 10:1). 
1H-NMR (100 MHz, CDCl3): δ= 7.97 (bs, 1H), 7.48 (m, 2H), 6.88 (m, 2H), 3.79 (s, 3H), 2.24-2.08 (m, 2H), 
1.55-1.44 (m, 2H), 1.40-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.1 (t, JC-F= 28.5 Hz), 157.2, 129.1, 122.0, 118.5 (t, JC-F= 251.6 Hz), 114.3, 
55.5, 33.9 (t, JC-F= 23.0 Hz), 31.9, 29.5, 29.4, 29.3, 29.3, 29.1, 22.7, 21.6 (t, JC-F= 4.1 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.6 (dt, JF-H= 2.2, 17.4 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 105.6 (s, 2F). 
MS (ESI): m/z calcd for C19H29F2NO2: 341.2; found: 364.1 [M+Na]+. 
HRMS (ESI): m/z calcd for C19H30F2NO2+: 342.2239; found: 342.2240 (Δ= 0.3 ppm). 
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Synthesis of 2,2-difluoro-N-(2-methoxyphenyl)dodecanamide (219)  
 
The product was synthesized following the general procedure for the synthesis of 185 analogues, and it was 
obtained as a colourless oil (81% yield). 
Rf= 0.49 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.68 (bs, 1H), 8.38 (dd, J= 1.5, 8.0 Hz, 1H), 7.12 (dt, J= 1.5, 7.8 Hz, 1H), 
6.99 (dt, J= 1.2, 7.8 Hz, 1H), 6.92 (dd, J= 1.2, 8.1 Hz, 1H), 3.91 (s, 3H), 2.26-2.10 (m, 2H), 1.57-1.46 (m, 2H), 
1.41-1.19 (m, 14H), 0.89 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.0 (t, JC-F= 28.6 Hz), 148.3, 126.0, 125.1, 121.1, 119.9, 118.4 (t, JC-F= 
251.7 Hz), 110.1, 55.8, 33.9 (t, JC-F= 23.0 Hz), 31.9, 29.5, 29.4, 29.3, 29.3, 29.2, 22.7, 21.6 (t, JC-F= 4.2 Hz), 
14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 105.7 (dt, JF-H= 2.9, 17.3 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 105.7 (s, 2F). 
MS (ESI): m/z calcd for C19H29F2NO2: 341.2; found: 342.1 [M+H]+. 
HRMS (ESI): m/z calcd for C19H30F2NO2+: 342.2239; found: 342.2238 (Δ= - 0.3 ppm). 
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General procedure for the synthesis of 184 analogues 
Lauric acid (191) (300 mg, 1.50 mmol) was dissolved in dry DCM (10.0 mL) and few drops of dry DMF were 
added. Oxalyl chloride (3 eq.) was added at 0 °C and the reaction mixture was stirred at room temperature for 
4 h, then it was concentrated under reduced pressure. The residue was dissolved in dry DCM (7.0 mL) and a 
solution of DMAP (0.10 eq.), TEA (2 eq.) and desired aniline (1.5 eq.) in dry DCM (3.0 mL) was slowly added 
at 0 °C. The reaction mixture was stirred at room temperature overnight, then it was diluted with DMC, washed 
with 1 M aq. HCl and sat. aq. NaHCO3, dried over anhydrous Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography on silica gel (n-hexane/EtOAc) 
obtaining the desired product. 
 
Synthesis of N-(4-chloro-3-fluorophenyl)dodecanamide (220) 
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (88% yield) which recrystallizes as brown needles from n-hexane (m.p.= 67.5-68.4 
°C). 
Rf= 0.34 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.83 (bs, 1H), 7.61 (dd, J = 2.1, 11.1 Hz, 1H), 7.26 (m, 1H), 7.11 (m, 1H), 
2.37 (t, J= 7.4 Hz, 2H), 1.70 (tt, J= 7.4 Hz, 2H), 1.37-1.18 (m, 16H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 172.5, 157.9 (d, JC-F= 245.8 Hz), 138.1 (d, JC-F= 9.8 Hz), 130.3, 118.7 (d, JC-
F= 25.5 Hz), 116.1, 115.6 (d, JC-F= 17.9 Hz), 37.6, 31.9, 29.6, 29.5, 29.4, 29.3, 29.3, 25.6, 22.7, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 113.4 (m, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 113.4 (s, 1F). 
MS (ESI): m/z calcd for C18H2735ClFNO: 327.2; found: 328.2 [M+H]+. 
HRMS (ESI): m/z calcd for C18H2835ClFNO+: 328.1838; found: 328.1840 (Δ= 0.6 ppm). 
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Synthesis of N-(4-fluorophenyl)dodecanamide (221): 
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (93% yield). 
1H-NMR (400 MHz, CDCl3): δ= 7.49 (m, 2H), 7.14 (bs, 1H), 7.03 (m, 2H), 2.36 (t, J= 7.5 Hz, 2H), 1.74 (tt, 
J= 7.0, 7.5 Hz, 2H), 1.44-1.23 (m, 16H), 0.90 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 171.5, 159.3 (d, JC-F= 243.2 Hz), 133.9 (d, JC-F= 2.6 Hz), 121.7 (d, JC-F= 7.9 
Hz), 115.6 (d, JC-F= 22.5 Hz), 37.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.3, 25.6, 22.7, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 118.2 (tt, JF-H= 4.7, 8.3 Hz, 1F). 
MS (ESI): m/z calcd for C18H28FNO: 293.2; found: 294.2 [M+H]+. 
 
 
 
Synthesis of N-(4-chlorophenyl)dodecanamide (222): 
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (73% yield). 
1H-NMR (400 MHz, CDCl3): δ= 7.74-7.56 (bs, 1H), 7.49 (m, 2H), 7.27 (m, 2H), 2.35 (t, J= 7.5 Hz, 2H), 1.72 
(tt, J= 6.9, 7.5 Hz, 2H), 1.42-1.21 (m, 14H), 0.90 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 171.8, 136.6, 129.1, 128.9, 121.2, 37.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.3, 
25.6, 22.7, 14.1. 
MS (ESI): m/z calcd for C18H2835ClNO: 309.2; found: 310.1 [M+H]+. 
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Synthesis of N-phenyldodecanamide (223) 
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (quantitative yield) (m.p.= 81.5-82.8 °C) (lit. m.p.= 78 °C). [80] 
Rf= 0.39 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.52 (d, J= 7.8 Hz, 2H), 7.47 (bs, 1H), 7.33-7.26 (m, 3H), 7.08 (t, J= 7.4 Hz, 
1H), 2.34 (t, J= 7.5 Hz, 2H), 1.71 (qui, J= 7.5 Hz, 2H), 1.40-1.20 (m, 16H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 171.5, 138.0, 129.0, 124.1, 119.8, 37.8, 31.9, 29.6, 29.5, 29.4, 29.3, 29.3, 
25.7, 22.7, 14.1. 
MS (ESI): m/z calcd for C18H29NO: 275.2; found: 276.2 [M+H]+ (100). 
HRMS (ESI): m/z calcd for C18H30NO+: 276.2322; found: 276.2322 (Δ= 0.0 ppm). 
 
 
Synthesis of N-(4-methoxyphenyl)dodecanamide (224)  
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (quantitative yield). 
Rf= 0.30 (n-hexane/EtOAc, 8:2). 
1H-NMR (400 MHz, CDCl3): δ= 7.40 (m, 2H), 7.18 (bs, 1H), 6.84 (m, 2H), 3.78 (s, 3H), 2.32 (t, J= 7.5 Hz, 
2H), 1.71 (qui, J= 7.5 Hz, 2H), 1.41-1.18 (m, 16H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 171.3, 156.3, 131.1, 121.7, 114.1, 55.5, 37.7, 29.6, 29.5, 29.4, 29.3, 29.3, 
25.7, 22.7, 14.1. 
MS (ESI): m/z calcd for C19H31NO2: 305.2; found: 306.2 [M+H]+. 
HRMS (ESI): m/z calcd for C19H32NO2+: 306.2428; found: 306.2427 (Δ= - 0.2 ppm).  
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Synthesis of N-(2-methoxyphenyl)dodecanamide (225): 
 
The product was synthesized following the general procedure for the synthesis of 184 analogues, and it was 
obtained as a white solid (87% yield). 
1H-NMR (400 MHz, CDCl3): δ= 8.42 (dd, J= 1.1, 7.9 Hz, 1H), 7.87 (bs, 1H), 7.05 (m, 1H), 6.98 (m, 1H), 6.89 
(dd, J= 1.4, 8.0 Hz, 1H), 3.91 (s, 3H), 2.41 (t, J= 7.6 Hz, 2H), 1.72 (tt, J= 7.0, 7.6 Hz, 2H), 1.45-1.25 (m, 14H), 
0.90 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 171.3, 147.6, 127.8, 123.4, 121.1, 119.7, 109.8, 55.7, 38.1, 31.9, 29.6, 29.6, 
29.5, 29.4, 29.3, 29.3, 25.7, 22.7, 14.1. 
MS (ESI): m/z calcd for C19H31NO2: 305.2; found: 306.2 [M+H]+. 
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Synthesis of (±)-2,2-difluoro-3-hydroxy-N-phenyldodecanamide [(±)-233] 
 
LiHMDS (1.07 mL, 1.0 M in THF) was added at 0 °C to a solution of (±)-194 (100 mg, 0.356 mmol) and 
aniline (205) (48 µL, 0.534 mmol) in dry THF (7 mL). The reaction mixture was stirred at room temperature 
for 1 h, then it was quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. 
The organic phase was washed with 1 M aq. HCl, 5% aq. NaHCO3, dried over anhydrous Na2SO4, filtered and 
the solvent was removed under vacuum. The crude product was purified by column chromatography on silica 
gel (n-hexane/EtOAc, 3:1) obtaining (±)-2,2-difluoro-3-hydroxy-N-phenyldodecanamide [(±)-233] as a white 
solid (90 mg, 78% yield). 
Rf= 0.35 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.09 (bs, 1H), 7.56 (m, 2H), 7.37 (m, 2H), 7.20 (m, 1H), 4.25-4.12 (m, 1H), 
2.66-2.55 (m, 1H), 1.66-1.53 (m, 2H), 1.46-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 161.8 (t, JC-F= 28.1 Hz), 135.8, 129.2, 125.7, 120.3, 115.6 (dd, JC-F= 255.7, 
258.6 Hz), 71.2 (dd, JC-F= 25.5, 26.6 Hz), 31.9, 29.5, 29.4, 29.3, 29.3, 29.0 (m), 25.3, 22.7, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 113.3 (dd, JF-H= 6.1 Hz, JF-F= 261.3 Hz, 1F), - 122.1 (dd, JF-H= 15.4 Hz, 
JF-F= 261.3Hz, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 113.3 (d, JF-F= 261.3 Hz, 1F), - 122.1 (d, JF-F= 261.3 Hz, 1F). 
MS (ESI): m/z calcd for C18H27F2NO2: 327.2; found: 350.2 [M+Na]+. 
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Synthesis of 2,2-difluoro-3-oxo-N-phenyldodecanamide (235) 
 
DMP (155 mg, 0.366 mmol) was added at 0 °C to a solution of (±)-233 (60 mg, 0.183 mmol) in dry DCM (2 
mL). The reaction mixture was stirred at room temperature for 30 min, then DCM was added and the reaction 
was quenched with sat. aq. Na2S2O3 and phases were separated. The organic phase was washed with sat. aq. 
NaHCO3, dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude 
product was purified by column chromatography on silica gel (n-hexane/EtOAc, 10:1 to 5:1) as eluent 
obtaining 2,2-difluoro-3-oxo-N-phenyldodecanamide (235) as a colourless solid (59 mg, quantitative yield) 
(m.p.= 106.2-107.0 °C ). 
Rf= 0.57 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.09 (bs, 1H), 7.55 (m, 2H), 7.36 (m, 2H), 7.20 (m, 2H), 2.84 (t, J= 7.2 Hz, 
2H), 1.65 (qui, J= 7.2 Hz, 2H), 1.38-1.19 (m, 12H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 198.9 (t, JC-F= 27.0 Hz), 159.1 (t, JC-F= 26.8 Hz), 135.6, 129.2, 126.0, 120.3, 
109.2 (t, JC-F= 265.3 Hz), 37.7, 31.8, 29.3, 29.2, 29.2, 28.8, 22.6, 22.4, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 114.5 (s, 2F). 
MS (ESI): m/z calcd for C18H25F2NO2: 325.2; found: 348.1 [M+Na]+. 
HRMS (ESI): m/z calcd for C18H26F2NO2+: 326.1929; found: 326.1926 (Δ= 0.9 ppm). 
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Synthesis of (±)-2,2-difluoro-3-hydroxy-N-(2,4,6-trimethoxyphenyl)dodecanamide [(±)-234] 
 
LiHMDS (800 µL, 1.0 M in THF) was added at 0 °C to a solution of (±)-194 (75 mg, 0.267 mmol) and 189 
(73 mg, 0.400 mmol) in dry THF (2.6 mL). The reaction mixture was stirred at room temperature for 1 h, then 
it was quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. The organic 
phase was washed with 2 M aq. HCl, 5% aq. NaHCO3, dried over anhydrous Na2SO4, filtered and the solvent 
was removed under vacuum. The crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc, 1:1) obtaining (±)-2,2-difluoro-3-hydroxy-N-(2,4,6-trimethoxyphenyl)dodecanamide [(±)-
234] as a brown waxy solid (85 mg, 77% yield). 
Rf= 0.59 (n-hexane/EtOAc, 1:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.37 (bs, 1H), 6.16 (s, 2H), 4.18-4.05 (m, 1H), 3.81 (s, 9H), 2.72 (d, J= 5.8 
Hz, 1H), 1.69-1.57 (m, 2H), 1.48-1.20 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 162.7 (t, JC-F= 27.8 Hz), 160.6, 156.1, 116.1 (t, JC-F= 256.4 Hz), 104.9, 91.0, 
71.6 (t, JC-F= 25.7 Hz), 55.9, 55.5, 31.9, 29.6, 29.5, 29.3, 29.0, 25.4, 22.7, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ = - 115.7 (dd, JF-H= 8.3 Hz, JF-F= 256.3 Hz, 1F), - 121.8 (dd, JF-H= 14.4 Hz, 
JF-F= 256.3 Hz, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ = - 115.7 (d, J= 256.3 Hz, 1F), - 121.8 (d, J= 256.3 Hz, 1F). 
MS (ESI): m/z calcd for C21H33F2NO5: 417.2; found: 418.2 [M+H]+. 
HRMS (ESI): m/z calcd for C21H34F2NO5+: 418.2400; found: 418.2395 (Δ= - 1.1 ppm). 
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Synthesis of 2,2-difluoro-3-oxo-N-(2,4,6-trimethoxyphenyl)dodecanamide (236) 
 
DMP (107 mg, 0.252 mmol) was added at 0 °C to a solution of (±)-234 (70 mg, 0.168 mmol) in dry DCM (3.0 
mL). The reaction mixture was stirred at room temperature for 30 min, then DCM was added and reaction was 
quenched with sat. aq. Na2S2O3 and phases were separated. The organic phase was washed with sat. aq. 
NaHCO3, dried over anhydrous Na2SO4, filtered and the solvent was removed under vacuum. The crude 
product was purified by column chromatography on silica gel (n-hexane/EtOAc, 6:4) obtaining 2,2-difluoro-
3-oxo-N-(2,4,6-trimethoxyphenyl)dodecanamide (236) as a white solid (70 mg, quantitative yield). 
Rf= 0.56 (n-hexane/EtOAc, 6:4). 
1H-NMR (400 MHz, CDCl3): δ= 7.37 (bs, 1H), 6.12 (s, 2H), 3.78 (s, 3H), 3.78 (s, 6H), 2.82 (t, J= 7.2 Hz, 2H), 
1.65 (qui, J= 7.2 Hz, 2H), 1.37-1.18 (m, 12H), 0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 198.1 (t, JC-F= 26.3 Hz), 160.7, 159.7 (t, JC-F= 26.8 Hz), 156.0, 109.8 (t, JC-
F= 263.8 Hz), 104.5, 90.9, 55.9, 55.5, 37.4, 31.8, 29.4, 29.3, 29.2, 28.8, 22.6, 22.5, 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 115.3 (s, 2F). 
MS (ESI): m/z calcd for C21H31F2NO5: 415.2; found: 416.2 [M+H]+. 
HRMS (ESI): m/z calcd for C21H32F2NO5+: 416.2243; found: 416.2239 (Δ= - 1.0 ppm). 
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Synthesis of 2,2-difluoro-N-methyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (237) 
 
A solution of 185 (70 mg, 0.174 mmol) in dry THF (1.0 mL) was added at 0 °C to a suspension of NaH (15 
mg, 60% in mineral oil, 0.348 mmol) in dry THF (1.0 mL). The reaction mixture was stirred at 0 °C for 30 
min, then MeI (21.7 µL, 0.348 mmol) was added dropwise. The reaction mixture was stirred at room 
temperature overnight, then Et2O was added, washed with water, dried over anhydrous Na2SO4, filtered and 
the solvent was removed under vacuum. The crude product was purified by column chromatography on silica 
gel (n-hexane/EtOAc, 3:1) as eluent obtaining 2,2-difluoro-N-methyl-N-(2,4,6-
trimethoxyphenyl)dodecanamide (237) as a white solid (72 mg, quantitative yield) (m.p.= 86.4-87.1 °C). 
Rf= 0.45 (n-hexane/EtOAc, 3:1). 
1H-NMR (400 MHz, CDCl3): δ= 6.10 (s, 2H), 3.81 (s, 3H), 3.77 (s, 6H), 3.10 (s, 3H), 1.95-1.79 (m, 2H), 1.43-
1.32 (m, 2H), 1.32-1.17 (m, 14H), 0.86 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 165.3 (t, JC-F= 28.0 Hz), 160.8, 157.0, 118.8 (t, JC-F= 251.2 Hz), 113.0, 90.3, 
55.7, 55.4, 37.2, 35.0 (t, JC-F= 23.4 Hz), 31.9, 29.5, 29.5, 29.3, 29.3, 22.6, 21.5 (t, JC-F= 4.2 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 102.2 (t, J= 17.4 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 102.2 (s, 2F). 
MS (ESI): m/z calcd for C22H35F2NO4: 415.2; found: 416.2 [M+H]+. 
HRMS (ESI): m/z calcd for C22H36F2NO4+: 416.2607; found: 416.2600 (Δ= - 1.7 ppm). 
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Synthesis of N-benzyl-2,2-difluoro-N-(2,4,6-trimethoxyphenyl)dodecanamide (238) 
 
A solution of 185 (100 mg, 0.249 mmol) in dry THF (1 mL) was added at 0 °C to a suspension of NaH (20 
mg, 60% in mineral oil, 0.498 mmol) in dry THF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 
30 min, then benzyl bromide (59.2 µL, 0.498 mmol) was added dropwise. The reaction mixture was stirred at 
room temperature overnight, then Et2O was added, washed with water, dried over anhydrous Na2SO4, filtered 
and the solvent was removed under vacuum. The crude product was purified by column chromatography on 
silica gel (n-hexane/EtOAc, 10:1 to 5:1) obtaining N-benzyl-2,2-difluoro-N-(2,4,6-
trimethoxyphenyl)dodecanamide (238) as a colourless oil (114 mg, 93% yield).  
Rf= 0.51 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.18 (m, 5H), 5.99 (s, 2H), 4.71 (s, 2H), 3.78 (s, 3H), 3.52 (s, 6H), 2.00-1.34 
(m, 2H), 1.46-1.36 (m, 2H), 1.33-1.19 (m, 14H), 0.88 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 165.5 (t, JC-F= 27.9 Hz), 160.8, 157.2, 136.7, 129.9, 127.5, 127.2, 118.8 (t, 
JC-F= 251.7 Hz), 111.2, 90.2, 55.3, 55.3, 53.4, 35.1 (t, JC-F= 23.4 Hz), 31.9, 29.6, 29.5, 29.3, 29.3, 22.7, 21.5 
(t, JC-F= 4.0 Hz), 14.1. 
19F-NMR (376.45 MHz, CDCl3): δ= - 102.3 (t, J= 17.4 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 102.3 (s, 2F). 
MS (ESI): m/z calcd for C28H39F2NO4: 491.3; found: 492.3 [M+H]+. 
HRMS (ESI): m/z calcd for C28H40F2NO4+: 492.2920; found: 492.2915 (Δ= - 1.0 ppm). 
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Synthesis of (±)-ethyl 2,2-difluoro-3-hydroxy-3-phenylpropanoate [(±)-240] 
 
TMSCl (93.8 µL, 0.739 mmol) was added to a suspension of zinc dust (483 mg, 7.39 mmol) in dry THF (8 
mL) and the reaction mixture was gently heated for 5 min. After stirring at room temperature for additional 15 
min, benzaldehyde (239) (200 µL, 1.97 mmol) and ethyl bromodifluoroacetate (193) (631 µL, 4.92 mmol) 
were added. The reaction mixture was vigorously stirred at 55 °C until consumption of 193, then it was 
quenched with sat. aq. NH4Cl. EtOAc was added, the phases were separated and the aqueous phase was 
extracted with EtOAc. The pooled organic phases were washed with brine, dried over anhydrous Na2SO4, 
filtered and the solvent was removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc, 5:1) obtaining (±)-ethyl 2,2-difluoro-3-hydroxy-3-
phenylpropanoate [(±)-240] as a colourless oil (170 mg, 37% yield).  
Rf= 0.24 (n-hexane/EtOAc, 5:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.47-7.42 (m, 2H), 7.42-7.37 (m, 3H), 5.17 (ddd, JH-H= 5.3 Hz, JH-F= 8.3, 
15.7 Hz, 1H), 4.31 (q, J= 7.2 Hz, 2H), 2.69 (d, J= 5.3 Hz, 1H), 1.29 (t, J= 7.2 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 163.7 (t, JC-F= 31.5 Hz), 134.6 (m), 129.2, 128.4, 127.8, 113.9 (dd, JC-F= 
252.7, 257.7 Hz), 73.7 (dd, JC-F= 23.7, 27.5 Hz), 63.2, 13.7.  
19F-NMR (376.45 MHz, CDCl3): δ= - 113.9 (dd, JF-H= 8.3 Hz, JF-F =278.6 Hz, 1F), - 120.3 (dd, JF-H= 15.7 Hz, 
JF-F= 278.6 Hz, 1F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 113.9 (d, JF-F=278.6, 1F), - 120.3 (d, JF-F= 278.6 Hz, 1F). 
MS (ESI): m/z calcd for C11H12F2O3: 230.1; found: 253.1 [M+Na]+. 
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Synthesis of (±)-ethyl 3-(1H-imidazole-1-carbonothioyloxy)-2,2-difluoro-3-phenylpropanoate [(±)-241] 
 
DMAP (9 mg, 73.8 µmol) and 1,1’-thiocarbonyldiimidazole (198 mg, 1.11 mmol) were added at 0 °C to a 
solution of (±)-240 (170 mg, 0.738 mmol) in dry DCM (3.0 mL). The reaction mixture was stirred at room 
temperature for 1 h, then the solvent was removed under reduced pressure and the crude product was purified 
by column chromatography on silica gel (n-hexane/EtOAc, 3:1) obtaining (±)-ethyl 3-(1H-imidazole-1-
carbonothioyloxy)-2,2-difluoro-3-phenylpropanoate [(±)-241] as a yellow oil (234 mg, 93% yield). 
Rf= 0.27 (n-hexane/EtOAc, 3:1). 
1H-NMR (400 MHz, CDCl3): δ= 8.37 (m, 1H), 7.65 (m, 1H), 7.47-7.42 (m, 2H), 7.42-7.37 (m, 3H), 7.05 (m, 
1H), 6.81 (dd, JH-F= 8.9, 14.4 Hz, 1H), 4.31-4.21 (m, 2H), 1.21 (t, J= 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 181.2, 161.9 (t, JC-F= 31.0 Hz), 137.0, 131.3, 130.3, 129.5 (m), 128.8, 128.7, 
118.0, 112.2 (dd, JC-F= 254.1, 259.3 Hz), 80.7 (dd, JC-F= 24.6, 29.6 Hz), 63.7, 13.8. 
19F-NMR (376.45 MHz, CDCl3): δ= -113.2 (dd, JF-H= 8.9 Hz, JF-F=265.2 Hz, 1F), -115.7 (dd, JF-H= 14.4 Hz, 
JF-F= 265.2 Hz, 1H). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= -113.2 (d, JF-F =265.2 Hz, 1F), -115.7 (d, JF-F= 265.2 Hz, 1H). 
MS (ESI): m/z calcd for C15H14F2N2O3S: 340.1; found: 341.0 [M+H]+. 
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Synthesis of ethyl 2,2-difluoro-3-phenylpropanoate (242) 
 
A solution of (±)-241 (234 mg, 0.687 mmol) in dry toluene (2 mL) was added dropwise to a refluxing tributyltin 
hydride (370 µL, 1.37 mmol) solution in dry toluene (8 mL). The reaction was stirred under reflux for 1 h, 
then solvent was removed under reduced pressure. The crude product was purified by column chromatography 
on silica gel (n-hexane/EtOAc, 20:1 to 10:1) obtaining ethyl 2,2-difluoro-3-phenylpropanoate (242) as a 
colourless oil (40 mg, 27% yield). 
Rf= 0.39 (n-hexane/EtOAc, 10:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.35-7.30 (m, 3H), 7.30-7.25 (m, 2H), 4.25 (q, J= 7.2 Hz, 2H), 3.39 (t, JH-F= 
16.5 Hz, 2H), 1.25 (t, J= 7.2 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ= 163.9 (t, JC-F= 32.4 Hz), 130.7 (t, JC-F= 4.3 Hz), 130.4, 128.5, 127.9, 115.4 
(t, JC-F= 250.4 Hz), 62.8, 41.0 (t, JC-F= 23.6 Hz), 13.8. 
19F-NMR (376.45 MHz, CDCl3): δ= - 104.6 (t, JF-H= 16.5 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 104.6 (s, 2F). 
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Synthesis of 2,2-difluoro-3-phenyl-N-(2,4,6-trimethoxyphenyl)propanamide (243) 
 
LiHMDS (280 µL, 1.0 M in THF) was added at 0 °C to a solution of 242 (40 mg, 0.187 mmol) and 189 (51 
mg, 0.280 mmol) in dry THF (3.0 mL). The reaction mixture was stirred at room temperature for 1 h, then it 
was quenched at 0 °C with sat. aq. NH4Cl. EtOAc was added and the phases were separated. The organic phase 
was washed with 2 M aq. HCl, 5% aq. NaHCO3, dried over anhydrous Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc, 1:1) obtaining 2,2-difluoro-3-phenyl-N-(2,4,6-trimethoxyphenyl)propanamide (243) as a 
white solid (53 mg, 80% yield) (m.p.= 124.1-125.3 °C). 
Rf= 0.42 (n-hexane/EtOAc, 1:1). 
1H-NMR (400 MHz, CDCl3): δ= 7.39-7.27 (m, 5H), 7.19 (bs, 1H), 6.11 (s, 2H), 3.78 (s, 3H), 3.73 (s, 6H), 3.50 
(t, JH-F= 16.8 Hz, 2H). 
13C-NMR (100 MHz, CDCl3): δ= 162.4 (t, JC-F= 27.9 Hz), 160.4, 156.1, 131.3 (t, JC-F= 4.3 Hz), 130.8, 128.3, 
127.5, 117.6 (t, JC-F= 253.0 Hz), 105.1, 90.9, 55.9, 55.5, 40.4 (t, JC-F= 23.9 Hz). 
19F-NMR (376.45 MHz, CDCl3): δ= - 104.5 (dt, JF-H= 2.4, 16.8 Hz, 2F). 
19F-CPD-NMR (376.45 MHz, CDCl3): δ= - 104.5 (s, 2F). 
MS (ESI): m/z calcd for C18H19F2NO4: 351.1; found: 352.1 [M+H]+. 
HRMS (ESI): m/z calcd for C18H20F2NO4+: 352.1355; found: 352.1356 (Δ= 0.3 ppm).  
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12.3 Biology 
Chlamydia trachomatis inclusion assay 
Chlamydia trachomatis L2 EBs were harvested from infected HeLa cell cultures at 37 °C with 5% CO2, 
purified by discontinuous density gradient centrifugation in Renografin (Bracco Diagnostics, Princeton, NJ, 
USA), and titered for infectivity as measured by inclusion forming units (IFU). Cells were routinely cultivated 
at 37 °C with 5% CO2 in RPMI media supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 10 
μg/mL gentamicin (all from Invitrogen, Carlsbad, CA, USA). For infections, HeLa cells were plated to 85–
90% confluence on 13 mm glass coverslips. On the following day, monolayers were inoculated with C. 
trachomatis serovar L2. Plates were centrifuged at 1500 rpm at 4 °C prior to a 30 min invasion step at 37 °C. 
Inoculum was decanted, cells were washed with PBS, and incubated for 24 h in 100 μM of the compound or 
the solvent DMSO (1% final concentration). The samples were fixed and permeabilized with ice-cold MeOH 
and stained with convalescent human sera for 2 h at room temperature, followed by staining with Alexa-594-
conjugated mouse mAb anti-human IgG secondary antibody, phalloidin and DAPI for 1 h. The latter was used 
to visualise host cell nuclei to monitor cytotoxicity. Images were collected by fluorescence microscopy and 
processed using NIH ImageJ. [81] 
Experimental procedures for the other assays are not reported in the present thesis because they were performed 
by other research groups, as indicated in the relative chapters. 
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